A cyclic derivative and its preparation method and medical use

通过开发并环类衍生物作为GLP-1受体激动剂,解决了现有GLP-1受体激动剂在治疗II型糖尿病和减肥时的胃肠道不良反应问题,实现了有效控制血糖和减少 The effect of fat accumulation, while improving the safety of the drug.

CN115594669BActive Publication Date: 2024-11-05SHENZHEN SALUBRIS PHARMA CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202210815262.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2021-07-09
Filing Date
2022-07-08
Publication Date
2024-11-05
Estimated Expiration
2042-07-08

AI Technical Summary

Technical Problem

The existing GLP-1 receptor agonists are often accompanied by gastrointestinal adverse reactions such as nausea and vomiting in the treatment of type II diabetes and weight loss. Because small molecules are difficult to simulate the interaction between receptors and peptides, glucagon is limited. Discovery of small molecule drugs like peptide-1 receptor.

Method used

A series of cyclic derivatives have been developed as agonists for GLP-1 receptors, and through specific chemical structure design, new non-polypeptide compounds are provided for the treatment of diseases such as diabetes. These compounds include specific aromatic rings, heteroaromatic rings and alkyl substituent groups, with good biological properties and safety.

Benefits of technology

These compounds, as GLP-1 receptor agonists, can effectively control blood sugar levels, increase satiety, delay gastric emptying, and reduce fat accumulation. Due to their non-polypeptide structure, they reduce the occurrence of gastrointestinal adverse reactions, providing Safer treatment options.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_14
    Figure SMS_14
Patent Text Reader

Abstract

The present invention belongs to the field of chemical drug technology, and relates to a compound of formula (I), a preparation method thereof, and its application in medicine. Specifically, the present invention provides a compound of formula (I) or a stereoisomer, a tautomer, and a pharmaceutically acceptable salt thereof. These compounds are agonists of glucagon-like peptide-1 receptor (GLP-1R). The present invention also relates to a pharmaceutical composition comprising these compounds and the use of the compounds in drugs for treating diseases such as diabetes.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of chemical medicines, and provides a series of glucagon-like peptide-1 receptor (GLP-1R) agonists. The present invention also relates to pharmaceutical compositions containing these compounds and the use of the compounds in medicines for treating diseases such as diabetes. Background Art

[0002] Diabetes affects millions of people worldwide and is considered one of the leading threats to human mortality in the 21st century. Over time, uncontrolled diabetes can damage body systems, including the heart, blood vessels, eyes, kidneys, and nerves. The socioeconomic burden of diabetes is high worldwide.

[0003] There are two main types of diabetes, named type I and type II, of which type II diabetes (T2DM) accounts for more than 90% of all diabetes worldwide. Type I diabetes is characterized by insulin deficiency, mainly caused by autoimmune-mediated destruction of pancreatic β cells, and type II diabetes is characterized by abnormal insulin secretion and subsequent insulin resistance. To prevent ketoacidosis, patients with type I diabetes must take exogenous insulin to survive. Although patients with type II diabetes are not as dependent on exogenous insulin as patients with type I diabetes, they may need exogenous insulin to control blood sugar levels.

[0004] Glucagon-like peptide-1 (GLP-1) is a type of incretin secreted by intestinal epithelial L cells and exerts physiological effects by binding to its receptor. GLP-1 receptor (GLP-1R) belongs to the G protein-coupled receptor subfamily. When GLP-1 binds to the GLP-1 receptor, it triggers a series of biological effects. Studies have shown that GLP-1 promotes insulin secretion in a glucose-dependent manner, that is, when the blood glucose concentration in the human body increases, GLP-1 stimulates pancreatic cells, increases insulin secretion, and lowers blood sugar. GLP-1 receptor agonists are a new type of hypoglycemic drug that can effectively control blood sugar levels without causing hypoglycemia; they can also effectively reduce body weight by increasing satiety, delaying gastric emptying, suppressing appetite, and reducing fat accumulation, thereby achieving the purpose of weight loss.

[0005] At present, peptide drugs based on GLP-1 receptor agonists such as liraglutide, exenatide, and semaglutide have been used in obese patients with type II diabetes and simple obese or overweight patients, and have shown a significant effect in reducing body weight, but are often accompanied by gastrointestinal adverse reactions such as nausea and vomiting. Oral non-peptide drugs have always been the drugs that research institutions have tried to use for the treatment of type II diabetes and weight loss, but because small molecules are difficult to simulate the interaction between receptors and peptides, the discovery of small molecule drugs for glucagon-like peptide-1 receptors is limited.

[0006] At present, the patent applications for non-peptide GLP-1 receptor agonists are WO2009 / 111700, WO2010 / 114824, WO2011 / 114271, WO2013 / 090454, WO2018 / 056453, WO2018 / 109607, WO2019239319, WO2019239371, WO2020103815, etc. Among them, only vTv's TTP-273 and Pfizer's PF-06882961 have entered the Phase II clinical study.

[0007] Therefore, the present invention aims to discover new non-peptide GLP-1 receptor agonists, especially new compounds with good biological properties that can be safely applied to the human body. The present invention also provides the necessary tools for preventing and / or treating GLP-1 related diseases, especially diabetes related diseases. Summary of the invention

[0008] The present invention provides a series of annular derivatives, preparation methods thereof and medical applications thereof.

[0009] Specifically, the present invention provides compounds of formula (I) or stereoisomers, tautomers, pharmaceutically acceptable salts thereof, wherein all variables are as defined herein.

[0010]

[0011] These compounds are agonists of glucagon-like peptide 1 receptor (GLP-1R). The present invention also relates to pharmaceutical compositions containing these compounds and the use of the compounds in drugs for treating diseases such as diabetes.

[0012] Specifically, the present invention is implemented by the following technical solutions:

[0013] Compounds of formula (I):

[0014]

[0015] or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein:

[0016] A is selected from an aromatic ring, a heteroaromatic ring, and an 8- to 10-membered fused aromatic ring;

[0017] R 1 is selected from hydrogen, halogen, cyano, alkyl, alkoxy, haloalkyl, haloalkoxy, alkoxyalkyl, cycloalkyl, heterocycloalkyl, 1 or more R 7 Substituted alkyl, 1 or more R 8 substituted aryl and heteroaryl groups;

[0018] m is 0, 1, 2 or 3;

[0019] W is selected from -O-, -(CH 2 ) n CHR 5 O-、-(CH 2 ) n CHR 5 NH-、-CHR 5 (CH 2 ) n -、-OCHR 5 (CH 2 ) n -、-ΝHCHR 5 (CH 2 ) n -;

[0020] R 5 is selected from the group consisting of hydrogen, halogen, hydroxy, alkyl, haloalkyl, alkoxy, haloalkoxy, alkoxyalkyl, cycloalkyl, heterocycloalkyl, alkylcycloalkyl, alkylheterocycloalkyl;

[0021] Where n is 0, 1 or 2;

[0022] Z 1 , Z 2 and Z 3 Each independently is -CR Z or N, each R Z are independently H, F, Cl or -CH 3 ;

[0023] R 2 is selected from hydrogen, halogen, cyano, alkyl, haloalkyl, alkoxy, alkoxyalkyl;

[0024] Where p is 0, 1 or 2;

[0025] X is CH or N;

[0026] Y 1 , Y 2 Each is independently -(CH 2 ) q CR 3 2 -or-CR 3 2 (CH 2 ) q -;

[0027] R 3 are independently selected from hydrogen, fluorine, hydroxyl, cyano, C 1-3 Alkyl, OC 1-3 Alkyl, C 3-4Cycloalkyl, or 2 R 3 Together to form an oxo group (= O), or two R 3 Cyclize to C 3-4 Spirocycloalkyl, wherein C 1-3 Alkyl, OC 1-3 Alkyl, C 3-4 Cycloalkyl or C 3-4 The spirocycloalkyl group may be substituted by 0 to 3 fluorine atoms or by 0 to 1 hydroxyl group when the valence permits;

[0028] Where q is 0, 1 or 2;

[0029] L is selected from -CHR 5 -、-OCHR 5 -、-ΝHCHR 5 -;

[0030] R 4 For -C 1-3 Alkyl, -C 0-3 Alkylene-C 3-6 Cycloalkyl, -C 0-3 Alkylene-R 9 or -C 1-3 Alkylene-R 6 wherein the alkyl group may be substituted by 0 to 3 substituents independently selected from 0 to 3 F atoms or by 0 to 1 substituent selected from -C 0-1 Alkylene -CN, -C 0-1 Alkylene-OR O or -N(R N ) 2 wherein the alkylene and cycloalkyl groups are independently substituted with 0 to 2 substituents independently selected from 0 to 2 F atoms or 0 to 1 substituent selected from -C 0-1 Alkylene -CN, -C 0-1 Alkylene-OR O or -N(R N ) 2 Substituents are substituted;

[0031] R 9 is a 4- to 6-membered heterocycloalkyl group, wherein the heterocycloalkyl group may be substituted with 0 to 2 substituents independently selected from the following when valence permits:

[0032] 0 to 1 oxo (=O),

[0033] 0 to 1 -CN,

[0034] 0 to 2 F atoms, or

[0035] 0 to 2 independently selected from -C 1-3 Alkyl or -OC1-3 Alkyl substituents, where C 1-3 Alkyl and OC 1-3 The alkyl group of the alkyl group may be substituted, when valency permits, with 0 to 3 substituents independently selected from the following:

[0036] 0 to 3 F atoms,

[0037] 0 to 1 -CN, or

[0038] 0 to 1 -OR O ;

[0039] R 6 is a 5- to 6-membered heteroaryl group, wherein the heteroaryl group may be substituted with 0 to 2 substituents independently selected from the following when valence permits:

[0040] 0 to 2 halogens,

[0041] 0 to 1 selected from -OR O and -N(R N ) 2 A substituent, or

[0042] 0 to 2 -C 1-3 Alkyl, wherein the alkyl may be substituted with 0 to 3 substituents independently selected from the following when valence permits:

[0043] 0 to 3 F atoms, or

[0044] 0 to 1 -OR O ;

[0045] Each R O are independently H or -C 1-3 Alkyl, where C 1-3 The alkyl group may be substituted by 0 to 3 F atoms;

[0046] Each R N are independently H or -C 1-3 alkyl;

[0047] Z 1 , Z 2 and Z 3 Each independently is -CR Z or N, each R Z are independently H, F, Cl or -CH 3 ;

[0048] R 7 is selected from halogen, cyano, hydroxy, cycloalkyl, heterocycloalkyl, sulfone;

[0049] R 8Selected from halogen, cyano, alkyl, haloalkyl, alkoxy, haloalkoxy, alkoxyalkyl, cycloalkyl, heterocycloalkyl, sulfone.

[0050] As a preferred embodiment of the present invention, the alkyl group refers to a branched, unbranched and cyclic saturated hydrocarbon chain containing a specified number of carbon atoms, preferably selected from C 1-6 The alkyl group, the C 1-6 The alkyl group is selected from methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, sec-pentyl, 1-ethylpropyl, 2-methylbutyl, tert-pentyl, 1,2-dimethylpropyl, isopentyl, neopentyl, n-hexyl, isohexyl, sec-hexyl, tert-hexyl, neohexyl, 2-methylpentyl, 1,2-dimethylbutyl, and 1-ethylbutyl.

[0051] As a preferred embodiment of the present invention, the alkoxy group refers to an alkyl ether free radical, preferably selected from C 1-6 The alkoxy group, the C 1-6 The alkoxy group is selected from methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, n-pentoxy, sec-pentoxy, 1-ethylpropoxy, 2-methylbutoxy, tert-pentoxy, 1,2-dimethylpropoxy, isopentyloxy, neopentyloxy, n-hexyloxy, isohexyloxy, sec-hexyloxy, tert-hexyloxy, neohexyloxy, 2-methylpentyloxy, 1,2-dimethylbutoxy and 1-ethylbutoxy.

[0052] As a preferred embodiment of the present invention, the alkoxyalkyl group refers to an alkyl group in which one or more hydrogen atoms are replaced by an alkoxy group, preferably selected from C 1-4 Alkoxy C 1-4 The alkyl group is further selected from methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, propoxymethyl, propoxyethyl, propoxypropyl, propoxybutyl, butoxymethyl, butoxyethyl, butoxypropyl, butoxybutyl and the like.

[0053] As a preferred embodiment of the present invention, the halogen is selected from fluorine, chlorine, bromine and iodine; a haloalkyl group refers to one or more hydrogen atoms of an alkyl group being replaced by a halogen; a haloalkoxy group refers to one or more hydrogen atoms of an alkoxy group being replaced by a halogen; a hydroxyalkyl group refers to one or more hydrogen atoms of an alkyl group being replaced by a hydroxyl group; a heterocycloalkyl group refers to one or more hydrogen atoms of an alkyl group being replaced by a heterocycle; and a cycloalkyl methylene group refers to one or more hydrogen atoms of an alkyl group being replaced by a cycloalkane.

[0054] As a preferred embodiment of the present invention, the aromatic ring is selected from a four-membered ring, a condensed ring containing a four-membered ring, a five-membered ring, a condensed ring containing a five-membered ring, a six-membered ring, a condensed ring containing a six-membered ring, and a biphenyl-type aromatic ring; the condensed aromatic ring is selected from naphthalene or a condensed aromatic heterocycle, the condensed aromatic heterocycle refers to an aromatic ring or a heteroaromatic ring fused with a heteroaromatic ring, the heteroatoms on the heteroaromatic ring are selected from nitrogen, oxygen, and sulfur, and the heteroatoms are one or more.

[0055] As a preferred embodiment of the present invention, the fused aromatic heterocycle is selected from indazole, quinoline, isoquinoline, quinoxaline, indole, isoindole, cinnoline, quinazoline, phthalazine, purine, naphthyridine, pteridine, benzofuran, benzothiophene, benzoxazole, benzothiazole, benzisoxazole, benzisothiazole, benzoxadiazole, benzothiadiazole, benzotriazole, benzotriazine, benzimidazole, pyrazinopyr ... pyrimidine, pyrazinopyridazine, pyrazinotriazine, pyrimidopyrazole, pyrimidoimidazole, pyrimidotriazole, pyrimidotriazine, pyrimidopyrazine, pyridazinimidazole, pyridazinopyrazole, pyridazinotriazole, pyridazinotriazine, triazinimidazole, triazinopyrazole, triazinotriazole, pyridoimidazole, pyridopyridazine, pyridopyrazole, pyridopyrimidine, pyridotriazine, pyridooxazole, pyridothiazole, pyridothiazole, pyridotriazine, pyridooxazole, pyridothiazole, pyridotriazine ... pyridoisoxazole, pyridoisothiazole, pyridooxadiazole, pyridothiadiazole, pyridofuran, pyridopyrrole, pyrazinoimidazole, pyrazinotriazole, pyrazinoxazole, pyrazinothiazole, pyrazinoisoxazole, pyrazinoisothiazole, pyrazinooxadiazole, pyrazinothiadiazole, pyrazinofuran, pyrazinopyrrole, pyrimidooxazole, pyrimidothiazole, pyrimidoisoxazole, pyrimidoisothiazole, Pyrimidooxadiazole, pyrimidothiadiazole, pyrimidofuran, pyrimidopyrrole, pyridazinoxazole, pyridazinothiazole, pyridazinoisoxazole, pyridazinoisothiazole, pyridazinooxadiazole, pyridazinothiadiazole, pyridazinofuran, pyridazinopyrrole, triazinooxazole, triazinothiazole, triazinoisoxazole, triazinoisothiazole, triazinooxadiazole, triazinothiadiazole, triazinofuran, triazinopyrrole. wherein the naphthyridine is selected from The pyridoimidazole is selected from The pyrazinoimidazole is selected from The pyrazinotriazole is selected from The pyrimidopyrazole is selected from The pyrimidoimidazole is selected from The pyrimidotriazole is selected from The pyridazine imidazole is selected from The pyridazinetriazole is selected from The triazinoimidazole is selected from The pyridopyridazine is selected from The pyridopyrazole is selected from The pyridopyrimidine is selected from The pyridotriazine is selected from The pyrimidotriazine is selected from

[0056] As a preferred embodiment of the present invention, the heterocyclic ring of the heterocycloalkyl is selected from a 4- to 10-membered heterocyclic ring, and the 4- to 10-membered heterocyclic ring is selected from The aryl group is selected from phenyl; the heteroaryl group is selected from 5 to 12 membered heteroaryl groups, and the 5 to 12 membered heteroaryl groups are selected from

[0057] As a preferred embodiment of the present invention, the "alkylene group" refers to an alkyl group which can be independently substituted by 0 to 2 substituents when the valence permits.

[0058] As a preferred embodiment of the present invention, the "heterocycle" refers to a saturated or unsaturated heterocycle containing one or more heteroatoms (nitrogen, oxygen, sulfur); the "aromatic ring" refers to a benzene ring; the "heteroaromatic ring" refers to a heterocycle with a closed conjugated system of 4n+2 π electrons, such as furan, thiophene, tetrahydropyrrole, dihydropyrazole, imidazole, thiazole, isothiazole, thiadiazole, oxazole, oxadiazole, isoxazole, piperidine, piperazine, pyridazine, pyrazine, triazine, pyrimidine, morpholine or pyridine, etc.; the "plurality" refers to two, three, or four.

[0059] As a preferred embodiment of the present invention, the cycloalkane is selected from C 3-6 Cycloalkane, C 3-6 The cycloalkane is selected from cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

[0060] As a preferred embodiment of the present invention, A is selected from a benzene ring, a thiophene ring, a pyridine ring, a pyridazine ring, a biphenyl ring, a quinoline ring, and an indazole ring.

[0061] As a preferred embodiment of the present invention, the compound or its stereoisomers, tautomers, and pharmaceutically acceptable salts, wherein: the A is selected from a benzene ring, a thiophene ring, a pyridine ring, a pyridazine ring, a biphenyl, a quinoline ring, and an indazole ring.

[0062] As a preferred embodiment of the present invention, Selected from

[0063] As a preferred embodiment of the present invention, the R 1 is selected from hydrogen, cyano, fluorine, chlorine, bromine, methyl, trifluoromethoxy, methoxy, trifluoromethyl, trifluoroethyl, methanesulfonyl;

[0064] W is -O-, -OCH 2 -、-CH 2 O-、-CH 2 CH 2 O-、-CH 2 CH 2 -、 -NHCH 2 -or-CH 2 NH-;

[0065] Selected from

[0066] R 2 For hydrogen, fluorine, chlorine;

[0067] R 3 is hydrogen;

[0068] R 4 is oxetane-2-ylmethyl;

[0069] L is selected from -CH 2 ;

[0070] Z 1 , Z 2 , Z 3 is CH or N. As a preferred embodiment of the present invention, the compound or its pharmaceutically acceptable salt is selected from the following compounds:

[0071]

[0072]

[0073]

[0074]

[0075]

[0076]

[0077] As a preferred embodiment of the present invention, the pharmaceutically acceptable salt refers to a salt prepared from a compound and a pharmaceutically acceptable acid or base.

[0078] As a preferred embodiment of the present invention, one or more hydrogen atoms in the compound are substituted by deuterium isotope.

[0079] Another object of the present invention is to provide a pharmaceutical composition, comprising the aforementioned compound of formula (I), or its stereoisomers, tautomers, pharmaceutically acceptable salts and one or more pharmaceutically acceptable carriers.

[0080] Another object of the present invention is to provide the use of the compound of formula (I), or its stereoisomers, tautomers, and pharmaceutically acceptable salts in the preparation of drugs for treating GLP-1 related diseases, specifically, the use of drugs for diabetes related diseases.

[0081] Unless otherwise indicated, the following terms and phrases used herein are intended to have the following meanings. A particular term or phrase should not be considered to be uncertain or unclear in the absence of a particular definition, but should be understood in accordance with the common meaning. When a trade name appears in this article, it is intended to refer to its corresponding commodity or its active ingredient. The term "pharmaceutically acceptable" used herein refers to those compounds, materials, compositions and / or dosage forms that are within the scope of reliable medical judgment, suitable for use in contact with human and animal tissues, without excessive toxicity, irritation, allergic reactions or other problems or complications, and commensurate with a reasonable benefit / risk ratio.

[0082] The term "pharmaceutically acceptable salt" refers to salts of the compounds of the present invention, which are prepared from the compounds having specific substituents discovered in the present invention and pharmaceutically acceptable acids or bases.

[0083] In addition to the form of salts, compounds provided by the present invention also exist in prodrug forms. Prodrugs of compounds described herein easily undergo chemical changes under physiological conditions to be converted into compounds of the present invention. In addition, prodrugs can be converted to compounds of the present invention by chemical or biochemical methods in an in vivo environment.

[0084] Certain compounds of the present invention may exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to the unsolvated forms and are encompassed within the scope of the present invention.

[0085] The compounds of the present invention may exist in specific geometric or stereoisomeric forms. The present invention contemplates all such compounds, including cis and trans isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers, (D)-isomers, (L)-isomers, and racemic mixtures and other mixtures thereof, such as enantiomerically or diastereomerically enriched mixtures, all of which are within the scope of the present invention. Additional asymmetric carbon atoms may be present in substituents such as alkyl. All of these isomers and their mixtures are included within the scope of the present invention.

[0086] Optically active (R)- and (S)-isomers, as well as D and L isomers, can be prepared by chiral synthesis or chiral reagents or other conventional techniques. If one enantiomer of a compound of the present invention is desired, it can be prepared by asymmetric synthesis or derivatization with a chiral auxiliary, wherein the resulting diastereomeric mixture is separated and the auxiliary group is cleaved to provide the pure desired enantiomer. Alternatively, when the molecule contains a basic functional group (such as an amino group) or an acidic functional group (such as a carboxyl group), a diastereomeric salt is formed with an appropriate optically active acid or base, and then the diastereoisomers are separated by conventional methods known in the art, and then the pure enantiomer is recovered. In addition, the separation of enantiomers and diastereomers is usually accomplished by using chromatography, which uses a chiral stationary phase and is optionally combined with a chemical derivatization method (for example, a carbamate is generated from an amine).

[0087] The atoms of the molecules of the compounds of the present invention are isotopes, and isotope derivatization can generally extend the half-life, reduce the clearance rate, stabilize metabolism, and improve the in vivo activity. In addition, an embodiment is included in which at least one atom is replaced by an atom with the same atomic number (proton number) and a different mass number (proton and neutron sum). Examples of isotopes included in the compounds of the present invention include hydrogen atoms, carbon atoms, nitrogen atoms, oxygen atoms, phosphorus atoms, sulfur atoms, fluorine atoms, and chlorine atoms, which respectively include 2 H. 3 H. 13 C. 14 C. 15 N. 17 O. 18 O. 31 P. 32 P. 35 S. 18 F. 36 In particular, radioactive isotopes that emit radiation as they decay, such as 3 H or 14 C can be used for local anatomy inspection of pharmaceutical preparations or compounds in vivo. Stable isotopes neither decay or change with their amount nor have radioactivity, so they can be used safely. When the atoms constituting the molecules of the compounds of the present invention are isotopes, the isotopes can be converted according to general methods by replacing the reagents used in the synthesis with reagents containing the corresponding isotopes.

[0088] The compounds of the invention may contain unnatural proportions of atomic isotopes on one or more of the atoms that make up the compound. For example, the compounds may be labeled with radioactive isotopes, such as deuterium ( 2 H), iodine-125( 125 I) or C-14( 14C) All isotopic variations of the compounds of the present invention, whether radioactive or not, are included within the scope of the present invention.

[0089] Furthermore, the compounds of the present invention may have one or more hydrogen atoms deuterated with isotopes of deuterium ( 2 After deuteration, the compounds of the present invention have the effects of extending half-life, reducing clearance rate, stabilizing metabolism and improving in vivo activity.

[0090] The preparation method of the isotope derivative generally includes: a phase transfer catalytic method. For example, a preferred deuteration method uses a phase transfer catalyst (e.g., tetraalkylammonium salt, NBu 4 HSO 4 ). The use of a phase transfer catalyst to exchange the methylene protons of the diphenylmethane compound results in the introduction of higher deuterium than reduction with deuterated silanes (e.g., triethyldeuterated silane) in the presence of an acid (e.g., methanesulfonic acid) or with a Lewis acid such as aluminum trichloride using sodium deuterated borate.

[0091] The term "pharmaceutically acceptable carrier" refers to any formulation carrier or medium that can deliver an effective amount of the active substance of the present invention, does not interfere with the biological activity of the active substance, and has no toxic side effects on the host or patient. Representative carriers include water, oil, vegetables and minerals, cream bases, lotion bases, ointment bases, etc. These bases include suspending agents, viscosity enhancers, transdermal enhancers, etc. Their preparations are well known to those skilled in the art of cosmetics or topical drugs. For other information about the carrier, reference can be made to Remington: The Science and Practice of Pharmacy, 21st Ed., Lippincott, Williams & Wilkins (2005), the contents of which are incorporated herein by reference.

[0092] The term "excipient" generally refers to a carrier, diluent and / or vehicle required to formulate an effective pharmaceutical composition.

[0093] With respect to a drug or pharmacologically active agent, the term "effective amount" or "therapeutically effective amount" refers to a sufficient amount of a drug or agent that is non-toxic but can achieve the desired effect. For oral dosage forms of the present invention, an "effective amount" of an active substance in a composition refers to the amount required to achieve the desired effect when used in combination with another active substance in the composition. The determination of the effective amount varies from person to person, depending on the age and general condition of the recipient, and also on the specific active substance. The appropriate effective amount in each case can be determined by a person skilled in the art based on routine experiments.

[0094] The terms "active ingredient," "therapeutic agent," "active substance," or "active agent" refer to a chemical entity that is effective in treating a target disorder, disease, or condition.

[0095] "Optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not.

[0096] Indicates a connection key.

[0097] The compounds of the present invention can be prepared by a variety of synthetic methods known to those skilled in the art, including the specific embodiments listed below, embodiments formed by combining them with other chemical synthesis methods, and equivalent substitutions known to those skilled in the art. Preferred embodiments include but are not limited to the examples of the present invention. DETAILED DESCRIPTION

[0098] The present invention is further described in detail below with reference to examples, but the embodiments of the present invention are not limited thereto.

[0099] The structures of the compounds were determined by nuclear magnetic resonance (NMR) or mass spectrometry (MS). -6 The NMR measurements were performed using a Bruker AVANCE-III NMR spectrometer, and the solvent used was deuterated dimethyl sulfoxide (DMSO-d 6 ), deuterated chloroform (CDCl 3 ), and tetramethylsilane (TMS) was used as the internal standard.

[0100] MS was measured using ISQ EC mass spectrometer (manufacturer: Thermo, model: ISQ EC).

[0101] High performance liquid chromatography (HPLC) analysis was performed using a Thermo U3000 HPLC DAD and an Agilent 1260 HPLC.

[0102] The CombiFlash rapid preparation instrument uses CombiFlash Rf+LUMEN (TELEDYNE ISCO).

[0103] Thin layer chromatography silica gel plate using Yantai Yinlong HSGF 254 or GF 254 Silica gel plate: The specifications of silica gel plates used in thin layer chromatography (TLC) are 0.17mm to 0.23mm, and the specifications used for thin layer chromatography separation and purification products are 0.4mm to 0.5mm.

[0104] Silica gel column chromatography generally uses Rushan Shangbang silica gel 100-200 mesh silica gel as the carrier.

[0105] Reagents: LDA-lithium diisopropylamide, THF-tetrahydrofuran, TEA-triethylamine, Dioxane-1,4-dioxane, BH 3 -borane, EDCl-1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, HOBT-1-hydroxybenzotriazole, DIPEA-N,N-diisopropylethylamine, DMF-N,N-dimethylformamide, K 2 CO 3 -potassium carbonate, DMSO-dimethyl sulfoxide, EtOH-ethanol, NaH-sodium hydride, toluene-toluene, rt-room temperature, PdCl 2 (dppf)-[1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride, Pd(OAc)2-palladium acetate, PhMe-toluene, HCl-dioxane-hydrochloric acid dioxane, NaCO 3 -sodium carbonate, MeOH-methanol, DCE-dichloroethane, NCS-N-chlorosuccinimide, TfOH-trifluoromethanesulfonic acid, TFA-trifluoroacetic acid, AcOH-acetic acid, (CH 2 O)n paraformaldehyde, CDI-N,N'-carbonyldiimidazole, LAH-lithium aluminum hydride, PPA-polyphosphoric acid, TsOH-toluenesulfonic acid, NBS-N-bromosuccinimide, BPO-benzoyl peroxide.

[0106] abs means absolute configuration.

[0107] Example 1

[0108] Synthesis of (S)-2-((6-((4-cyano-2-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0109]

[0110] The specific synthetic route is as follows:

[0111] Step A: Synthesis of tert-butyl 6-((4-cyano-2-fluorobenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate

[0112]

[0113] At room temperature, tert-butyl 6-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxylate (200.4 mg, 0.8 mmol), 4-(bromomethyl)-3-fluorobenzonitrile (342.2 mg, 1.6 mmol), and potassium carbonate (331.3 mg, 2.4 mmol) were dissolved and added to N,N-dimethylformamide (10 ml). The temperature was raised to 60 degrees Celsius and the reaction was carried out for 24 hours. After the reaction was complete, water (50 ml) was added to dilute, ethyl acetate (25 ml × 3 times) was used for extraction, saturated brine (50 ml × 1 time) was washed, dried over anhydrous sodium sulfate, filtered, and concentrated. The obtained residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 5 / 1) to obtain 180.4 mg of yellow oily tert-butyl 6-((4-cyano-2-fluorobenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate (yield: 58.6%). LC-MS: RT = 2.80 min, [M+Na] + =405.26.

[0114] Step B: Synthesis of 3-fluoro-4-(((1,2,3,4-tetrahydroisoquinolin-6-yl)oxy)methyl)benzonitrile

[0115]

[0116] At room temperature, tert-butyl 6-((4-cyano-2-fluorobenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate (180.0 mg, 470.6 μmol) was dissolved in 4 mol hydrochloric acid ethyl acetate solution (10.0 ml) and reacted for 1 hour. After the reaction was complete, it was concentrated, diluted with water (50 ml), and saturated sodium carbonate aqueous solution was added dropwise to adjust to alkalinity, extracted with ethyl acetate (25 ml × 3 times), washed with saturated brine (25 ml × 1 time), dried over anhydrous sodium sulfate, and concentrated. 100.7 mg of yellow oily 3-fluoro-4-(((1,2,3,4-tetrahydroisoquinolin-6-yl)oxy)methyl)benzonitrile was obtained and used directly in the next step without purification. LC-MS: RT = 3.34 min, [M+H] + =283.15.

[0117] Step C: Synthesis of (S)-2-((6-((4-cyano-2-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester

[0118]

[0119] At room temperature, the compound 3-fluoro-4-(((1,2,3,4-tetrahydroisoquinolin-6-yl)oxy)methyl)benzonitrile (100.7 mg, 354.0 μmol), (S)-2-(chloromethyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (115.3 mg, 389.4 μmol) and potassium carbonate (250.5 mg, 1.6 mmol) were dissolved in acetonitrile (10 ml) and reacted at 50 degrees Celsius for 16 hours. After the reaction was complete, water (80 ml) was added for dilution, ethyl acetate (50 ml × 3 times) was extracted, saturated brine (50 ml × 1 time) was washed, dried over anhydrous sodium sulfate, and finally concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1 to dichloromethane / methanol = 10 / 1) to obtain 190.3 mg of light yellow solid (S)-2-((6-((4-cyano-2-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetane-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (yield: 99.3%). LC-MS: RT = 2.09 min, [M+H] + =541.39.

[0120] Step D: Synthesis of (S)-2-((6-((4-cyano-2-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0121]

[0122] Compound (S)-2-((6-((4-cyano-2-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (190.3 mg, 354.8 μmol) was dissolved in tetrahydrofuran (10 ml) and water (3 ml) solution, and sodium hydroxide (74.2 mg, 1.7 mmol) was added and reacted at room temperature for 48 hours. After the reaction was completed, 1N citric acid aqueous solution was added dropwise to the reaction solution until the pH of the solution reached 5, and then diluted with water (50 ml), extracted with ethyl acetate (25 ml × 3 times), washed with saturated brine (25 ml × 1 time), dried over anhydrous sodium sulfate, and finally concentrated under reduced pressure. The obtained residue was further purified by reverse phase HPLC (mobile phase: water / acetonitrile = 90 / 10 to 5 / 95) and lyophilized to give 54.2 mg of white solid (S)-2-((6-((4-cyano-2-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl))-1H-benzo[d]imidazole-6-carboxylic acid (yield: 29.1%). LC-MS: RT = 3.80 min, [M+H] + =527.32.

[0123] Example 2

[0124] Synthesis of (S)-2-((7-((4-cyano-2-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0125]

[0126] The specific synthetic route is as follows:

[0127] Step A: Synthesis of tert-butyl 7-bromo-3,4-dihydroisoquinoline-2(1H)-carboxylate

[0128]

[0129] At room temperature, 7-bromo-1,2,3,4-tetrahydroisoquinoline (5.0 g, 20.1 mmol) and triethylamine (5.5 ml, 40.2 mmol) were dissolved in dichloromethane (50 ml) solution. Di-tert-butyl dicarbonate (8.7 g, 40.2 mmol) was slowly added dropwise, and the reaction was stirred at room temperature overnight. After the reaction was complete, ethyl acetate (200 ml) was added to dilute, and the mixture was washed with 1 mol / L hydrochloric acid (40 ml × 3 times), saturated brine (30 ml × 2 times), dried over anhydrous sodium sulfate, and concentrated. The obtained 6.0 g of light yellow oily tert-butyl 7-bromo-3,4-dihydroisoquinoline-2(1H)-carboxylate was directly used in the next step without further purification. (Yield: 95.8%).

[0130] Step B: Synthesis of tert-butyl 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate

[0131]

[0132] Tert-butyl 7-bromo-3,4-dihydroisoquinoline-2(1H)-carboxylate (6.0 g, 19.2 mmol), bis(pinacol)diboron (9.8 g, 38.4 mmol), 2-dicyclohexylphospho-2,4,6-triisopropylbiphenyl (366.0 mg, 768.0 μmol) and potassium acetate (5.6 g, 57.6 mmol) were dissolved in dioxane (60 ml) at room temperature. The reaction mixture was replaced with nitrogen three times, and under the protection of nitrogen, trisdibenzylideneacetone dipalladium (703.2 mg, 768.0 μmol) was added, and nitrogen was replaced three times, heated to reflux and stirred overnight. After the reaction was complete, the mixture was filtered with celite, and the filtrate was diluted with ethyl acetate (250 ml), washed with water (50 ml × 2 times), washed with saturated brine (50 ml × 1 time), dried over anhydrous sodium sulfate, and finally concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 15 / 1) to obtain 6.2 g of light yellow oily tert-butyl 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (yield 89.6%). LC-MS: RT = 3.80 min, [M+H] + =304.12.

[0133] Step C: Synthesis of tert-butyl 7-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxylate

[0134]

[0135] At room temperature, tert-butyl 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (6.2 g, 17.3 mmol) was dissolved in tetrahydrofuran (60 ml) solution. 1 mol sodium hydroxide aqueous solution (51.8 ml, 51.8 mmol) and 30% hydrogen peroxide (11.3 ml, 103.8 mmol) were slowly added. After the addition, the reaction was allowed to react at room temperature for 2 hours. After the reaction was complete, the temperature was lowered to zero degrees Celsius and the pH was adjusted to 6-7 with 1 mol hydrochloric acid aqueous solution. The organic phases were combined and washed with saturated brine (40 ml × 1 time), dried over anhydrous sodium sulfate, and finally concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 10 / 1) to obtain 3.7 g of white solid tert-butyl 7-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxylate (yield 86.5%). LC-MS: RT = 1.52 min, [M-tBu] + =194.15.

[0136] Step D: Synthesis of tert-butyl 7-((4-cyano-2-fluorobenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate

[0137]

[0138] At room temperature, tert-butyl 7-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxylate (118.2 mg, 473.3 μmol), 4-(bromomethyl)-3-fluorobenzonitrile (202 mg, 946.6 mmol), and potassium carbonate (196.0 mg, 1.4 mmol) were dissolved and added to N,N-dimethylformamide (10 ml). The temperature was raised to 60 degrees Celsius and reacted for 24 hours. After the reaction was complete, water (50 ml) was added for dilution, ethyl acetate (25 ml × 3 times) was extracted, saturated brine (50 ml × 1 time) was washed, dried over anhydrous sodium sulfate, and finally concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 5 / 1) to obtain 157.0 mg of yellow oily tert-butyl 7-((4-cyano-2-fluorobenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate (yield: 86.7%). LC-MS: RT = 4.47 min, [M+Na] + =404.99.

[0139] Step E: Synthesis of 3-fluoro-4-(((1,2,3,4-tetrahydroisoquinolin-7-yl)oxy)methyl)benzonitrile

[0140]

[0141] At room temperature, tert-butyl 7-((4-cyano-2-fluorobenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate (157.0 mg, 410.5 μmol) was dissolved in 4 mol hydrochloric acid ethyl acetate solution (10 ml) and stirred for 1 hour. A white solid gradually precipitated. After the reaction was complete, the reaction solution was concentrated under reduced pressure, diluted with water (50 ml), and a saturated sodium carbonate aqueous solution was added dropwise to adjust the mixture to alkalinity. The mixture was extracted with ethyl acetate (25 ml × 3 times), washed with saturated brine (25 ml × 1 time), dried over anhydrous sodium sulfate, and finally concentrated under reduced pressure. 101.2 mg of yellow oily 3-fluoro-4-(((1,2,3,4-tetrahydroisoquinolin-7-yl)oxy)methyl)benzonitrile was obtained and used directly in the next step without purification. LC-MS: RT = 3.35min, [M+H] + =283.15.

[0142] Step F: Synthesis of (S)-methyl 2-((7-((4-cyano-2-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate

[0143]

[0144] At room temperature, the compound 3-fluoro-4-(((1,2,3,4-tetrahydroisoquinolin-7-yl)oxy)methyl)benzonitrile (101.0 mg, 357.5 μmol), (S)-2-(chloromethyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (116.0 mg, 393.3 μmol) and potassium carbonate (249.2 mg, 1.8 mmol) were dissolved in acetonitrile (10 ml) and reacted at 50 degrees Celsius for 16 hours. After the reaction was complete, water (80 ml) was added for dilution, ethyl acetate (50 ml × 3 times) was used for extraction, saturated brine (50 ml × 1 time) was washed, dried over anhydrous sodium sulfate, and finally concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1 to dichloromethane / methanol = 10 / 1) to obtain 160.2 mg of light yellow solid (S)-2-((7-((4-cyano-2-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (yield: 83.0%). LC-MS: RT = 2.27 min, [M+H] + =541.25.

[0145] Step G: Synthesis of (S)-2-((7-((4-cyano-2-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0146]

[0147] At room temperature, compound (S)-2-((7-((4-cyano-2-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (160.2 mg, 296.3 μmol) was dissolved in tetrahydrofuran (10 ml) and water (3 ml) solution, sodium hydroxide (118.5 mg, 0.3 mmol) was added, and the mixture was reacted at room temperature for 48 hours. After the reaction was completed, 1N citric acid aqueous solution was added dropwise to the reaction solution until the pH of the solution reached 5, and water (50 ml) was added to dilute the mixture, and ethyl acetate (25 ml × 3 times) was used for extraction, and saturated brine (25 ml × 1 time) was used for washing, and the mixture was dried over anhydrous sodium sulfate, and finally concentrated under reduced pressure. The obtained residue was further purified by reverse phase HPLC (mobile phase: water / acetonitrile = 90 / 10 to 5 / 95) and lyophilized to give 50.1 mg of white solid (S)-2-((4-(7-((4-cyano-2-fluorobenzyl)amino)pyridin-2-yl)piperidin-1-yl)methyl-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (yield: 43.6%). LC-MS: RT = 1.78 min, [M+H] + =526.98. 1 H NMR (400 MHz, DMSO-d 6)δ8.29 (s,1H),7.92(d,J=9.8Hz,1H),7.85(d,J=8.5Hz,1H),7.80–7.60(m,3H),7.06(d,J=8.6Hz,1H),6.83(dd, J=8.6,2.7Hz,1H),6.78(s,1H),5.19(s,2H),5.07(d,J=7.7Hz,1H),4.83(dd,J=15.5,7.2Hz,1H),4.68(d, J=14.8Hz,1H),4.48(q,J=7.4Hz,1H),4.43–4.30(m,1H),4.13(d,J=13.6Hz,1H),3.98(d,J=13.2Hz, 1H), 3.63 (d, J=4.1Hz, 2H), 2.78 (d, J=6.5Hz, 4H), 2.63 (q, J=8.7, 8.2Hz, 1H), 2.45–2.34 (m, 1H).

[0148] Example 3

[0149] Synthesis of (S)-2-((8-((4-cyano-2-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0150]

[0151] The specific synthetic route is as follows:

[0152] Step A: Synthesis of tert-butyl 8-((4-cyano-2-fluorobenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate

[0153]

[0154] At room temperature, 8-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxylic acid tert-butyl ester (200.0 mg, 0.8 mmol), 4-(bromomethyl)-3-fluorobenzonitrile (342.2 mg, 1.6 mmol), and potassium carbonate (330.0 mg, 2.4 mmol) were dissolved and added to N,N-dimethylformamide (10 ml). The mixture was reacted at room temperature for 24 hours. After the reaction was complete, water (50 ml) was added for dilution, ethyl acetate (25 ml × 3 times) was used for extraction, saturated brine (50 ml × 1 time) was used for washing, and the mixture was dried over anhydrous sodium sulfate and finally concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 5 / 1) to obtain 185.5 mg of yellow oily 8-((4-cyano-2-fluorobenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylic acid tert-butyl ester (yield: 58.8%). LC-MS: RT = 2.85 min, [M + Na] + =405.26.

[0155] Step B: Synthesis of 3-fluoro-4-(((1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)methyl)benzonitrile

[0156]

[0157] At room temperature, tert-butyl 8-((4-cyano-2-fluorobenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate (185.5 mg, 475.6 μmol) was dissolved in 4 mol hydrochloric acid ethyl acetate solution (10.0 ml) and stirred for 1 hour. A white solid gradually precipitated. After the reaction was complete, the reaction solution was concentrated under reduced pressure, diluted with water (50 ml), and the pH was adjusted to alkaline with saturated sodium carbonate aqueous solution. The solution was extracted with ethyl acetate (25 ml × 3 times), washed with saturated brine (25 ml × 1 time), dried over anhydrous sodium sulfate, and finally concentrated under reduced pressure. 103.7 mg of yellow oily 3-fluoro-4-(((1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)methyl)benzonitrile was obtained and used directly in the next step without purification. LC-MS: RT = 3.54 min, [M+H] + =283.15.

[0158] Step C: Synthesis of (S)-2-((8-((4-cyano-2-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester

[0159]

[0160] At room temperature, the compound 3-fluoro-4-(((1,2,3,4-tetrahydroisoquinolin-6-yl)oxy)methyl)benzonitrile (75.3 mg, 265.5 μmol), (S)-2-(chloromethyl)-1-((oxetane-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (90.2 mg, 292.0 μmol) and potassium carbonate (73.4 mg, 531.0 mmol) were dissolved in acetonitrile (10 ml) and reacted at 50 degrees Celsius for 16 hours. After the reaction was complete, water (80 ml) was added for dilution, ethyl acetate (50 ml × 3 times) was used for extraction, saturated brine (50 ml × 1 time) was washed, dried over anhydrous sodium sulfate, and finally concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1 to dichloromethane / methanol = 10 / 1) to obtain 115.2 mg of light yellow solid (S)-2-((6-((4-cyano-2-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (yield: 81.4%). LC-MS: RT = 2.29 min, [M+H] + =541.39.

[0161] Step D: Synthesis of (S)-2-((8-((4-cyano-2-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0162]

[0163] At room temperature, compound (S)-2-((8-((4-cyano-2-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetane-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (115.2 mg, 212.3 μmol) was dissolved in tetrahydrofuran (6 ml), ethanol (2 ml) and water (2 ml) solution and sodium hydroxide (87.8 mg, 2.2 mmol) was added and reacted at room temperature for 24 hours. After the reaction was complete, 1 mol / L citric acid aqueous solution was added dropwise to the reaction solution to adjust the pH to 5. Water (50 ml) was added for dilution, ethyl acetate (25 ml × 3 times) was used for extraction, the organic layers were combined, washed with saturated brine (25 ml × 1 time), dried over anhydrous sodium sulfate, and finally concentrated under reduced pressure. The obtained residue was further purified by reverse phase HPLC (mobile phase: water / acetonitrile = 90 / 10 to 5 / 95) and lyophilized to give 48.2 mg of white solid (S)-2-((8-((4-cyano-2-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (yield: 42.1%). LC-MS: RT = 3.80 min, [M+H] + =527.32.

[0164] Example 4

[0165] Synthesis of (S)-2-((8-((4-chloro-2-fluorobenzyl)oxy)-2-oxo-1,2,4,5-tetrahydro-3H-benzo[d]azepine -3-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0166]

[0167] The specific synthetic route is as follows:

[0168] Step A: Synthesis of N-(2,2-dimethoxyethyl)-2-(3-methoxyphenylacetamide)

[0169]

[0170] At room temperature, 3-methoxyphenylacetic acid (2.0 g, 12.0 mmol) and 2,2-dimethoxyethylamine (1.9 g, 18.0 mmol) were dissolved in a dry dichloromethane solution (20 ml), and 4-dimethylaminopyridine (146.4 mg, 1.2 mmol) and 1-ethyl-3 (3-dimethylpropylamine) carbodiimide (4.6 g, 24.0 mmol) were added in sequence. The reaction was carried out at room temperature for 4 hours. After the reaction was complete, ethyl acetate (150 ml) was added to dilute, and the mixture was washed with 1 mol hydrochloric acid (40 ml × 2), washed with saturated brine (40 ml × 1), dried over anhydrous sodium sulfate, and finally concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 6 / 1) to obtain 2.8 g of white solid N-(2,2-dimethoxyethyl)-2-(3-methoxyphenylacetamide) (yield 93.2%). LC-MS: RT = 1.25 min, [M + Na] + =276.22.

[0171] Step B: Synthesis of 8-methoxy-1,3-dihydro-2H-benzo[d]azepine -2-Keto

[0172]

[0173] At room temperature, N-(2,2-dimethoxyethyl)-2-(3-methoxyphenylacetamide) (2.8 g, 11.0 mmol) was dissolved in glacial acetic acid (10 ml), and concentrated hydrochloric acid (6 ml) was slowly added dropwise. The reaction was allowed to proceed at room temperature for 16 hours. After the reaction was complete, ethyl acetate (150 ml) was added for dilution, and the mixture was washed with water (40 ml × 2), saturated sodium bicarbonate aqueous solution (40 ml × 2), and saturated brine (40 ml × 1) in sequence, dried over anhydrous sodium sulfate, and finally concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1 to dichloromethane / methanol = 10 / 1) to obtain 1.2 g of white solid 8-methoxy-1,3-dihydro-2H-benzo[d]azepine -2-ketone (yield 60.6%). LC-MS: RT = 3.23 min, [M+H] + =190.04.

[0174] Step C: Synthesis of 8-methoxy-1,3,4,5-tetrahydro-2H-benzo[d]azepine -2-Keto

[0175]

[0176] At room temperature, 8-methoxy-1,3-dihydro-2H-benzo[d]azepine -2-ketone (1.2 g, 6.3 mmol) was dissolved in methanol (12 ml), and platinum dioxide (136.2 mg, 0.6 mmol) was added. The hydrogen gas was replaced three times, and the reaction was allowed to proceed overnight in a hydrogen atmosphere. After the reaction was complete, the mixture was filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1) to obtain 767.5 mg of a light yellow solid 8-methoxy-1,3,4,5-tetrahydro-2H-benzo[d]azepine -2-ketone (yield 62.3%). LC-MS: RT = 2.77 min, [M+H] + =192.23.

[0177] Step D: Synthesis of 8-hydroxy-1,3,4,5-tetrahydro-2H-benzo[d]azepine -2-Keto

[0178]

[0179] At room temperature, 8-methoxy-1,3,4,5-tetrahydro-2H-benzo[d]azepine -2-ketone (767.5 mg, 4.0 mmol) was dissolved in dry dichloromethane solution (10 ml), replaced with nitrogen three times, and cooled to -10 degrees Celsius under nitrogen protection. 1 mol per liter of dichloromethane solution of boron tribromide (8 ml) was slowly dripped in, and after the dripping was completed, the temperature was raised to zero degrees Celsius and reacted for 1 hour. After the reaction was complete, saturated aqueous ammonium chloride solution was slowly dripped at zero degrees Celsius to quench, extracted with ethyl acetate (150 ml), washed with water (40 ml × 2) and saturated brine (40 ml × 1) in turn, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 10 / 1) to obtain 488.6 mg of light yellow oily 8-hydroxy-1,3,4,5-tetrahydro-2H-benzo[d]azepine -2-ketone (yield 68.7%). LC-MS: RT = 1.80 min, [M + H] + =178.12.

[0180] Step E: Synthesis of 8-((4-chloro-2-fluorobenzyl)oxy)-1,3,4,5-tetrahydro-2H-benzo[d]azepine -2-Keto

[0181]

[0182] At room temperature, 8-hydroxy-1,3,4,5-tetrahydro-2H-benzo[d]azepine -2-ketone (240.2 mg, 1.3 mmol) and 4-chloro-2-fluorobenzyl bromide (417.3 mg, 1.9 mmol) were dissolved in N,N-dimethylformamide (3 ml), potassium carbonate (542.1 mg, 3.9 mmol) was added, and the mixture was reacted at room temperature for 6 hours. After the reaction was complete, ethyl acetate (100 ml) was added for dilution, and the mixture was washed with water (30 ml × 2) and saturated brine (30 ml × 1) in turn, dried over anhydrous sodium sulfate, and finally concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1 to dichloromethane / methanol = 15 / 1) to obtain 173.2 mg of a light yellow oily substance 8-((4-chloro-2-fluorobenzyl)oxy)-1,3,4,5-tetrahydro-2H-benzo[d]azepine -2-ketone (yield 42.3%). LC-MS: RT = 2.93 min, [M+H] + =320.09.

[0183] Step F: Synthesis of (S)-2-((8-((4-chloro-2-fluorobenzyl)oxy)-2-oxo-1,2,4,5-tetrahydro-3H-benzo[d]azepine -3-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester

[0184]

[0185] At room temperature, 8-((4-chloro-2-fluorobenzyl)oxy)-1,3,4,5-tetrahydro-2H-benzo[d]azepine -2-ketone (86.6 mg, 279.0 μmol) was dissolved in dry tetrahydrofuran (5 ml), replaced with nitrogen three times, and protected by nitrogen. The temperature was lowered to zero degrees Celsius, and sodium hydride (33.5 mg, 837.3 μmol) was added in batches, and the reaction was continued for 15 minutes. (S)-2-(chloromethyl)-1-((oxetane-2-yl(methyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (98.4 mg, 334.8 μmol) was added, and the reaction was continued for 2 hours. After the reaction was complete, saturated aqueous ammonium chloride solution was added to quench, and ethyl acetate (100 ml) was used for extraction, and the mixture was washed with water (30 ml × 2) and saturated brine (30 ml × 1) in turn, dried over anhydrous sodium sulfate, and finally concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1 to dichloromethane / methanol = 15 / 1). 81.3 mg of light yellow oily (S)-2-((8-((4-chloro-2-fluorobenzyl)oxy)-2-oxo-1,2,4,5-tetrahydro-3H-benzo[d]azepine was obtained. -3-yl) methyl)-1-((oxetan-2-yl(methyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (yield 51.3%). LC-MS: RT = 2.80 min, [M+H] + =578.24.

[0186] Step G: Synthesis of (S)-2-((8-((4-chloro-2-fluorobenzyl)oxy)-2-oxo-1,2,4,5-tetrahydro-3H-benzo[d]azepine -3-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0187]

[0188] At room temperature, (S)-2-((8-((4-chloro-2-fluorobenzyl)oxy)-2-oxo-1,2,4,5-tetrahydro-3H-benzo[d]azepine -3-yl)methyl)-1-((oxetane-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (81.3 mg, 143.1 μmol) was dissolved in a tetrahydrofuran / water / ethanol = 3: 1: 1 (8 ml) mixed solvent, and sodium hydroxide (28.6 mg, 715.6 μmol) was added. The reaction was allowed to proceed overnight at room temperature. After the reaction was complete, the pH of the solution was adjusted to 3-4 with a 1M citric acid aqueous solution under ice bath conditions. The solution was extracted with ethyl acetate (150 ml), washed with water (30 ml × 2 times) and saturated brine (30 ml × 1 time) in sequence, dried over anhydrous sodium sulfate, and finally concentrated under reduced pressure. The resulting residue was purified by reverse phase HPLC (mobile phase: water / acetonitrile = 90 / 10 to 5 / 95) and lyophilized to give 10.2 mg of (S)-2-((8-((4-chloro-2-fluorobenzyl)oxy)-2-oxo-1,2,4,5-tetrahydro-3H-benzo[d]azepine as a white solid. -3-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (yield: 12.9%). LC-MS: RT = 1.60 min, [M+H] + =564.18.

[0189] Example 5

[0190] Synthesis of (S)-2-((7-((4-chloro-2-fluorobenzyl)oxy)-1,2,4,5-tetrahydro-3H-benzo[d]azepine -3-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0191]

[0192] The specific synthetic route is as follows:

[0193] Step A: Synthesis of 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-((trifluoromethyl)sulfonyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine

[0194]

[0195] 7-Bromo-3-((trifluoromethyl)sulfonyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine was added at room temperature. (500 mg, 1.40 mmol), pinacol borate (534 mg, 2.10 mmol), potassium acetate (274 mg, 2.80 mmol) and palladium catalyst (102 mg, 0.10 mmol) were dissolved in dioxane (30 ml) and refluxed at 100 degrees Celsius for 6 hours under nitrogen protection. After the reaction, diatomaceous earth was used for suction filtration, dichloromethane was rinsed (10 ml × 2 times), and the organic phase was concentrated. The crude product was purified by silica gel column chromatography (eluent: ethyl acetate / n-hexane = 1 / 10) to obtain 350 mg of white solid 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-((trifluoromethyl)sulfonyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (Yield: 62%).

[0196] Step B: Synthesis of 3-((trifluoromethyl)sulfonyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine -7-ol

[0197]

[0198] 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-((trifluoromethyl)sulfonyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (150 mg, 0.37 mmol) was dissolved in a mixed solvent (4 ml, acetone / water = 3 / 1) at room temperature, potassium persulfate (455 mg, 0.74 mmol) was added, and the mixture was reacted at room temperature for 1 hour. After the reaction was completed, saturated sodium bisulfite was added to quench the reaction, and the mixture was extracted with ethyl acetate (10 ml × 3 times). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by silica gel column chromatography (eluent: ethyl acetate / n-hexane = 1 / 1) to obtain 100 mg of 3-((trifluoromethyl)sulfonyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol as a white solid (yield: 92%).

[0199] Step C: Synthesis of 7-((4-chloro-2-fluorobenzyl)oxy)-3-((trifluoromethyl)sulfonyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine

[0200]

[0201] At room temperature, 3-((trifluoromethyl)sulfonyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol (200 mg, 0.68 mmol) was dissolved in N,N-dimethylformamide (15 ml), 1-(bromomethyl)-4-chloro-2-fluorobenzene (151 mg, 0.68 mmol) and cesium carbonate (442 mg, 1.36 mmol) were added, and the temperature was raised to 70 °C for 3 hours.

[0202] After the reaction was completed, saturated sodium chloride was added to quench the reaction, and the reaction was extracted with ethyl acetate (10 ml × 2 times) and a mixed solvent (10 ml × 2 times, dichloromethane / methanol = 30 / 1) in sequence. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by silica gel column chromatography (eluent: ethyl acetate / n-hexane = 1 / 3) to give 220 mg of a white solid synthetic 7-((4-chloro-2-fluorobenzyl)oxy)-3-((trifluoromethyl)sulfonyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (yield: 74%).

[0203] Step D: Synthesis of 7-((4-chloro-2-fluorobenzyl)oxy)-2,3,4,5-tetrahydro-1H-benzo[d]azepine

[0204]

[0205] At room temperature, 7-((4-chloro-2-fluorobenzyl)oxy)-3-((trifluoromethyl)sulfonyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (220 mg, 0.50 mmol) was dissolved in toluene (8 ml), cooled to zero degrees Celsius, and red aluminum (0.5 ml) was added. The mixture was reacted at zero degrees Celsius for 2 hours. After the reaction, the mixture was dried by rotary evaporation, extracted with dichloromethane (20 ml), washed twice with water, dried over anhydrous sodium sulfate, filtered, and concentrated to give 126 mg of 7-((4-chloro-2-fluorobenzyl)oxy)-2,3,4,5-tetrahydro-1H-benzo[d]azepine as a white solid (yield: 82%). LC-MS: RT = 1.73 min, [M+H] + =306.21.

[0206] Step E: Synthesis of (S)-2-((7-((4-chloro-2-fluorobenzyl)oxy)-1,2,4,5-tetrahydro-3H-benzo[d]azepine -3-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester

[0207]

[0208] At room temperature, 7-((4-chloro-2-fluorobenzyl)oxy)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (126 mg, 0.41 mmol) was dissolved in N,N-dimethylformamide (2 ml), and (S)-methyl 2-(chloromethyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (121 mg, 0.41 mmol) was added. Cesium carbonate (267 mg, 0.82 mmol) was added, and the temperature was raised to 50 °C for 3 hours. After the reaction was completed, saturated sodium chloride was added to quench, and the mixture was extracted with ethyl acetate (10 ml x 2 times). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product, which was purified by silica gel column chromatography (eluent: ethyl acetate / n-hexane = 1 / 1) to obtain 56 mg of colorless oily liquid (S)-2-(((7-((4-chloro-2-fluorobenzyl)oxy)-1,2,4,5-tetrahydro-3H-benzo[d]azepin-3-yl)methyl)-1-((oxetane-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (yield: 24%). LC-MS: RT = 1.84 min, [M+H] + =564.29.

[0209] Step F: Synthesis of (S)-2-((7-((4-chloro-2-fluorobenzyl)oxy)-1,2,4,5-tetrahydro-3H-benzo[d]azepine -3-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0210]

[0211] (S)-2-(((7-((4-chloro-2-fluorobenzyl)oxy)-1,2,4,5-tetrahydro-3H-benzo[d]azepine -3-yl)methyl)-1-((oxetane-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (56 mg, 0.10 mmol) was dissolved in a mixed solvent (7 ml, tetrahydrofuran / methanol / water = 5 / 1 / 1), lithium hydroxide (33 mg, 0.79 mmol) was added, and the temperature was raised to 40 degrees Celsius for reaction for 3 hours. After the reaction was completed, saturated ammonium chloride was added to quench, and the reaction was successively extracted with ethyl acetate (10 ml × 2 times) and a mixed solvent (10 ml × 2 times, dichloromethane / methanol = 30 / 1). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was prepared by high performance liquid chromatography to obtain 19.95 mg of a white solid (S)-2-((7-((4-chloro-2-fluorobenzyl)oxy)-1,2,4,5-tetrahydro-3H-benzo[d]azepine -3-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (yield: 36%). LC-MS: RT = 1.79 min, [M+H] + =550.22. 1 H NMR (500 MHz, DMSO-d 6 )δ12.95(s, 1H),8.37(s,1H),7.93–7.88(m,1H),7.80(d,J=8.5Hz,1H),7.57(t,J=8.2Hz,1H),7.49(dd,J=10.0,1.9 Hz,1H),7.33(dd,J=8.2,1.8Hz,1H),7.13(d,J=8.3Hz,1H),6.91(d,J=2.3Hz,1H),6.86(dd,J=8.3,2.4 Hz,1H),5.10(s,2H),5.00(d,J=5.1Hz,1H),4.79(dd,J=15.5,7.2Hz,3H),4.68–4.62(m,1H),4.47(dd,J= 13.7,7.7Hz,1H),4.33(dt,J=8.9,6.0Hz,1H),3.59(s,4H),3.10(s,4H),2.74–2.67(m,1H),2.35–2.27(m,1H).

[0212] Example 6

[0213] Synthesis of (S)-2-((7-((4-cyano-2-fluorobenzyl)oxy)-1-oxo-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetane-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0214]

[0215] The specific synthetic route is as follows:

[0216] Step A: Synthesis of 3-fluoro-4-(((1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)oxy)methyl)benzonitrile

[0217]

[0218] At room temperature, 7-hydroxy-3,4-dihydroisoquinolin-2(1H)-one (300.0 mg, 1.8 mmol), 4-(bromomethyl)-3-fluorobenzonitrile (590.2 mg, 2.7 mmol), and potassium carbonate (508.0 mg, 3.7 mmol) were added to N,N-dimethylformamide (10 ml). The mixture was reacted at room temperature for 24 hours. After the reaction was complete, water (50 ml) was added for dilution, ethyl acetate (25 ml × 3 times) was used for extraction, saturated brine (50 ml × 1 time) was used for washing, and the mixture was dried over anhydrous sodium sulfate and finally concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 5 / 1) to obtain 450.0 mg of yellow oily 3-fluoro-4-(((1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)oxy)methyl)benzonitrile (yield: 82.4%). LC-MS: RT = 3.23 min, [M+H] + =297.20.

[0219] Step B: Synthesis of (S)-2-((7-((4-cyano-2-fluorobenzyl)oxy)-1-oxo-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester

[0220]

[0221] Under ice bath, compound 3-fluoro-4-(((1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)oxy)methyl)benzonitrile (101.0 mg, 357.5 μmol) was dissolved in dry tetrahydrofuran (10 ml), sodium hydride (249.2 mg, 1.8 mmol) was slowly added in batches, and the mixture was reacted at 0°C for 15 minutes. (S)-methyl 2-(chloromethyl)-1-((oxetane-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (116.2 mg, 393.3 μmol) was added, and the mixture was reacted at room temperature for 2 hours. After the reaction was complete, water (80 ml) was added for dilution, ethyl acetate (50 ml × 3 times) was used for extraction, saturated brine (50 ml × 1 time) was used for washing, dried over anhydrous sodium sulfate, and finally concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1 to dichloromethane / methanol = 10 / 1) to obtain 140.2 mg of light yellow solid (S)-2-((7-((4-cyano-2-fluorobenzyl)oxy)-1-oxo-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (yield: 75.2%). LC-MS: RT = 2.85 min, [M+H] + =555.46.

[0222] Step C: Synthesis of (S)-2-((7-((4-cyano-2-fluorobenzyl)oxy)-1-oxo-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0223]

[0224] At room temperature, compound (S)-2-((7-((4-cyano-2-fluorobenzyl)oxy)-1-oxo-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetane-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (160.2 mg, 296.3 μmol) was dissolved in tetrahydrofuran (10 ml) and water (3 ml), sodium hydroxide (118.5 mg, 0.3 mmol) was added, and the mixture was reacted at room temperature for 48 hours. After the reaction was completed, 1 mol / L citric acid aqueous solution was added dropwise to the reaction solution until the pH of the solution reached 5, and water (50 ml) was added to dilute the mixture, and ethyl acetate (25 ml × 3 times) was used for extraction, and saturated brine (25 ml × 1 time) was used for washing, drying over anhydrous sodium sulfate, and filtering. Concentration under reduced pressure was performed. The obtained residue was further purified by reverse phase HPLC (mobile phase: water / acetonitrile = 90 / 10 to 5 / 95) and lyophilized to give 50.1 mg of white solid ((S)-2-((7-((4-cyano-2-fluorobenzyl)oxy)-1-oxo-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (yield: 43.6%). LC-MS: RT = 1.99 min, [M+H] + =541.12.

[0225] Example 7

[0226] Synthesis of 2-((7-((4-chloro-2-fluorobenzyl)oxy)-1,2,3,4-tetrahydronaphthalen-2-yl)methyl)-1-(((S)oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0227]

[0228] The specific synthetic route is as follows:

[0229] Step A: Synthesis of ethyl 2-(7-methoxy-3,4-dihydronaphthalen-2-yl)acetate

[0230]

[0231] 7-Methoxy-3,4-dihydronaphthalen-2(1H)-one (5 g, 0.028 mol) and ethoxycarbonylmethylenetriphenylphosphine (9.88 g, 0.028 mol) were dissolved in toluene (100 ml) and heated to 120 degrees Celsius under nitrogen protection for 12 hours. After the reaction, the mixture was cooled and concentrated. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 20 / 1) to obtain 1.96 g of colorless oily ethyl 2-(7-methoxy-3,4-dihydronaphthalen-2-yl)acetate (yield: 28%). LC-MS: RT = 1.386 min, [M+H] + =247.1.

[0232] Step B: Synthesis of ethyl 2-(7-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)acetate

[0233]

[0234] Dissolve ethyl 2-(7-methoxy-3,4-dihydronaphthalen-2-yl)acetate (1 g, 4.06 mmol) in ethanol (50 ml), then add palladium carbon (10%, 100 mg). React at room temperature for 12 hours under 1 atmosphere of hydrogen. After the reaction is completed, filter and rinse with ethanol (50 ml). The filtrate is concentrated to obtain 0.96 g of colorless oily ethyl 2-(7-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)acetate (yield: 95%). LC-MS: RT = 1.371 min, [M+H] + =249.2.

[0235] Step C: Synthesis of ethyl 2-(7-hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)acetate

[0236]

[0237] Ethyl 2-(7-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)acetate (250 mg, 1.068 mmol) was dissolved in dichloromethane (10 ml), cooled to zero degrees, and boron tribromide (0.3 ml, 3.204 mmol) was added dropwise. The mixture was reacted at zero degrees for 0.5 hours. After the reaction was completed, methanol (5 ml) was added dropwise at zero degrees, and water (100 ml) was added for dilution. Dichloromethane (50 ml × 2 times) was used for extraction, and the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 5 / 1) to obtain 0.68 g of colorless oily ethyl 2-(7-hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)acetate (yield: 28%). LC-MS: RT = 1.264 min, [M+Na] + =257.1.

[0238] Step D: Synthesis of ethyl 2-(7-((4-chloro-2-fluorobenzyl)oxy)-1,2,3,4-tetrahydronaphthalen-2-yl)acetate

[0239]

[0240] Ethyl 2-(7-hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)acetate (250 mg, 1.068 mmol) was dissolved in N,N-dimethylformamide (5 ml), and 1-(bromomethyl)-4-chloro-2-fluorobenzene (284 mg, 1.281 mmol), potassium carbonate (442 mg, 3.204 mmol) and potassium iodide (177 mg, 1.068 mmol) were added. The mixture was reacted under nitrogen protection at room temperature for 0.5 hour. After the reaction, water (100 ml) was added for dilution, and ethyl acetate (50 ml x 2 times) was used for extraction. The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated, and the residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 10 / 1) to obtain 400 mg of colorless oily ethyl 2-(7-((4-chloro-2-fluorobenzyl)oxy)-1,2,3,4-tetrahydronaphthalen-2-yl)acetate (yield: 99%). LC-MS: RT = 1.477 min, [M+Na] + =399.1.

[0241] Step E: Synthesis of 2-(7-((4-chloro-2-fluorobenzyl)oxy)-1,2,3,4-tetrahydronaphthalen-2-yl)acetic acid

[0242]

[0243] Ethyl 2-(7-((4-chloro-2-fluorobenzyl)oxy)-1,2,3,4-tetrahydronaphthalen-2-yl)acetate (360 mg, 0.957 mmol) was dissolved in tetrahydrofuran (3 ml), ethanol (3 ml), water (2 ml) and lithium hydroxide (230 mg, 9.57 mmol) were added, and the temperature was raised to 60 degrees Celsius for 0.5 hours. After the reaction was completed, water (100 ml) was added to dilute and the organic solvent was removed by concentration. Potassium hydrogen sulfate (1.49 g, 11 mmol) was added under ice bath to adjust the pH value to 3, and ethyl acetate (50 ml × 2 times) was used for extraction. The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated to obtain 330 mg of 2-(7-((4-chloro-2-fluorobenzyl)oxy)-1,2,3,4-tetrahydronaphthalen-2-yl)acetic acid as a white solid (yield: 99%). LC-MS: RT = 1.376 min, [M + H] + =349.1.

[0244] Step F: Synthesis of methyl 2-((7-((4-chloro-2-fluorobenzyl)oxy)-1,2,3,4-tetrahydronaphthalen-2-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate

[0245]

[0246] 2-(7-((4-chloro-2-fluorobenzyl)oxy)-1,2,3,4-tetrahydronaphthalen-2-yl)acetic acid (120 mg, 0.344 mmol), (S)-methyl 4-amino-3-(((oxetan-2-yl)methyl)amino)benzoate (50 mg, 0.211 mmol), 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (196 mg, 0.516 mmol) and N,N-diisopropylethylamine (90 mg, 0.688 mmol) were dissolved in N,N-dimethylformamide (5 ml) and reacted at 80°C for 1 hour.

[0247] After the reaction is completed, water (100 ml) is added for dilution, and ethyl acetate (50 ml x 2 times) is used for extraction. The organic phases are combined, washed with saturated brine, and dried over anhydrous sodium sulfate. The intermediate obtained by filtration and concentration is dissolved in toluene (5 ml), acetic acid (1 ml) is added, and the mixture is heated to 120 degrees under nitrogen protection and reacted for 5 hours.

[0248] After the reaction was completed, the temperature was lowered to room temperature, and the reaction solution was poured into an ice-water solution of sodium bicarbonate (100 ml), and extracted with ethyl acetate (50 ml x 2 times). The organic phases were combined, washed with saturated brine, and dried over anhydrous sodium sulfate. The residue obtained after filtration and concentration was purified by silica gel column chromatography (eluent: 100% ethyl acetate) to obtain 100 mg of white solid 2-((7-((4-chloro-2-fluorobenzyl)oxy)-1,2,3,4-tetrahydronaphthalen-2-yl)methyl)-1-(((S)-oxetaned-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (yield: 86%). LC-MS: RT = 1.532 min, [M+H] + =549.1.

[0249] Step G: Synthesis of 2-((7-((4-chloro-2-fluorobenzyl)oxy)-1,2,3,4-tetrahydronaphthalen-2-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0250]

[0251] Methyl 2-((7-((4-chloro-2-fluorobenzyl)oxy)-1,2,3,4-tetrahydronaphthalen-2-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (100 mg, 0.182 mmol) was dissolved in tetrahydrofuran (5 ml), and ethanol (5 ml), water (3 ml) and lithium hydroxide (50 mg, 1.82 mmol) were added, and the mixture was reacted at 60 degrees Celsius for 0.5 hours.

[0252] After the reaction, water (100 ml) was added to dilute, and the organic solvent was removed by concentration. Potassium hydrogen sulfate (272 mg, 2.00 mmol) was added under ice bath to adjust the pH value to 3, and the mixture was purified by reverse phase flash column chromatography (0.1% formic acid / acetonitrile / water) to obtain 39.6 mg of brown solid 2-((7-((4-chloro-2-fluorobenzyl)oxy)-1,2,3,4-tetrahydronaphthalen-2-yl)methyl)-1-(((S)-oxetane-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (yield: 41%). LC-MS: RT = 1.282 min, [M+H] + =535.0. 1 H NMR (400 MHz, DMSO-d 6 )δ12.73(s,1H),8.18(s,1H),7.76 (dd,J=8.4,1.5Hz,1H),7.59(d,J=8.4Hz,1H),7.52(t,J=8.2Hz,1H),7.45(dd,J=10.0,2.0Hz,1H),7.2 9(dd,J=8.2,1.9Hz,1H),6.96(d,J=8.4Hz,1H),6.75–6.62(m,2H),5.07–4.93(m,3H),4.62(dd,J=15.5, 7.1Hz,1H),4.53–4.38(m,2H),4.29–4.25(m,1H),3.02–2.81(m,3H),2.75–2.61(m,3H),2.55–2.51(m,1H), 2.42–2.29(m,2H),1.95(d,J=10.9Hz,1H),1.54–1.41(m,1H).

[0253] Example 8

[0254] Synthesis of (S)-2-((7-(4-chlorophenethoxy)-1-oxo-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((-oxetane-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0255]

[0256] The specific synthetic route is as follows:

[0257] Step A: Synthesis of 7-(4-chlorophenethoxy)-3,4-dihydroisoquinolin-1(2H)-one

[0258]

[0259] At room temperature, 7-hydroxy-3,4-dihydroisoquinolin-2(1H)-one (200.2 mg, 1.2 mmol), 1-(2-bromoethyl)-4-chlorobenzene (878.52 mg, 4.9 mmol) and potassium carbonate (681.1 mg, 4.9 mmol) were added to N,N-dimethylformamide (10 ml). The mixture was reacted at room temperature for 24 hours. After the reaction was complete, water (50 ml) was added for dilution, and ethyl acetate (25 ml × 3 times) was used for extraction. The organic layers were combined, washed with saturated brine (50 ml × 1 time), dried over anhydrous sodium sulfate, and finally concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 5 / 1) to obtain 202.0 mg of yellow oily 7-(4-chlorophenethoxy)-3,4-dihydroisoquinolin-1(2H)-one (yield: 54.6%). LC-MS: RT = 3.23 min, [M+H] + =302.06.

[0260] Step B: Synthesis of (S)-2-((7-(4-chlorophenethoxy)-1-oxo-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetane-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester

[0261]

[0262] Under ice bath, compound 7-(4-chlorophenethoxy)-3,4-dihydroisoquinolin-1(2H)-one (120.5 mg, 0.4 mmol) was dissolved in dry tetrahydrofuran (10 ml), sodium hydride (56.2 mg, 1.4 mmol) was slowly added, and the mixture was reacted at 0°C for 15 minutes. (S)-2-(chloromethyl)-1-((oxetane-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (116 mg, 393.3 μmol) was added, and the mixture was reacted at room temperature for 2 hours. After the reaction was complete, water (80 ml) was added to dilute the mixture, and ethyl acetate (50 ml × 3 times) was used for extraction. The organic phases were combined, washed with saturated brine (50 ml × 1 time), dried over anhydrous sodium sulfate, and finally concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1 to dichloromethane / methanol = 10 / 1) to obtain 210.2 mg of light yellow solid (S)-2-((7-(4-chlorophenethoxy)-1-oxo-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (yield: 62.9%). LC-MS: RT = 3.40 min, [M+H] + =560.26.

[0263] Step C: Synthesis of (S)-2-((7-(4-chlorophenethoxy)-1-oxo-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetane-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0264]

[0265] At room temperature, compound (S)-2-((7-(4-chlorophenethoxy)-1-oxo-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetane-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (160.2 mg, 296.3 μmol) was dissolved in tetrahydrofuran (10 ml) and water (3 ml) solution, sodium hydroxide (118.5 mg, 0.3 mmol) was added, and the mixture was reacted at room temperature for 48 hours. After the reaction was completed, 1 mol citric acid aqueous solution was added dropwise until the pH of the solution reached 5, and water (50 ml) was added for dilution, and ethyl acetate (25 ml × 3 times) was used for extraction. The organic layers were combined, washed with saturated brine (25 ml × 1 time), dried over anhydrous sodium sulfate, and finally concentrated under reduced pressure. The obtained residue was further purified by reverse phase HPLC (mobile phase: water / acetonitrile = 90 / 10 to 5 / 95) and lyophilized to give 73.1 mg of white solid (S)-2-((7-(4-chlorophenethoxy)-1-oxo-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (yield: 43.6%). LC-MS: RT = 2.73 min, [M+H] + =546.26.

[0266] Example 9

[0267] Synthesis of 2-((7-((4-cyano-2-fluorobenzyl)oxy)-1,2,3,4-tetrahydronaphthalen-2-yl)amino)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0268]

[0269] The specific synthetic route is as follows:

[0270] Step A: Synthesis of 7-hydroxy-3,4-dihydronaphthalen-2(1H)-one

[0271]

[0272] At room temperature, 7-methoxy-2-tetralone (3.0 g, 14.7 mmol) was added to a hydrobromic acid aqueous solution (48 wt.%, 21.8 g, 129.3 mmol) and reacted at 90 degrees Celsius for 16 hours. After the reaction, the temperature was lowered to 5 degrees Celsius, and a 50% sodium hydroxide aqueous solution was slowly added to adjust the pH value to 2-3. The mixture was extracted with ethyl acetate (100 ml x 2 times), and the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and finally concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 2 / 1) to obtain 1.2 g of light yellow solid 7-hydroxy-3,4-dihydronaphthalene-2(1H)-one (yield: 50%). 1 H NMR (400 MHz, CDCl 3 )δ7.09(d,J=8.1Hz,1H),6.69(dd,J=8.1,2.6Hz,1H),6.62(d,J=2.5Hz,1H),3.53(s,2H),2.99(t,J=6.6Hz,2H),2.57–2.51(m,2H).

[0273] Step B: Synthesis of 1,2,3,4-tetrahydronaphthalene-2,7-diol

[0274]

[0275] At room temperature, 7-hydroxy-3,4-dihydronaphthalene-2(1H)-one (900 mg, 5.55 mmol) was dissolved in anhydrous ethanol (10 ml), and sodium borohydride (420 mg, 11.1 mmol) was added in batches. After the addition, the mixture was reacted at room temperature for 1 hour. After the reaction was completed, saturated aqueous ammonium chloride solution was added to quench the mixture, and the mixture was extracted with ethyl acetate (20 ml × 2 times). The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and finally concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 2 / 1) to obtain 750 mg of white solid 1,2,3,4-tetrahydronaphthalene-2,7-diol (yield: 82%). 1 HNMR (400MHz, CDCl 3 )δ6.96(d,J=8.2Hz,1H),6.62(dd,J=8.2,2.6Hz,1H), 6.56(d,J=2.5Hz,1H),4.20–4.11(m,1H),3.03(dd,J=16.4,5.0Hz,1H),2.92–2.81(m,1H),2.81–2.68(m, 2H),2.07–1.99(m,1H),1.85–1.76(m,1H).

[0276] Step C: Synthesis of 3-fluoro-4-((7-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)oxy)methyl)benzonitrile

[0277]

[0278] At room temperature, 1,2,3,4-tetrahydronaphthalene-2,7-diol (300 mg, 1.83 mmol) was dissolved in N,N-dimethylformamide (6 ml), and potassium carbonate (505 mg, 3.65 mmol), 4-(bromomethyl)-3-fluorobenzonitrile (430 mg, 2.01 mmol) and potassium iodide (30 mg, 0.18 mmol) were added. After the addition, the mixture was reacted at room temperature for 1 hour.

[0279] After the reaction, ethyl acetate (50 ml) was added for extraction, washed with saturated brine, dried over anhydrous sodium sulfate, and finally concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 2 / 1) to obtain 280 mg of yellow oily 3-fluoro-4-((7-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)oxy)methyl)benzonitrile (yield: 51%). 1 H NMR (400 MHz, CDCl 3 )δ7.68(t,J=7.5Hz,1H), 7.49(dd,J=8.0,1.3Hz,1H),7.38(dd,J=9.3,1.4Hz,1H),7.03(d,J=8.4Hz,1H), 6.75(dd,J=8.4,2.7Hz, 1H),6.69(d,J=2.6Hz,1H),5.15(s,2H),4.20–4.14(m,1H),3.06(dd,J=16.3,4.9H z,1H),2.94–2.86(m,1H),2.83–2.70(m,2H),2.07–1.96(m,1H),1.84–1.80(m,1H).

[0280] Step D: Synthesis of 3-fluoro-4-(((7-oxo-5,6,7,8-tetrahydronaphthalen-2-yl)oxy)methyl)benzonitrile

[0281]

[0282] At room temperature, 3-fluoro-4-((7-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)oxy)methyl)benzonitrile (280 mg, 1.01 mmol) was dissolved in dichloromethane (6 ml), and pyridinium chlorochromate (435 mg, 2.02 mmol) was added in batches. After the addition, the reaction was allowed to proceed at room temperature for 2 hours. After the reaction was completed, the mixture was filtered and washed with dichloromethane (10 ml x 2 times). The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1) to obtain 80 mg of yellow oily 3-fluoro-4-(((7-oxo-5,6,7,8-tetrahydronaphthalen-2-yl)oxy)methyl)benzonitrile (yield: 27%). LC-MS: RT = 1.393 min, [M+H] + =296.0

[0283] Step E: Synthesis of (S)-methyl 4-(2-((tert-butyloxycarbonyl)amino)acetamido)-3-(((oxetane-2-yl)methyl)amino)benzoate

[0284]

[0285] At room temperature, (S)-methyl 4-amino-3-(((oxetane-2-yl)methyl)amino)benzoate (100 mg, 0.42 mmol) was dissolved in N,N-dimethylformamide (2 ml), and (tert-butyloxycarbonyl)glycine (89 mg, 0.51 mmol), 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (321 mg, 0.85 mmol) and N,N-diisopropylethylamine (109 mg, 0.85 mmol) were added. After the addition, the mixture was reacted at room temperature for 1 hour. After the reaction, ethyl acetate (50 ml) was added for extraction, washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated. The obtained residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 2 / 1) to obtain 90 mg of yellow solid (S)-methyl 4-(2-((tert-butyloxycarbonyl)amino)acetamido)-3-(((oxetane-2-yl)methyl)amino)benzoate (yield: 54%). LC-MS: RT = 1.144 min, [M+H] + =394.1

[0286] Step F: Synthesis of (S)-methyl 2-(((tert-butyloxycarbonyl)amino)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate

[0287]

[0288] At room temperature, (S)-methyl 4-(2-((tert-butyloxycarbonyl)amino)acetamido)-3-(((oxetan-2-yl)methyl)amino)benzoate (80 mg, 0.20 mmol) was added to toluene (2 ml), and acetic acid (61 mg, 1.02 mmol) was added. After the addition, the temperature was raised to 80 degrees Celsius for 5 hours.

[0289] After the reaction was completed, ethyl acetate (50 ml) was added for extraction. The mixture was washed with saturated sodium bicarbonate aqueous solution (20 ml × 2 times) and saturated brine (20 ml × 2 times), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1) to obtain 60 mg of yellow solid (S)-2-(((tert-butyloxycarbonyl)amino)methyl)-1-((oxetane-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (yield: 80%). LC-MS: RT = 1.046 min, [M+H] + =376.1.

[0290] Step G: Synthesis of (S)-methyl 2-(aminomethyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate

[0291]

[0292] At room temperature, (S)-methyl 2-(((tert-butyloxycarbonyl)amino)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (60 mg, 0.22 mmol) was dissolved in dichloromethane (2 ml), and trifluoroacetic acid (0.4 ml) was added. The mixture was reacted at room temperature for 1 hour.

[0293] After the reaction, the mixture was diluted with dichloromethane (10 ml), washed with saturated sodium bicarbonate aqueous solution (10 ml x 2 times) and saturated brine (10 ml), dried over anhydrous sodium sulfate, and concentrated to give 50 mg of yellow solid (S)-2-(aminomethyl)-1-((oxetane-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (yield: 83%). LC-MS: RT = 0.698 min, [M+H] + =276.0.

[0294] Step H: Synthesis of methyl 2-(((7-((4-cyano-2-fluorobenzyl)oxy)-1,2,3,4-tetrahydronaphthalen-2-yl)amino)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate

[0295]

[0296] At room temperature, (S)-2-(aminomethyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (30 mg, 0.11 mmol) was dissolved in dichloromethane (2 ml), and 3-fluoro-4-(((7-oxo-5,6,7,8-tetrahydronaphthalen-2-yl)oxy)methyl)benzonitrile (32 mg, 0.11 mmol) and acetic acid (0.01 ml) were added. After the addition, the mixture was reacted at room temperature for 0.5 hour, and sodium triacetylborohydride (35 mg, 0.16 mmol) was added, and the mixture was reacted at room temperature for 16 hours.

[0297] After the reaction, the mixture was diluted with dichloromethane (10 ml), washed with saturated sodium bicarbonate aqueous solution (10 ml × 2 times) and saturated brine (10 ml × 2 times), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 5 / 1) to obtain 28 mg of yellow solid 2-(((7-((4-cyano-2-fluorobenzyl)oxy)-1,2,3,4-tetrahydronaphthalen-2-yl(amino)methyl)-1-(((S)-oxetane-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (yield: 46%). LC-MS: RT = 1.252 min, [M+H] + =555.2.

[0298] Step I: Synthesis of 2-(((7-((4-cyano-2-fluorobenzyl)oxy)-1,2,3,4-tetrahydronaphthalen-2-yl)amino)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0299]

[0300] At room temperature, methyl 2-(((7-((4-cyano-2-fluorobenzyl)oxy)-1,2,3,4-tetrahydronaphthalen-2-yl)amino)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (28 mg, 0.05 mmol) was dissolved in tetrahydrofuran (1 ml), and isopropanol (1 ml), water (0.5 ml) and anhydrous lithium hydroxide (12 mg, 0.51 mmol) were added. After the addition, the reaction was carried out at room temperature for 5 hours.

[0301] After the reaction, the pH value was adjusted to 2-3 with dilute hydrochloric acid (1 M) and purified by Pre-HPLC (0.1% trifluoroacetic acid / acetonitrile / water) to obtain 2.4 mg of white solid 2-(((7-((4-cyano-2-fluorobenzyl)oxy)-1,2,3,4-tetrahydronaphthalen-2-yl)amino)methyl)-1-(((S)-oxetane-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (yield: 9%). LC-MS: RT = 1.202 min, [M+H] + =541.2. 1 H NMR (400MHz, CD 3 OD)δ8.32(s,1H),8.02(d,J=8.5Hz,1H),7.79(d,J=8.5Hz,1H),7.72(t,J=7.6Hz,1H),7.60(dd,J =7.6,5.8Hz,2H),7.09(d,J=8.5Hz,1H),6.87(d,J=8.4Hz,1H),6.81(s,1H),5.22–5.20(m,3H),4.75–4.71( m,1H),4.66–4.60(m,3H),4.42–4.32(m,2H),3.81–3.71(s,2H),3.02–2.78(m,5H),2.51–2.38(m,2H),1.95– 1.91(m,1H),1.33–1.29(m,1H).

[0302] Example 10

[0303] Synthesis of (S)-2-(((7-(4-chlorophenethoxy)-1,2,4,5-tetrahydro-3H-benzo[d]azepine -3-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0304]

[0305] The specific synthetic route is as follows:

[0306] Step A: Synthesis of 7-((4-chlorophenyl)acetoxy)-3-((trifluoromethyl)sulfonyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine

[0307]

[0308] 3-((Trifluoromethyl)sulfonyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol (380 mg, 1.29 mmol) was dissolved in N,N-dimethylformamide (10 ml) at room temperature, 2-bromo-1-(4-chlorophenyl)ethan-1-one (300 mg, 1.29 mmol) was added, and potassium carbonate (356 mg, 2.58 mmol) was added, and the mixture was reacted at room temperature for 3 hours.

[0309] After the reaction was completed, saturated sodium chloride was added to quench, and the mixture was extracted with ethyl acetate (10 ml x 2 times). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated. The crude product was purified by silica gel column chromatography (eluent: ethyl acetate / n-hexane = 1 / 1) to obtain 295 mg of white solid synthetic 7-((4-chlorophenyl)acetoxy)-3-((trifluoromethyl)sulfonyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (yield: 53%). LC-MS: RT = 2.20 min.

[0310] Step B: Synthesis of 7-(4-chlorophenethoxy)-2,3,4,5-tetrahydro-1H-benzo[d]azepine

[0311]

[0312] 7-((4-chlorophenyl)acetoxy)-3-((trifluoromethyl)sulfonyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (95 mg, 0.21 mmol) was dissolved in tetrahydrofuran (3 ml) at room temperature, cooled to zero degrees Celsius, and a tetrahydrofuran solution of lithium aluminum hydroxide (9 mg, 0.21 mmol) and aluminum trichloride (28 mg, 0.21 mmol) was added, and the mixture was reacted at room temperature for 2 hours.

[0313] After the reaction was completed, saturated sodium chloride was added to quench, extracted with ethyl acetate (20 ml), washed twice with water, dried over anhydrous sodium sulfate, and concentrated to obtain 48 mg of white solid 7-(4-chlorophenethoxy)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (yield: 76%). LC-MS: RT = 2.16 min, [M+Na] + =324.44.

[0314] Step C: Synthesis of (S)-2-(((7-(4-chlorophenethoxy)-1,2,4,5-tetrahydro-3H-benzo[d]azepine -3-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester

[0315]

[0316] 7-(4-Chlorophenethoxy)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (38 mg, 0.12 mmol) was dissolved in N,N-dimethylformamide (5 ml) at room temperature, (S)-methyl 2-(chloromethyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (37 mg, 0.12 mmol) was added, and cesium carbonate (81 mg, 0.25 mmol) was added, and the mixture was reacted at room temperature for 3 hours.

[0317] After the reaction was completed, saturated sodium chloride was added to quench the reaction, and the reaction was extracted with ethyl acetate (10 ml × 2 times). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated. The crude product was purified by silica gel column chromatography (eluent: ethyl acetate / n-hexane = 1 / 1) to give 43 mg of white solid (S)-2-(((7-(4-chlorophenethoxy)-1,2,4,5-tetrahydro-3H-benzo[d]azepin-3-yl)methyl)-1-((oxetane-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (yield: 64%).

[0318] Step D: Synthesis of (S)-2-(((7-(4-chlorophenethoxy)-1,2,4,5-tetrahydro-3H-benzo[d]azepin-3-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0319]

[0320] At room temperature, ((S)-2-(((7-(4-chlorophenethoxy)-1,2,4,5-tetrahydro-3H-benzo[d]azepin-3-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (43 mg, 0.08 mmol) was dissolved in a mixed solvent (7 ml, tetrahydrofuran / methanol / water = 3 / 3 / 1), lithium hydroxide (32 mg, 0.78 mmol) was added, and the temperature was raised to 40°C for reaction for 3 hours.

[0321] After the reaction, saturated ammonium chloride was added to quench, and the reaction was extracted with ethyl acetate (10 ml × 2 times), and then with a mixed solvent (10 ml × 2 times, dichloromethane / methanol = 30 / 1). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated. The crude product was prepared by high performance liquid chromatography to obtain 10.18 mg of a white solid synthesis of (S)-2-(((7-(4-chlorophenethoxy)-1,2,4,5-tetrahydro-3H-benzo[d]azepin-3-yl)methyl)-1-((oxetane-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (yield: 24%). LC-MS: RT = 2.11 min.

[0322] Embodiment 11

[0323] Synthesis of (S)-2-((7-(4-chloro-2-fluorophenethoxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetane-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0324]

[0325] The specific synthetic route is as follows:

[0326] Step A: Synthesis of 2,2,2-trifluoro-N-(4-fluorophenethyl)acetamide

[0327]

[0328] 2-(4-Fluorophenyl)ethane-1-amine (5.0 g, 36 mmol) and triethylamine (9.1 g, 90 mmol) were dissolved in 2-dichloromethane (100 ml), trifluoroacetic anhydride (9.0 g, 43 mmol) was added dropwise under ice bath, and the mixture was naturally heated to room temperature and reacted for 3 hours.

[0329] After the reaction, the reaction solution was poured into ice water, extracted with ethyl acetate (300 ml x 3 times), washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated to obtain 8.0 g of colorless oily 2,2,2-trifluoro-N-(4-fluorophenethyl)acetamide (yield: 94%). LC-MS: RT = 1.350 min, [M+H] + =236.1.

[0330] Step B: Synthesis of 2,2,2-trifluoro-1-(7-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)ethan-1-one

[0331]

[0332] 2,2,2-Trifluoro-N-(4-fluorophenethyl)acetamide (8.0 g, 34 mmol) and paraformaldehyde (1.6 g, 51 mmol) were dissolved in acetic acid (50 ml), and concentrated sulfuric acid (34 ml, 612 mmol) was added dropwise under ice bath. After the addition was completed, the mixture was heated to room temperature and reacted for 8 hours.

[0333] After the reaction, the reaction solution was carefully poured into ice water to quench, extracted with ethyl acetate (300 ml x 3 times), combined, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and the resulting residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 20 / 1) to obtain 5.5 g of white solid 2,2,2-trifluoro-1-(7-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)ethan-1-one (yield: 65%). LC-MS: RT = 1.426 min, [M+H] + =248.0.

[0334] Step C: Synthesis of 2,2,2-trifluoro-1-(7-fluoro-8-nitro-3,4-dihydroisoquinolin-2(1H)-yl)ethan-1-one

[0335]

[0336] 2,2,2-Trifluoro-1-(7-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)ethane-1-one (2.5 g, 10.1 mmol) was dissolved in concentrated sulfuric acid (10 ml), cooled to zero degrees Celsius under nitrogen protection, and fuming nitric acid (1.9 g, 30.3 mmol) was added. The mixture was reacted in an ice bath for 1 hour. After the reaction was completed, the reaction solution was carefully poured into ice water to quench, extracted with ethyl acetate (300 ml × 3 times), combined, washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated. The crude product was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 10 / 1) to obtain 1.0 g of yellow solid 2,2,2-trifluoro-1-(7-fluoro-8-nitro-3,4-dihydroisoquinolin-2(1H)-yl)ethane-1-one (yield: 34%). LC-MS: RT = 1.389 min, [M + H] + =293.0.

[0337] Step D: Synthesis of 7-(4-chloro-2-fluorophenethoxy)-8-nitro-3,4-dihydroisoquinoline

[0338]

[0339] Dissolve 2,2,2-trifluoro-1-(7-fluoro-8-nitro-3,4-dihydroisoquinolin-2(1H)-yl)ethan-1-one (1 g, 3.4 mmol) in tetrahydrofuran (20 ml), add sodium hydride (60%, 410 mg, 10.2 mmol) under ice bath, react for 0.5 hour under ice bath, add 2-(4-chloro-2-fluorophenyl)ethan-1-ol (710 mg, 4.1 mmol) dropwise, and after completion of dropwise addition, warm to room temperature and react for 1 hour.

[0340] After the reaction was completed, saturated aqueous ammonium chloride solution was used for quenching, and ethyl acetate (50 ml x 3 times) was used for extraction. The mixture was combined, washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated. The crude product was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 3 / 2) to obtain 300 mg of yellow solid 7-(4-chloro-2-fluorophenethoxy)-8-nitro-3,4-dihydroisoquinoline (yield: 25%). LC-MS: RT = 1.281 min, [M+H] + =349.1.

[0341] Step E: Synthesis of 7-(4-chloro-2-fluorophenethoxy)-3,4-dihydroisoquinolin-8-amine

[0342]

[0343] 7-(4-chloro-2-fluorophenethoxy)-8-nitro-3,4-dihydroisoquinoline (300 mg, 0.86 mmol) was dissolved in methanol (15 ml), and ammonium chloride (456 mg, 8.6 mmol) and reduced iron powder (481 mg, 8.6 mmol) were added, and the temperature was raised to 65 °C for 18 hours.

[0344] After the reaction, the mixture was cooled to room temperature, extracted with ethyl acetate (50 ml x 3 times) and saturated sodium bicarbonate aqueous solution, combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated, and the obtained crude product was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 20 / 1) to obtain 200 mg of yellow solid 7-(4-chloro-2-fluorophenethoxy)-3,4-dihydroisoquinolin-8-amine (yield: 73%). LC-MS: RT = 1.134 min, [M+H] + =319.0.

[0345] Step F: Synthesis of 8-bromo-7-(4-chloro-2-fluorophenethoxy)-3,4-dihydroisoquinoline

[0346]

[0347] 7-(4-chloro-2-fluorophenethoxy)-3,4-dihydroisoquinolin-8-amine (200 mg, 0.63 mmol) was dissolved in acetonitrile (5 ml), added to a solution of cuprous bromide (180 mg, 1.26 mmol) and tert-butyl nitrite (130 mg, 1.26 mmol) in acetonitrile (10 ml), and the temperature was raised to 50 °C for reaction for 1 hour.

[0348] After the reaction, the mixture was cooled to room temperature, extracted with ethyl acetate (50 ml x 3 times) and saturated sodium bicarbonate aqueous solution, combined, washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated. The crude product was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 3 / 1) to obtain 50 mg of yellow solid 8-bromo-7-(4-chloro-2-fluorophenethoxy)-3,4-dihydroisoquinoline (yield: 21%). LC-MS: RT = 1.267 min, [M+H] + = 383.9.

[0349] Step G: Synthesis of 7-(4-chloro-2-fluorophenethoxy)-1,2,3,4-tetrahydroisoquinoline

[0350]

[0351] 8-Bromo-7-(4-chloro-2-fluorophenethoxy)-3,4-dihydroisoquinoline (50 mg, 0.13 mmol) was dissolved in methanol (10 ml), palladium chloride (50 mg, 0.28 mmol) was added and reacted at room temperature under 1 atmospheric pressure of hydrogen for 1 hour.

[0352] After the reaction was completed, the mixture was filtered and concentrated to obtain 38 mg of colorless oily 7-(4-chloro-2-fluorophenethoxy)-1,2,3,4-tetrahydroisoquinoline (yield: 92%). LC-MS: RT = 1.141 min, [M+H] + =306.1.

[0353] Step H: Synthesis of (S)-2-((7-(4-chloro-2-fluorophenethoxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester

[0354]

[0355] 7-(4-Chloro-2-fluorophenethoxy)-1,2,3,4-tetrahydroisoquinoline (38 mg, 0.12 mmol) was dissolved in acetonitrile (15 ml), potassium carbonate (83 mg, 0.6 mmol) and (S)-methyl 2-(chloromethyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (38 mg, 0.13 mmol) were added, and the temperature was raised to 75 °C for 2 hours.

[0356] After the reaction, the mixture was extracted with ethyl acetate and saturated brine, dried over anhydrous sodium sulfate, and concentrated. The crude product was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 2 / 1) to obtain 20 mg of white solid (S)-2-((7-(4-chloro-2-fluorophenethoxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetane-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (yield: 30%). LC-MS: RT = 1.321 min, [M+H] + =564.1.

[0357] Step I: Synthesis of (S)-2-((7-(4-chloro-2-fluorophenethoxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0358]

[0359] (S)-2-((7-(4-chloro-2-fluorophenethoxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (15 mg, 0.027 mmol) was dissolved in methanol (5 ml) and water (5 ml), lithium hydroxide monohydrate (11 mg, 0.27 mmol) was added, and the temperature was raised to 50 °C for 1 hour.

[0360] After the reaction, the methanol was removed by concentration, the pH value was adjusted to 4 to 5 with 1M dilute hydrochloric acid, the product was extracted with ethyl acetate and dried over anhydrous sodium sulfate, concentrated, and purified by reverse phase column chromatography (0.1% formic acid / acetonitrile / water) to obtain 2.5 mg of a white solid (S)-2-((7-(4-chloro-2-fluorophenethoxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetane-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (yield: 17%). LC-MS: RT = 1.242 min, [M+H] + =550.1. 1 H NMR (400MHz, CD 3OD)δ8.31(d,J=0.8Hz,1H),7.97(dd,J=8.4,1.2Hz,1H),7.69 (d,J=8.4Hz,1H),7.31(t,J=8.4Hz,1H),7.17-7.06(m,2H),6.98(d,J=8.4Hz,1H),6.68(dd,J=8.4,2.4 Hz,1H),6.54(d,J=2.4Hz,1H),5.22-5.16(m,,1H),4.70(dd,J=15.2,2.8Hz,1H),4.61-4.55(m,2H), 4.44-4.39(m,1H),4.21-4.05(m,4H),3.71-3.62(m,2H),3.04(t,J=6.4Hz,2H),2.88-2.79(m,4H),2.73-2.66(m,1H),2.50-2.42(m,1H).

[0361] Example 12

[0362] Synthesis of (S)-2-((9-((4-cyano-2-fluorobenzyl)oxy)-2-oxo-1,2,4,5-tetrahydro-3H-benzo[d]azepine -3-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0363]

[0364] The specific synthetic route is as follows:

[0365] Step A: Synthesis of 3-fluoro-4-(((4-oxo-2,3,4,5-tetrahydro-1H-benzo[d]azepine -6-yl)oxy)methyl)benzonitrile

[0366]

[0367] At room temperature, 9-hydroxy-1,3,4,5-tetrahydro-2H-benzo[d]azepine -2-ketone (210.3 mg, 1.2 mmol) and 4-(bromomethyl)-3-fluorobenzonitrile (513.6 mg, 2.4 mmol) were dissolved in N,N-dimethylformamide (3 ml) solution, and anhydrous potassium carbonate (500.4 mg, 3.6 mmol) was added. The reaction was continued at room temperature overnight. After the reaction was complete, it was diluted with ethyl acetate (100 ml), washed with water (30 ml × 2 times) and saturated brine (30 ml × 1 time), dried over anhydrous sodium sulfate, and concentrated. The resulting residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1 to dichloromethane / methanol = 15 / 1) to obtain 256.3 mg of light yellow oily 3-fluoro-4-(((4-oxo-2,3,4,5-tetrahydro-1H-benzo[d]azepine -6-yl)oxy)methyl)benzonitrile (yield 71.2%).

[0368] Step B: Synthesis of (S)-2-((9-((4-cyano-2-fluorobenzyl)oxy)-2-oxo-1,2,4,5-tetrahydro-3H-benzo[d]azepine -3-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester

[0369]

[0370] 3-Fluoro-4-(((4-oxo-2,3,4,5-tetrahydro-1H-benzo[d]azepine 6-( ... The resulting residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1 to dichloromethane / methanol = 15 / 1) to obtain 52.3 mg of a pale yellow oily substance (S)-2-((9-((4-cyano-2-fluorobenzyl)oxy)-2-oxo-1,2,4,5-tetrahydro-3H-benzo[d]azepine. -3-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (yield 22.8%).

[0371] Step C: Synthesis of (S)-2-((9-((4-cyano-2-fluorobenzyl)oxy)-2-oxo-1,2,4,5-tetrahydro-3H-benzo[d]azepine -3-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0372]

[0373] (S)-2-((9-((4-cyano-2-fluorobenzyl)oxy)-2-oxo-1,2,4,5-tetrahydro-3H-benzo[d]azepine methyl)-1-((oxetane-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (52.3 mg, 92.1 μmol) was dissolved in tetrahydrofuran (6 ml), ethanol (2 ml) and water (2 ml) solution, sodium hydroxide (18.4 mg, 460.3 μmol) was added, and the mixture was reacted at room temperature for 24 hours. After the reaction was completed, 1 mol citric acid aqueous solution was added to adjust the pH to 5. Water (50 ml) was added for dilution, ethyl acetate (25 ml × 3 times) was used for extraction, the mixture was combined, washed with saturated brine (25 ml × 1 time), dried over anhydrous sodium sulfate, and concentrated. The resulting residue was further purified by reverse phase HPLC (mobile phase: (0.1% aqueous ammonia / water) / acetonitrile = 95 / 5 to 55 / 45) and lyophilized to give 9.3 mg of a white solid (S)-2-((9-((4-cyano-2-fluorobenzyl)oxy)-2-oxo-1,2,4,5-tetrahydro-3H-benzo[d]azepine. -3-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (yield: 18.6%). LC-MS: RT = 1.84 min, [M+H] + =555.29.

[0374] Embodiment 13

[0375] Synthesis of (S)-2-((6-((4-chloro-2-fluorobenzyl)oxy)-1,2,4,5-tetrahydro-3H-benzo[d]azepine -3-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0376]

[0377] The specific synthesis is as follows:

[0378] Step A: Synthesis of 9-bromo-1,3,4,5-tetrahydro-2H-benzo[d]azepine -2-Keto

[0379]

[0380] Under ice bath conditions, 8-bromo-3,4-dihydronaphthalene-2(1H)-one (1.0 g, 4.4 mmol) was dissolved in methanesulfonic acid (10 ml) solution, and sodium azide (314.6 mg, 4.8 mmol) was slowly added. The mixture was warmed to room temperature and reacted for 1 hour. After the reaction was complete, it was diluted with ethyl acetate (150 ml), washed with water (30 ml × 2 times), saturated sodium bicarbonate (30 ml × 2 times), and saturated brine (30 ml × 1 time), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1 to dichloromethane / methanol = 15 / 1) to obtain 764.3 mg of light yellow oily 9-bromo-1,3,4,5-tetrahydro-2H-benzo[d]azepine -2-ketone (yield 72.1%). LC-MS: RT = 3.29 min, [M+H] + =240.04.

[0381] Step B: Synthesis of 9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,4,5-tetrahydro-2H-benzo[d]azepine -2-Keto

[0382]

[0383] At room temperature, 9-bromo-1,3,4,5-tetrahydro-2H-benzo[d]azepine -2-one (764.3 mg, 3.2 mmol), bis(pinacol)diboron (1.6 g, 6.4 mmol), 2-dicyclohexylphospho-2,4,6-triisopropylbiphenyl (60.9 mg, 127.3 μmol) and potassium acetate (937.1 mg, 9.6 mmol) were dissolved in a dioxane (10 ml) solution. The mixture was replaced with nitrogen three times, and trisdibenzylideneacetone dipalladium (116.6 mg, 127.3 μmol, replaced with nitrogen three times) was added under nitrogen protection, and the mixture was reacted under reflux overnight. After the reaction was complete, the mixture was filtered, and the filtrate was diluted with ethyl acetate (150 ml), washed with water (30 ml × 2 times) and saturated brine (30 ml × 1 time), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1 to dichloromethane / methanol = 15 / 1) to obtain 809.2 mg of a light yellow oily mixture of 9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,4,5-tetrahydro-2H-benzo[d]azepine -2-ketone (yield 88.3%). LC-MS: RT = 4.22 min, [M+H] + =288.22. 1 H NMR (400 MHz, CDCl 3 )δ7.83– 7.74(m,1H),7.35(d,J=7.5Hz,1H),7.26(t,J=7.4Hz,1H),4.04(s,2H),3.10(t,J=6.7Hz,2H),2.59(t,J=6.7Hz,2H),1.38(s,13H).

[0384] Step C: Synthesis of 9-hydroxy-1,3,4,5-tetrahydro-2H-benzo[d]azepine -2-Keto

[0385]

[0386] At room temperature, 9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,4,5-tetrahydro-2H-benzo[d]azepine -2-ketone (809.2 mg, 2.8 mmol) was dissolved in tetrahydrofuran (10 ml). 1 mol sodium hydroxide aqueous solution (8 ml) and 30% hydrogen peroxide (2 ml) were slowly added. The reaction was allowed to react at room temperature for 2 hours. After the reaction was complete, the pH was adjusted to 6-7 with 1 mol hydrochloric acid aqueous solution at zero degrees Celsius. The mixture was extracted with ethyl acetate (30 ml × 3 times), the organic phases were combined, washed with saturated brine (30 ml × 1 time), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by reverse semi-preparative HPLC (mobile phase: (0.1% TFA / water) / acetonitrile = 95 / 5 to 55 / 45) to obtain 120.8 mg of light yellow oily 9-hydroxy-1,3,4,5-tetrahydro-2H-benzo[d]azepine -2-ketone (yield 35.9%). LC-MS: RT = 2.17 min, [M+H] + =178.19. 1 H NMR (400MHz, CD 3 OD) δ7.00 (q, J=7.4Hz, 1H), 6.74–6.62 (m, 2H), 3.97 (d, J=4.0Hz, 2H), 3.56 (q, J=6.0, 5.4Hz, 2H), 3.11 (q, J=5.2Hz, 2H).

[0387] Step D: Synthesis of 9-((4-chloro-2-fluorobenzyl)oxy)-1,3,4,5-tetrahydro-2H-benzo[d]azepine -2-Keto

[0388]

[0389] At room temperature, 9-hydroxy-1,3,4,5-tetrahydro-2H-benzo[d]azepine -2-ketone (90.2 mg, 0.5 mmol) and 2-fluoro-4-chlorobenzyl bromide (223.4 mg, 1.0 mmol) were dissolved in N,N-dimethylformamide (3 ml), and anhydrous potassium carbonate (282.4 mg, 2.0 mmol) was added. The reaction was allowed to proceed overnight at room temperature. After the reaction was complete, the product was diluted with ethyl acetate (100 ml), washed with water (30 ml × 2 times) and saturated brine (30 ml × 1 time), dried over anhydrous sodium sulfate, and concentrated. The resulting residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1 to dichloromethane / methanol = 15 / 1) to obtain 103.2 mg of a light yellow oily substance 9-((4-chloro-2-fluorobenzyl)oxy)-1,3,4,5-tetrahydro-2H-benzo[d]azepine -2-ketone (yield 63.5%). LC-MS: RT = 3.00 min, [M+H] + =320.03.

[0390] Step E: Synthesis of 6-((4-chloro-2-fluorobenzyl)oxy)-2,3,4,5-tetrahydro-1H-benzo[d]azepine

[0391]

[0392] 9-((4-chloro-2-fluorobenzyl)oxy)-1,3,4,5-tetrahydro-2H-benzo[d]azepine was added under ice-cooling conditions. -2-ketone (103.2 mg, 323.5 μmol) was dissolved in dry tetrahydrofuran (5 ml), and 1 mol borane tetrahydrofuran solution (1.9 ml, 19 mmol) was slowly added dropwise under nitrogen protection. The reaction was carried out under ice bath for 0.5 hours, and the temperature was raised to 60 degrees for 1 hour. After the reaction was complete, saturated ammonium chloride aqueous solution was slowly added dropwise under ice bath to quench, and ethyl acetate (100 ml) was diluted, and the mixture was washed with water (30 ml × 2 times) and saturated brine (30 ml × 1 time) in turn, dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1 plus 0.5% triethylamine) to obtain 85.3 mg of light yellow oily 6-((4-chloro-2-fluorobenzyl)oxy)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (Yield 86.1%). LC-MS: RT = 1.78 min, [M+H] + =306.18.

[0393] Step F: Synthesis of (S)-2-((6-((4-chloro-2-fluorobenzyl)oxy)-1,2,4,5-tetrahydro-3H-benzo[d]azepine tert-Butyl-3-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate

[0394]

[0395] At room temperature, 6-((4-chloro-2-fluorobenzyl)oxy)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (85.3 mg, 278.7 μmol) and (S)-2-(chloromethyl)-1-((oxetane-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid tert-butyl ester (112.4 mg, 334.5 μmol) were dissolved in N,N-dimethylformamide (4 ml), and anhydrous potassium carbonate (116.2 mg, 836.1 μmol) was added. The mixture was reacted at room temperature for 6 hours. After the reaction was complete, ethyl acetate (150 ml) was added to dilute the mixture, and the mixture was washed with water (30 ml × 2 times) and saturated brine (30 ml × 1 time) in turn, dried over anhydrous sodium sulfate, and concentrated. The resulting residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1 to dichloromethane / methanol 15 / 1) to obtain 63.2 mg of a pale yellow oily substance (S)-2-((6-((4-chloro-2-fluorobenzyl)oxy)-1,2,4,5-tetrahydro-3H-benzo[d]azepine. -3-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid tert-butyl ester (yield: 37.3%). LC-MS: RT=3.67 min, [M+H] + =606.32.

[0396] Step G: Synthesis of (S)-2-((6-((4-chloro-2-fluorobenzyl)oxy)-1,2,4,5-tetrahydro-3H-benzo[d]azepine -3-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0397]

[0398] At room temperature, (S)-2-((6-((4-chloro-2-fluorobenzyl)oxy)-1,2,4,5-tetrahydro-3H-benzo[d]azepine tert-Butyl (S)-2-((6-((4-chloro-2-fluorobenzyl)oxy)-1,2,4,5-tetrahydro-3H-benzo[d]imidazole-6-carboxylate (63.2 mg, 104.4 μmol) was dissolved in dichloromethane (3 ml) and trifluoroacetic acid (1 ml) was added. The mixture was reacted at room temperature for 3 hours. After the reaction was completed, water (5 ml) was added to quench the mixture and the pH was adjusted to about 8 with saturated sodium bicarbonate aqueous solution. The mixture was extracted with dichloromethane / methanol = 10 / 1 (30 ml × 3 times). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated. The residue was purified by reverse phase HPLC (mobile phase: (0.1% ammonia / water) / acetonitrile = 95 / 5 to 55 / 45) and lyophilized to obtain 19.7 mg of white solid (S)-2-((6-((4-chloro-2-fluorobenzyl)oxy)-1,2,4,5-tetrahydro-3H-benzo[d]azepine -3-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (yield: 34.3%). LC-MS: RT = 2.29 min, [M+H] + =550.31. 1 H NMR (400 MHz, DMSO-d6) δ8.29(s,1H),7.83(d,J=8.5Hz,1H),7.66(d,J=8.4Hz,1H),7.58(t,J=8.1Hz,1H), 7.50(dd,J=9.9,2.1Hz,1H),7.34(d,J=8.2Hz,1H),7.09(d,J=7.7Hz,1H),6.98(d,J=8.3Hz,1H),6.79 (d,J=7.5Hz,1H),5.11(s,3H),4.85(dd,J=15.3,7.3Hz,2H),4.69(d,J=14.9Hz,2H),4.52(q,J=7.1Hz, 2H), 4.41 (d, J = 20.9Hz, 2H), 4.03 (d, J = 13.9Hz, 2H), 3.89 (d, J = 13.7Hz, 2H), 2.95 (s, 2H), 2.87 (d, J = 6.3Hz, 2H).

[0399] Embodiment 14

[0400] Synthesis of (S)-2-((7-((4-chloro-2-fluorobenzyl)oxy)-2-oxo-1,2,4,5-tetrahydro-3H-benzo[d]azepine -3-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0401]

[0402] The specific synthetic route is as follows:

[0403] Step A: Synthesis of 7-bromo-1,3,4,5-tetrahydro-2H-benzo[d]azepine -2-Keto

[0404]

[0405] Under ice bath conditions, 6-bromo-3,4-dihydronaphthalene-2(1H)-one (1.0 g, 4.4 mmol) was dissolved in methanesulfonic acid (10 ml), sodium azide (314.6 mg, 4.8 mmol) was added, and the mixture was heated to room temperature for 1 hour. After the reaction was complete, it was diluted with ethyl acetate (150 ml), washed with water (30 ml × 2 times), saturated sodium bicarbonate (30 ml × 2 times), saturated brine (30 ml × 1 time), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1 to dichloromethane / methanol = 15 / 1) to obtain 764.3 mg of light yellow oily 7-bromo-1,3,4,5-tetrahydro-2H-benzo[d]azepine -2-ketone (yield 72.1%). LC-MS: RT = 1.68 min, [M+H] + =240.11.

[0406] Step B: Synthesis of 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,4,5-tetrahydro-2H-benzo[d]azepine -2-Keto

[0407]

[0408] At room temperature, 7-bromo-1,3,4,5-tetrahydro-2H-benzo[d]azepine -2-one (764.3 mg, 3.2 mmol), bis(pinacol)diboron (1.6 g, 6.4 mmol), 2-dicyclohexylphospho-2,4,6-triisopropylbiphenyl (60.9 mg, 127.3 μmol) and potassium acetate (937.1 mg, 9.6 mmol) were dissolved in dioxane (10 ml). The mixture was replaced with nitrogen three times, and trisdibenzylideneacetone dipalladium (116.6 mg, 127.3 μmol) was added under nitrogen protection. The mixture was refluxed overnight. After the reaction was complete, the mixture was filtered, and the filtrate was diluted with ethyl acetate (150 ml), washed with water (30 ml × 2 times) and saturated brine (30 ml × 1 time), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1 to dichloromethane / methanol = 15 / 1) to obtain 809.2 mg of a light yellow oily mixture of 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,4,5-tetrahydro-2H-benzo[d]azepine -2-ketone (yield 88.3%). LC-MS: RT = 2.17 min, [M+H] + =288.29.

[0409] Step C: Synthesis of 7-hydroxy-1,3,4,5-tetrahydro-2H-benzo[d]azepine -2-Keto

[0410]

[0411] At room temperature, the mixture 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,4,5-tetrahydro-2H-benzo[d]azepine -2- ketone (809.2 mg, 2.8 mmol) was dissolved in tetrahydrofuran (10 ml). 1 mol sodium hydroxide aqueous solution (8 ml) and 30% hydrogen peroxide (2 ml) were slowly added. The reaction was allowed to react at room temperature for 2 hours. After the reaction was complete, the temperature was lowered to zero degrees Celsius and the pH was adjusted to 6-7 with 1 mol hydrochloric acid aqueous solution. The mixture was extracted with ethyl acetate (30 ml × 3 times), the organic phases were combined, washed with saturated brine (30 ml × 1 time), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1 to dichloromethane / methanol = 15 / 1) to obtain 302.3 mg of a light yellow oily substance 7-hydroxy-1,3,4,5-tetrahydro-2H-benzo[d]azepine -2-ketone (yield 70.4%). LC-MS: RT = 1.99 min, [M+H] + =178.12. 1 H NMR (400MHz, CD 3 OD)δ7.02(d,J=8.1Hz,1H),6.99–6.92 (m,2H),6.68(s,1H),6.61(d,J=5.9Hz,4H),4.31(s,2H),3.76(s,3H),3.59(t,J=5.9Hz,3H),3.09–3.00(m,6H),2.76(d,J=7.2Hz,2H).

[0412] Step D: Synthesis of 7-((4-chloro-2-fluorobenzyl)oxy)-1,3,4,5-tetrahydro-2H-benzo[d]azepine -2-Keto

[0413]

[0414] At room temperature, the mixture 7-hydroxy-1,3,4,5-tetrahydro-2H-benzo[d]azepine -2-ketone (302.3 mg, 1.7 mmol) and 2-fluoro-4-chlorobenzyl bromide (754.8 mg, 3.4 mmol) were dissolved in N,N-dimethylformamide (3 ml), and anhydrous potassium carbonate (708.9 mg, 5.1 mmol) was added. The mixture was reacted overnight at room temperature. After the reaction was complete, it was diluted with ethyl acetate (100 ml), washed with water (30 ml × 2 times) and saturated brine (30 ml × 1 time), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1 to dichloromethane / methanol = 15 / 1) to obtain 273.5 mg of a light yellow oily mixture of 7-((4-chloro-2-fluorobenzyl)oxy)-1,3,4,5-tetrahydro-2H-benzo[d]azepine -2-ketone (yield 50.1%). LC-MS: RT = 3.00 min, [M+H] + =320.03.

[0415] Step E: Synthesis of (S)-2-((7-((4-chloro-2-fluorobenzyl)oxy)-2-oxo-1,2,4,5-tetrahydro-3H-benzo[d]azepine tert-Butyl-3-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate

[0416]

[0417] 7-((4-chloro-2-fluorobenzyl)oxy)-1,3,4,5-tetrahydro-2H-benzo[d]azepine was added under ice-cooling conditions. -2-ketone (273.5 mg, 0.8 mmol) was dissolved in dry tetrahydrofuran (5 ml), and 60% sodium hydride (128.2 mg, 3.2 mmol) was added in batches, and the mixture was reacted for 15 minutes under ice bath conditions, and (S)-2-(chloromethyl)-1-((oxetane-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid tert-butyl ester (302.4 mg, 0.9 mmol) was added and reacted for 2 hours. After the reaction was complete, the mixture was quenched with saturated aqueous ammonium chloride solution, diluted with ethyl acetate (100 ml), washed with water (30 ml × 2 times) and saturated brine (30 ml × 1 time), dried over anhydrous sodium sulfate, and concentrated. The resulting residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1 to dichloromethane / methanol = 15 / 1) to obtain 368.2 mg of a pale yellow oily mixture of (S)-2-((7-((4-chloro-2-fluorobenzyl)oxy)-2-oxo-1,2,4,5-tetrahydro-3H-benzo[d]azepine -3-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid tert-butyl ester (yield 69.5%). LC-MS: RT = 3.82 min, [M+H] + =620.32.

[0418] Step F: (S)-2-((7-((4-chloro-2-fluorobenzyl)oxy)-2-oxo-1,2,4,5-tetrahydro-3H-benzo[d]azepine -3-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0419]

[0420] At room temperature, (S)-2-((7-((4-chloro-2-fluorobenzyl)oxy)-2-oxo-1,2,4,5-tetrahydro-3H-benzo[d]azepine tert-butyl (S)-2-((7-((4-chloro-2-fluorobenzyl)methyl)-1-((oxetane-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (368.2 mg, 593.8 μmol) was dissolved in dichloromethane (3 ml), trifluoroacetic acid (1 ml) was added, and the mixture was reacted at room temperature for 3 hours. After the reaction was completed, water (5 ml) was added to quench the mixture, and the pH was adjusted to about 8 with saturated sodium bicarbonate aqueous solution. The mixture was extracted with dichloromethane / methanol = 10 / 1 (30 ml × 3 times), and the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated. The resulting residue was purified by reverse phase HPLC (mobile phase: water / acetonitrile = 90 / 10 to 5 / 95) and lyophilized to obtain the first peak of 26.1 mg of white solid (S)-2-((7-((4-chloro-2-fluorobenzyl)oxy)-2-oxo-1,2,4,5-tetrahydro-3H-benzo[d]azepine -3-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (yield: 15.6%). LC-MS: RT = 1.62 min, [M+H] + =564.18. 1H NMR(400MHz, DMSO-d6)δ8.26(d,J=16.0Hz,1H),7.87(d,J=8.5Hz,1H),7.72(t,J=8.4Hz,1H), 7.61(d,J=8.2Hz,1H),7.53(d,J=9.9Hz,1H),7.37(d,J=8.5Hz,1H),7.18–6.95(m,1H),6.89(d,J=2.5 Hz,1H),6.84(d,J=9.6Hz,1H),5.19–5.09(m,3H),4.96(d,J=8.9Hz,1H),4.82(dd,J=15.7,8.1Hz,1H), 4.77–4.67(m,1H),4.66(s,1H),4.64–4.55(m,1H),4.55–4.46(m,1H),4.38(d,J=8.3Hz,1H),3.91(s,2H), 3.11(d,J=6.8Hz,2H), 2.95(t,J=6.8Hz,1H), 2.70(s,1H), 2.36(d,J=10.4Hz,1H).

[0421] Embodiment 15

[0422] Synthesis of (S)-2-((6-(4-chlorophenethoxy)-1,2,4,5-tetrahydro-3H-benzo[d]azepine -3-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0423]

[0424] The specific synthetic route is as follows:

[0425] Step A: Synthesis of 9-(4-chlorophenethoxy)-1,3,4,5-tetrahydro-2H-benzo[d]azepine -2-Keto

[0426]

[0427] At room temperature, 9-hydroxy-1,3,4,5-tetrahydro-2H-benzo[d]azepine -2-ketone (71.1 mg, 0.4 mmol) and 1-(2-bromoethyl)-4-chlorobenzene (252.2 mg, 1.6 mmol) were dissolved in N,N-dimethylformamide (3 ml), anhydrous potassium carbonate (278.7 mg, 1.0 mmol) was added, and the mixture was reacted overnight at room temperature. After the reaction was complete, the mixture was diluted with ethyl acetate (100 ml), washed with water (30 ml × 2 times) and saturated brine (30 ml × 1 time), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1 to dichloromethane / methanol = 15 / 1) to obtain 64.5 mg of light yellow oily 9-(4-chlorophenethoxy)-1,3,4,5-tetrahydro-2H-benzo[d]azepine -2-ketone (yield 50.9%). LC-MS: RT = 3.17 min, [M+H] + =316.05.

[0428] Step B: Synthesis of 6-(4-chlorophenethoxy)-2,3,4,5-tetrahydro-1H-benzo[d]azepine

[0429]

[0430] 9-(4-chlorophenethoxy)-1,3,4,5-tetrahydro-2H-benzo[d]azepine was added under ice-cooling conditions. -2-ketone (64.5 mg, 204.7 μmol) was dissolved in dry tetrahydrofuran (5 ml), and 1 mol borane tetrahydrofuran solution (1.2 ml, 1.2 mmol) was slowly added dropwise under nitrogen protection. After reacting for 0.5 hours under ice bath, the temperature was raised to 60 degrees Celsius for 1 hour. After the reaction was complete, saturated ammonium chloride aqueous solution was quenched under ice bath, diluted with ethyl acetate (100 ml), washed with water (30 ml × 2 times) and saturated brine (30 ml × 1 time) in turn, dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1 plus 0.5% triethylamine) to obtain 35.2 mg of light yellow oily 6-(4-chlorophenethoxy)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (Yield 57.1%). LC-MS: RT = 4.65 min, [M+H] + =302.34.

[0431] Step C: Synthesis of (S)-2-((6-(4-chlorophenethoxy)-1,2,4,5-tetrahydro-3H-benzo[d]azepine tert-Butyl-3-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate

[0432]

[0433] At room temperature, 6-(4-chlorophenethoxy)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (35.2 mg, 116.9 μmol) and (S)-tert-butyl 2-(chloromethyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (47.1 mg, 140.3 μmol) were dissolved in N,N-dimethylformamide (4 ml), anhydrous potassium carbonate (48.7 mg, 350.7 μmol) was added, and the mixture was reacted at room temperature for 6 hours. After the reaction was complete, it was diluted with ethyl acetate (150 ml), washed with water (30 ml × 2 times) and saturated brine (30 ml × 1 time), dried over anhydrous sodium sulfate, and concentrated. The resulting residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1 to dichloromethane / methanol 15 / 1) to obtain 46.2 mg of a pale yellow oily substance (S)-2-((6-(4-chlorophenethoxy)-1,2,4,5-tetrahydro-3H-benzo[d]azepine -3-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid tert-butyl ester (yield: 65.8%). LC-MS: RT = 3.95 min, [M+H] + =602.20.

[0434] Step D: Synthesis of (S)-2-((6-(4-chlorophenethoxy)-1,2,4,5-tetrahydro-3H-benzo[d]azepine -3-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0435]

[0436] At room temperature, (S)-2-((6-(4-chlorophenethoxy)-1,2,4,5-tetrahydro-3H-benzo[d]azepine tert-butyl (S)-2-((6-(4-chlorophenethoxy)-1,2,4,5-tetrahydro-3H-benzo[d]imidazole-6-carboxylate (46.2 mg, 76.8 μmol) was dissolved in dichloromethane (3 ml), trifluoroacetic acid (1 ml) was added, and the mixture was reacted at room temperature for 3 hours. After the reaction was completed, water (5 ml) was added to quench the mixture, and the pH was adjusted to about 8 with saturated sodium bicarbonate aqueous solution. The mixture was extracted with dichloromethane / methanol = 10 / 1 (30 ml × 3 times), and the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated. The resulting residue was purified by reverse phase HPLC (mobile phase: (0.1% ammonia / water) / acetonitrile = 95 / 5 to 55 / 45) and lyophilized to obtain 5.6 mg of a white solid (S)-2-((6-(4-chlorophenethoxy)-1,2,4,5-tetrahydro-3H-benzo[d]azepine -3-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (yield: 13.7%). LC-MS: RT = 2.07 min, [M+H] + =546.13.

[0437] Example 16

[0438] Synthesis of (S)-2-((9-(4-chlorophenethoxy)-1,3,4,5-tetrahydro-2H-benzo[c]azepine -2-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0439]

[0440] The specific synthesis is as follows:

[0441] Step A: Synthesis of 9-(4-chlorophenethoxy)-1,2,4,5-tetrahydro-3H-benzo[c]azepine -3-Keto

[0442]

[0443] At room temperature, 9-hydroxy-1,2,4,5-tetrahydro-3H-benzo[c]azepine -3-one (71.1 mg, 0.4 mmol) and 1-(2-bromoethyl)-4-chlorobenzene (252.2 mg, 1.6 mmol) were added to N,N-dimethylformamide (3 ml), and anhydrous potassium carbonate (278.7 mg, 1.0 mmol) was added. The mixture was reacted overnight at room temperature. After the reaction was complete, the mixture was diluted with ethyl acetate (100 ml), washed with water (30 ml × 2 times) and saturated brine (30 ml × 1 time), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1 to dichloromethane / methanol = 15 / 1) to obtain 64.5 mg of 9-(4-chlorophenethoxy)-1,2,4,5-tetrahydro-3H-benzo[c]azepine -3-ketone (yield 50.9%). LC-MS: RT = 3.17 min, [M+H] + =316.05.

[0444] Step B: Synthesis of 9-(4-chloroethoxy)-2,3,4,5-tetrahydro-1H-benzo[c]azepine

[0445]

[0446] 9-(4-chlorophenethoxy)-1,2,4,5-tetrahydro-3H-benzo[c]azepine was added under ice-cooling conditions. -3-ketone (64.5 mg, 204.7 μmol) was dissolved in dry tetrahydrofuran (5 ml), and 1 mol borane tetrahydrofuran solution (1.2 ml, 1.2 mmol) was slowly added dropwise under nitrogen protection. After reacting for 0.5 hours under ice bath, the temperature was raised to 60 degrees Celsius for 1 hour. After the reaction was complete, saturated aqueous ammonium chloride solution was quenched. It was extracted with ethyl acetate (100 ml), washed with water (30 ml × 2 times) and saturated brine (30 ml × 1 time), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1 plus 0.5% triethylamine) to obtain 35.2 mg of light yellow oily 9-(4-chloroethoxy)-2,3,4,5-tetrahydro-1H-benzo[c]azepine (Yield 57.1%). LC-MS: RT = 4.65 min, [M+H] + =302.34.

[0447] Step C: Synthesis of (S)-2-((9-(4-chlorophenethoxy)-1,3,4,5-tetrahydro-2H-benzo[c]azepine tert-Butyl-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate

[0448]

[0449] At room temperature, 9-(4-chloroethoxy)-2,3,4,5-tetrahydro-1H-benzo[c]azepine The mixture was stirred for 6 hours at room temperature and diluted with ethyl acetate (150 ml). The mixture was washed with water (30 ml × 2 times) and saturated brine (30 ml × 1 time), dried over anhydrous sodium sulfate and concentrated. The resulting residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1 to dichloromethane / methanol 15 / 1) to obtain 46.2 mg of a pale yellow oily substance (S)-2-((9-(4-chlorophenethoxy)-1,3,4,5-tetrahydro-2H-benzo[c]azepine -2-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid tert-butyl ester (yield: 65.8%). LC-MS: RT = 3.75 min, [M+H] + =602.20.

[0450] Step D: Synthesis of (S)-2-((9-(4-chlorophenethoxy)-1,3,4,5-tetrahydro-2H-benzo[c]azepine -2-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0451]

[0452] At room temperature, (S)-2-((9-(4-chlorophenethoxy)-1,3,4,5-tetrahydro-2H-benzo[c]azepine tert-butyl (S)-2-((9-(4-chlorophenethoxy)-1,3,4,5-tetrahydro-2H-benzo[c]azepine-6-carboxylate (46.2 mg, 76.8 μmol) was dissolved in dichloromethane (3 ml), trifluoroacetic acid (1 ml) was added, and the reaction was allowed to proceed at room temperature for 3 hours. After the reaction was completed, water (5 ml) was added to quench the reaction, and the pH was adjusted to about 8 with saturated sodium bicarbonate aqueous solution. The reaction was extracted with dichloromethane / methanol = 10 / 1 (30 ml × 3 times), and the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated. The resulting residue was purified by reverse phase HPLC (mobile phase: (0.1% ammonia / water) / acetonitrile = 95 / 5 to 55 / 45) and lyophilized to obtain 1.4 mg of a white solid (S)-2-((9-(4-chlorophenethoxy)-1,3,4,5-tetrahydro-2H-benzo[c]azepine -2-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (yield: 3.4%). LC-MS: RT = 2.02 min, [M+H] + =546.13.

[0453] Embodiment 17

[0454] Synthesis of (S)-1-((oxetane-2-yl)methyl)-2-((7-((quinolin-6-yl)methoxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0455]

[0456] The specific synthetic route is as follows:

[0457] Step A: Synthesis of tert-butyl 7-bromo-3,4-dihydroisoquinoline-2(1H)-carboxylate

[0458]

[0459] At room temperature, 7-bromo-1,2,3,4-tetrahydroisoquinoline (5.0 g, 20.1 mmol) and triethylamine (5.5 ml, 40.2 mmol) were dissolved in dichloromethane (50 ml). Di-tert-butyl dicarbonate (8.7 g, 40.2 mmol) was added dropwise, and the mixture was reacted overnight at room temperature. After the reaction was complete, the mixture was diluted with ethyl acetate (200 ml), washed with 1 mol / L hydrochloric acid (40 ml × 3 times) and saturated brine (30 ml × 2 times), dried over anhydrous sodium sulfate, and concentrated. The obtained 6.0 g of light yellow oily tert-butyl 7-bromo-3,4-dihydroisoquinoline-2(1H)-carboxylate was used directly in the next step without further purification. (Yield: 95.8%).

[0460] Step B: Synthesis of tert-butyl 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate

[0461]

[0462] Tert-butyl 7-bromo-3,4-dihydroisoquinoline-2(1H)-carboxylate (6.0 g, 19.2 mmol), bis(pinacol)diboron (9.8 g, 38.4 mmol), 2-dicyclohexylphospho-2,4,6-triisopropylbiphenyl (366.0 mg, 768.0 μmol) and potassium acetate (5.6 g, 57.6 mmol) were dissolved in dioxane (60 ml) at room temperature. The atmosphere was replaced with nitrogen three times, and trisdibenzylideneacetone dipalladium (703.2 mg, 768.0 μmol) was added under nitrogen protection, and the reaction was carried out under reflux overnight. After the reaction was complete, the mixture was filtered, diluted with ethyl acetate (250 ml), washed with water (50 ml × 2 times) and saturated brine (50 ml × 1 time), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 15 / 1) to obtain 6.2 g of light yellow oily tert-butyl 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (yield 89.6%). LC-MS: RT = 3.80 min, [M+H] + =304.12.

[0463] Step C: Synthesis of tert-butyl 7-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxylate

[0464]

[0465] At room temperature, tert-butyl 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (6.2 g, 17.3 mmol) was dissolved in tetrahydrofuran (60 ml). 1 mol sodium hydroxide aqueous solution (51.8 ml, 51.8 mmol) and 30% hydrogen peroxide (11.3 ml, 103.8 mmol) were slowly added and reacted at room temperature for 2 hours. After the reaction was complete, the temperature was lowered to zero degrees Celsius and the pH was adjusted to 6-7 with 1 mol hydrochloric acid aqueous solution. The mixture was extracted with ethyl acetate (80 ml × 3 times), the organic phases were combined, washed with saturated brine (40 ml × 1 time), dried over anhydrous sodium sulfate, and concentrated. The obtained residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 10 / 1) to obtain 3.7 g of white solid tert-butyl 7-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxylate (yield 86.5%). LC-MS: RT = 1.52 min, [M-tBu] + =194.15.

[0466] Step D: Synthesis of 6-(bromomethyl)quinoline

[0467]

[0468] Under ice bath, quinolin-6-ylmethanol (250.0 mg, 1.6 mmol) was dissolved in dry dichloromethane (5 ml), phosphorus tribromide (510.1 mg, 1.8 mmol) was slowly added dropwise, and the mixture was heated to room temperature for 4 hours. After the reaction was complete, the pH was adjusted to 7-8 with saturated sodium bicarbonate aqueous solution, and extracted with dichloromethane (40 ml × 3 times), the organic phases were combined, washed with saturated brine (30 ml × 1 time), dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 5 / 1) to obtain 329.3 mg of light yellow oily 6-(bromomethyl)quinoline (yield 94.3%). LC-MS: RT = 1.28 min, [M+H] + =221.96.

[0469] Step E: Synthesis of tert-butyl 7-(quinolin-6-ylmethoxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate

[0470]

[0471] At room temperature, 6-(bromomethyl)quinoline (63.5 mg, 286.2 μmol) and tert-butyl 7-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxylate (59.4 mg, 238.5 μmol) were dissolved in N,N-dimethylformamide (3 ml), and anhydrous potassium carbonate (99.4 mg, 715.5 μmol) was added. The mixture was reacted overnight at room temperature. After the reaction was complete, the mixture was diluted with ethyl acetate (100 ml), washed with water (30 ml × 2 times) and saturated brine (30 ml × 1 time), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 4 / 1) to obtain 83.7 mg of tert-butyl 7-(quinolin-6-ylmethoxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate (yield 89.9%). LC-MS: RT=2.25min, [M+H]+=391.07. 1H NMR (400MHz, CDCl 3 )δ8.98(dd,J=4.3,1.7Hz,1H),8.20(dd,J=14.6,8.6Hz,2H),7.93(d,J=1.7Hz,1H),7.82(dd,J=8.8,1.9Hz,1H),7.47(dd,J=8.2, 4.2Hz,1H),7.11(d,J=8.2Hz,1H),6.89(d,J=9.0Hz,1H),6.82(s,1H),5.29(s,2H),4.59(s,2H),3.68(s,2H),2.82(s,2H),1.54(s,9H).

[0472] Step F: Synthesis of 6-(((1,2,3,4-tetrahydroisoquinolin-7-yl)oxy)methyl)quinoline

[0473]

[0474] At room temperature, tert-butyl 7-((quinolin-6-yl)methoxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate (83.7 mg, 214.6 μmol) was dissolved in dichloromethane (4 ml), trifluoroacetic acid (1 ml) was added, and the mixture was reacted at room temperature for 1 hour. After the reaction was complete, the mixture was concentrated to obtain 80.2 mg of light yellow oily 6-(((1,2,3,4-tetrahydroisoquinolin-7-yl)oxy)methyl)quinoline, which was directly used in the next step without further purification.

[0475] Step G: Synthesis of (S)-tert-butyl 1-((oxetan-2-yl)methyl)-2-((7-((quinolin-6-yl)methoxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate

[0476]

[0477] At room temperature, 6-(((1,2,3,4-tetrahydroisoquinolin-7-yl)oxy)methyl)quinoline (80.2 mg, 276.5 μmol) and (S)-tert-butyl 2-(chloromethyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (111.5 mg, 331.8 μmol) were dissolved in N,N-dimethylformamide (3 ml), and anhydrous potassium carbonate (115.3 mg, 829.5 μmol) was added. The mixture was reacted overnight at room temperature. After the reaction was complete, the mixture was diluted with ethyl acetate (100 ml), washed with water (30 ml × 2 times) and saturated brine (30 ml × 1 time), dried over anhydrous sodium sulfate, and concentrated. The obtained residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1 to dichloromethane / methanol = 15 / 1) to obtain 105.3 mg of light yellow oily (S)-tert-butyl 1-((oxetan-2-yl)methyl)-2-((7-((quinolin-6-yl)methoxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (yield 83.2%). LC-MS: RT = 1.50 min, [M+H] + =591.22.

[0478] Step H: Synthesis of (S)-1-((oxetan-2-yl)methyl)-2-((7-((quinolin-6-yl)methoxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0479]

[0480] At room temperature, (S)-tert-butyl 1-((oxetane-2-yl)methyl)-2-((7-((quinolin-6-yl)methoxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (105.3 mg, 178.4 μmol) was dissolved in dichloromethane (3 ml), trifluoroacetic acid (1 ml) was added, and the reaction was carried out at room temperature for 3 hours. After the reaction was completed, water (5 ml) was added to quench the reaction, and the pH was adjusted to about 8 with saturated sodium bicarbonate aqueous solution. The mixture was extracted with dichloromethane / methanol = 10 / 1 (30 ml × 3 times), and the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated. The obtained residue was purified by reverse phase HPLC (mobile phase: (0.1% aqueous ammonia / water) / acetonitrile = 95 / 5 to 55 / 45) and lyophilized to give 20.0 mg of white solid (S)-1-((oxetan-2-yl)methyl)-2-((7-((quinolin-6-yl)methoxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (yield: 21.0%). LC-MS: RT = 1.25 min, [M+H] + =535.28.

[0481] Embodiment 18

[0482] Synthesis of (S)-1-((oxetane-2-yl)methyl)-2-((7-((quinolin-4-yl)methoxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0483]

[0484] The specific synthetic route is as follows:

[0485] Step A: Synthesis of quinolin-4-ylmethanol

[0486]

[0487] Under ice bath, quinoline-4-carboxaldehyde (1.0 g, 6.4 mmol) was dissolved in methanol (10 ml), sodium borohydride (483.5 mg, 12.7 mmol) was added, and the mixture was reacted under ice bath for 2 hours. After the reaction was complete, saturated aqueous ammonium chloride solution (15 ml) was used for quenching, and ethyl acetate (30 ml × 3 times) was used for extraction. The organic phases were combined, washed with saturated brine (30 ml × 1 time), dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1) to obtain 980.3 mg of white solid quinolin-4-ylmethanol (yield 98.3%). LC-MS: RT = 1.25 min, [M+H] + =160.04.

[0488] Step B: Synthesis of 4-(bromomethyl)quinoline

[0489]

[0490] Under ice bath, quinolin-4-ylmethanol (250.0 mg, 1.6 mmol) was dissolved in dry dichloromethane (5 ml), phosphorus tribromide (510.1 mg, 1.8 mmol) was added dropwise, and the mixture was heated to room temperature for 4 hours. After the reaction was complete, the pH was adjusted to 7-8 with saturated sodium bicarbonate aqueous solution, and extracted with dichloromethane (40 ml × 3 times). The organic phases were combined, washed with saturated brine (30 ml × 1 time), dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 5 / 1) to obtain 329.3 mg of light yellow oily 4-(bromomethyl)quinoline (yield 94.3%). LC-MS: RT = 1.28 min, [M+H] + =221.96.

[0491] Step C: Synthesis of tert-butyl 7-((quinolin-4-yl)methoxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate

[0492]

[0493] At room temperature, 4-(bromomethyl)quinoline (63.5 mg, 286.2 μmol) and tert-butyl 7-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxylate (59.4 mg, 238.5 μmol) were dissolved in N,N-dimethylformamide (3 ml), and anhydrous potassium carbonate (99.4 mg, 715.5 μmol) was added. The mixture was reacted overnight at room temperature. After the reaction was complete, the mixture was diluted with ethyl acetate (100 ml), washed with water (30 ml × 2 times) and saturated brine (30 ml × 1 time), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 4 / 1) to obtain 83.7 mg of tert-butyl 7-((quinolin-4-yl)methoxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate (yield 89.9%). LC-MS: RT=2.25min, [M+H]+=391.07.

[0494] Step D: Synthesis of 4-(((1,2,3,4-tetrahydroisoquinolin-7-yl)oxy)methyl)quinoline

[0495]

[0496] At room temperature, tert-butyl 7-(quinolin-4-ylmethoxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate (83.7 mg, 214.6 μmol) was dissolved in dichloromethane (4 ml), trifluoroacetic acid (1 ml) was added, and the mixture was reacted at room temperature for 1 hour. After the reaction was complete, the mixture was concentrated under reduced pressure to obtain 80.2 mg of a light yellow oily substance, 4-(((1,2,3,4-tetrahydroisoquinolin-7-yl)oxy)methyl)quinoline, which was directly used in the next step without further purification. LC-MS: RT = 3.43 min, [M+H] + =291.03.

[0497] Step E: Synthesis of (S)-tert-butyl 1-((oxetan-2-yl)methyl)-2-((7-((quinolin-4-yl)methoxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate

[0498]

[0499] At room temperature, 4-(((1,2,3,4-tetrahydroisoquinolin-7-yl)oxy)methyl)quinoline (80.2 mg, 276.5 μmol) and (S)-tert-butyl 2-(chloromethyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (111.5 mg, 331.8 μmol) were dissolved in N,N-dimethylformamide (3 ml), and anhydrous potassium carbonate (115.3 mg, 829.5 μmol) was added. The mixture was reacted overnight at room temperature. After the reaction was complete, the mixture was diluted with ethyl acetate (100 ml), washed with water (30 ml × 2 times) and saturated brine (30 ml × 1 time), dried over anhydrous sodium sulfate, and concentrated. The obtained residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1 to dichloromethane / methanol = 15 / 1) to obtain 105.3 mg of light yellow oily (S)-1-((oxetan-2-yl)methyl)-2-((7-((quinolin-4-yl)methoxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid tert-butyl ester (yield 83.2%). LC-MS: RT = 1.50 min, [M+H] + = 591.22.

[0500] Step F: Synthesis of (S)-1-((oxetan-2-yl)methyl)-2-((7-((quinolin-4-yl)methoxy-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0501]

[0502] At room temperature, (S)-tert-butyl 1-((oxetane-2-yl)methyl)-2-((7-((quinolin-4-yl)methoxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (105.3 mg, 178.4 μmol) was dissolved in dichloromethane (3 ml), and trifluoroacetic acid (1 ml) was added. The reaction was allowed to react at room temperature for 3 hours. After the reaction was completed, water (5 ml) was added to quench the reaction. The pH was adjusted to about 8 with saturated sodium bicarbonate aqueous solution, and the mixture was extracted with dichloromethane / methanol = 10 / 1 (30 ml × 3 times). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated. The obtained residue was purified by reverse phase HPLC (mobile phase: (0.1% aqueous ammonia / water) / acetonitrile = 95 / 5 to 55 / 45) and lyophilized to give 20.0 mg of white solid (S)-1-((oxetan-2-yl)methyl)-2-((7-((quinolin-4-yl)methoxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (yield: 21.0%). LC-MS: RT = 1.25 min, [M+H] + =535.28.

[0503] Embodiment 19

[0504] Synthesis of (S)-2-((7-((3-chlorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0505]

[0506] The specific synthetic route is as follows:

[0507] Step A: Synthesis of tert-butyl 7-((3-chlorobenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate

[0508]

[0509] At room temperature, 1-(bromomethyl)-3-chlorobenzene (40 mg, 0.197 mmol) and potassium carbonate (54.4 mg, 0.394 mmol) were added to acetonitrile (5.0 ml) containing tert-butyl 7-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxylate (50 mg, 0.210 mmol), and the mixture was reacted at 80 degrees Celsius for 2 hours. After the reaction was completed, water was added to quench the mixture, and the mixture was extracted with ethyl acetate (30 ml × 2 times), washed with saturated brine (30 ml), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (eluent: ethyl acetate / n-hexane = 1 / 3. 46 mg of tert-butyl 7-((3-chlorobenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate was obtained as a pale yellow solid (yield: 63.1%). LC-MS: RT = 2.23 min, [M+H] + =374.24.

[0510] Step B: Synthesis of 7-((3-chlorobenzyl)oxy)-1,2,3,4-tetrahydroisoquinoline

[0511]

[0512] Dissolve tert-butyl 7-((3-chlorobenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate (46 mg, 0.123 mmol) in 5 ml of methanol, add 2 ml of 4 molar hydrochloric acid dioxane solution, and react at room temperature for 30 minutes. After the reaction is completed, concentrate to obtain 36 mg of 7-((3-chlorobenzyl)oxy)-1,2,3,4-tetrahydroisoquinoline hydrochloride (yield: 97.8%). LC-MS: RT = 1.99 min, [M+H] + =274.27.

[0513] Step C: Synthesis of (S)-tert-butyl 2-((7-((3-chlorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate

[0514]

[0515] To a solution of 7-((3-chlorobenzyl)oxy)-1,2,3,4-tetrahydroisoquinoline (36.0 mg, 0.120 mmol) in N,N-dimethylformamide (5.0 ml) was added (S)-tert-butyl 2-(chloromethyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (37.1 mg, 0.120 mmol) and potassium carbonate (33.2 mg, 0.240 mmol) at room temperature and reacted at 50°C for 3 hours. After the reaction was completed, water was added to quench, extracted with ethyl acetate (30 ml x 2 times), washed with saturated brine (30 ml), dried over anhydrous sodium sulfate, concentrated, and the residue was purified by silica gel column chromatography (eluent: ethyl acetate / n-hexane = 5 / 1. 44 mg of light yellow solid (S)-2-((7-((3-chlorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetane-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid tert-butyl ester was obtained (yield: 63.9%). LC-MS: RT = 1.97 min, [M+H] + =574.27.

[0516] Step D: Synthesis of (S)-2-((7-((3-chlorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0517]

[0518] (S)-tert-butyl 2-((7-((3-chlorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (44.0 mg, 0.077 mmol) was dissolved in 4 ml of anhydrous dichloromethane, 2 ml of trifluoroacetic acid was added, and the mixture was reacted at room temperature for 40 minutes. After the reaction was completed, the reaction solution was poured into 20 ml of sodium bicarbonate solution, extracted with dichloromethane (30 ml × 2 times), the organic phases were combined, washed with saturated brine (20 ml × 2 times), dried over anhydrous sodium sulfate, and concentrated. The resulting residue was purified by silica gel column chromatography (eluent: methanol / dichloromethane = 10 / 1) to obtain 9.9 mg of white solid (S)-2-((7-((3-chlorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetane-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (yield: 25.1%). 1H NMR (400MHz, DMSO) δ12.83(s,1H),8.31(s,1H),7.85(d,J=8.7Hz,1H),7.72(d,J=8.6Hz,1H),7.46(s,1H),7.43–7.33(m,3H), 7.13–7.03(m,1H),6.87–6.78(m,2H),5.06(s,2H),5.04–4.97(m,1H),4.79(dd,J=15.4,7.2Hz,1H),4.65 (dd,J=15.3,2.6Hz,1H),4.46–4.41(m,1H),4.33–4.28(m,1H),2.95–2.77(m,3H),2.73–2.53(m,2H),2.40– 2.23(m,2H),2.08–1.90(m,1H),1.34–1.12(m,2H). LC-MS:RT=1.80min,[M+H] + =518.23.

[0519] Embodiment 20

[0520] Synthesis of (S)-2-((7-((3-(trifluoromethyl)benzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-2-yl)methyl)-1-((oxetan-2-yl(methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0521]

[0522] The specific synthetic route is as follows:

[0523] Step A: Synthesis of 1-(bromomethyl)-3-(trifluoromethyl)benzene

[0524]

[0525] Phosphorus tribromide (97.0 μL) was added dropwise to dichloromethane (3.0 mL) containing (3-(trifluoromethyl))methanol (300.0 mg, 1.70 mmol) at 0°C, and the mixture was reacted at room temperature for 1 hour. After the reaction was completed, water was added to quench the mixture, and the mixture was extracted with dichloromethane (20 mL × 3 times). The organic phases were combined, washed with saturated brine (20 mL × 2 times), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (eluent: ethyl acetate / n-hexane = 0 / 1). 77.0 mg of yellow oily 1-(bromomethyl)-3-(trifluoromethyl)benzene was obtained (yield: 19.0%). LC-MS: RT = 2.23 min.

[0526] Step B: Synthesis of tert-butyl 7-((3-(trifluoromethyl)benzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate

[0527]

[0528] At room temperature, tert-butyl 7-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxylate (80.0 mg, 0.32 mmol) and potassium carbonate (89.0 mg, 0.64 mmol) were added to N,N-dimethylformamide (1.0 ml) containing 1-(bromomethyl)-3-(trifluoromethyl)benzene (77.0 mg, 0.32 mmol) and reacted at room temperature for 2 hours. After the reaction was completed, water was added to quench the reaction, and ethyl acetate (20 ml × 3 times) was used for extraction. The organic phases were combined, washed with saturated brine (20 ml × 2 times), dried over anhydrous sodium sulfate, and concentrated. The resulting residue was purified by silica gel column chromatography (eluent: ethyl acetate / n-hexane = 1 / 5). 70.0 mg of yellow oily tert-butyl 7-((3-(trifluoromethyl)benzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate was obtained (yield: 53.7%). LC-MS: RT = 2.40 min, [M + H] + =408.19.

[0529] Step C: Synthesis of 7-((3-(trifluoromethyl)benzyl)oxy)-1,2,3,4-tetrahydroisoquinoline

[0530]

[0531] At room temperature, a solution of hydrochloric acid in dioxane (1.0 ml, 4 mol / L) was added to tert-butyl 7-((3-(trifluoromethyl)benzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate (70.0 mg, 0.17 mmol) in methanol (2.0 ml), and the mixture was reacted at room temperature for 3 hours. After the reaction, the reaction solution was directly dried to obtain 58.7 mg of white solid 7-((3-(trifluoromethyl)benzyl)oxy)-1,2,3,4-tetrahydroisoquinoline, which was used directly in the next step. LC-MS: RT = 1.72 min, [M+H] + =308.21.

[0532] Step D: Synthesis of (S)-tert-butyl 2-((7-((3-(trifluoromethyl)benzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-2-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate

[0533]

[0534] At room temperature, (S)-tert-butyl 2-(chloromethyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (57.2 mg, 0.17 mmol) and cesium carbonate (110.5 mg, 0.34 mmol) were added to N,N-dimethylformamide (2.0 ml) containing 7-((3-(trifluoromethyl)benzyl)oxy)-1,2,3,4-tetrahydroisoquinoline (58.7 mg, 0.17 mmol) and reacted at 50 degrees Celsius for 2 hours. After the reaction was completed, water was added to quench the reaction, and ethyl acetate (20 ml × 3 times) was used for extraction. The organic phases were combined, washed with saturated brine (20 ml × 2 times), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (eluent: ethyl acetate / n-hexane = 2 / 1). 90.0 mg of yellow oily (S)-tert-butyl 2-((7-((3-(trifluoromethyl)benzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-2-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate was obtained (yield: 86.9%). LC-MS: RT = 2.00 min, [M+H] + =608.39.

[0535] Step E: Synthesis of (S)-2-((7-((3-(trifluoromethyl)benzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-2-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0536]

[0537] At room temperature, (S)-tert-butyl 2-((7-((3-(trifluoromethyl)benzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-2-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (90.0 mg, 0.15 mmol) was added to dichloromethane (1.0 ml), and trifluoroacetic acid (0.5 ml) was added dropwise. The mixture was reacted at room temperature for 2 hours. After the reaction was completed, the organic solvent was removed by concentration, and the resulting residue was purified by silica gel column chromatography (eluent: methanol / dichloromethane = 1 / 20). 40.0 mg of white solid (S)-2-((7-((3-(trifluoromethyl)benzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-2-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid was obtained (yield: 48.3%). LC-MS: RT = 1.81 min, [M+H] + =552.29. 1H NMR (400MHz, DMSO) δ12.95 (s, 1H), 8.36 (s, 1H), 7.89 (d, J = 8.4Hz, 1H), 7.78(d,J=6.1Hz,2H),7.70(dd,J=13.5,7.6Hz,2H),7.62(t,J=7.7Hz,1H),7.16(d,J=8.4Hz,1H),6.95 (d,J=8.4Hz,1H),6.89(s,1H),5.18(s,2H),5.02(d,J=6.1Hz,1H),4.82(d,J=6.9Hz,2H),4.78(d,J=6.6 Hz,1H),4.66(d,J=14.0Hz,1H),4.54–4.35(m,3H),4.35–4.22(m,1H),3.21–2.92(m,3H),2.74–2.58(m, 1H),2.44–2.19(m,1H),1.23(s,1H).

[0538] Embodiment 21

[0539] Synthesis of (S)-2-((7-((3-chloro-5-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-2-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0540]

[0541] The specific synthetic route is as follows:

[0542] Step A: Synthesis of (3-chloro-5-fluorophenyl)methanol

[0543]

[0544] At 0°C, borane tetrahydrofuran solution (5.7 ml, 1.0 mol / L) was added dropwise to tetrahydrofuran (10.0 ml) containing 3-chloro-5-fluorobenzoic acid (500.0 mg, 2.86 mmol), and the mixture was reacted at 70°C for 1 hour under nitrogen protection. After the reaction was completed, water was added at 0°C to quench the mixture, and the mixture was extracted with ethyl acetate (20 ml × 3 times). The organic phases were combined, washed with saturated brine (20 ml × 2 times), dried over anhydrous sodium sulfate, and concentrated to obtain 440.0 mg of a yellow oil (3-chloro-5-fluorophenyl)methanol, which was used directly in the next step without purification. LC-MS: RT = 1.80 min.

[0545] Step B: Synthesis of 1-(bromomethyl)-3-chloro-5-fluorobenzene

[0546]

[0547] Phosphorus tribromide (107.0 μL) was added dropwise to dichloromethane (3.0 mL) containing (3-chloro-5-fluorophenyl)methanol (300.0 mg, 1.88 mmol) at 0°C and reacted at room temperature for 1 hour. After the reaction was completed, water was added to quench the reaction, and dichloromethane (20 mL × 3 times) was used for extraction. The organic phases were combined, washed with saturated brine (20 mL × 2 times), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (eluent: ethyl acetate / n-hexane = 0 / 1). 200.0 mg of yellow oily 1-(bromomethyl)-3-chloro-5-fluorobenzene was obtained (yield: 47.7%). LC-MS: RT = 2.21 min.

[0548] Step C: Synthesis of tert-butyl 7-((3-chloro-5-fluorobenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate

[0549]

[0550] At room temperature, tert-butyl 7-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxylate (76.9 mg, 0.31 mmol) and potassium carbonate (85.6 mg, 0.62 mmol) were added to N,N-dimethylformamide (1.0 ml) containing 1-(bromomethyl)-3-chloro-5-fluorobenzene (72.0 mg, 0.31 mmol) and reacted at room temperature for 2 hours. After the reaction was completed, water was added to quench the reaction, and ethyl acetate (20 ml × 3 times) was used for extraction. The organic phases were combined, washed with saturated brine (20 ml × 2 times), dried over anhydrous sodium sulfate, and concentrated. The resulting residue was purified by silica gel column chromatography (eluent: ethyl acetate / n-hexane = 1 / 5). 50.0 mg of yellow oily tert-butyl 7-((3-chloro-5-fluorobenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate was obtained (yield: 41.1%). LC-MS: RT = 2.36 min, [M + H] + =392.23.

[0551] Step D: Synthesis of 7-((3-chloro-5-fluorobenzyl)oxy)-1,2,3,4-tetrahydroisoquinoline

[0552]

[0553] At room temperature, a solution of hydrochloric acid in dioxane (1.0 ml, 4 mol / L) was added to tert-butyl 7-((3-chloro-5-fluorobenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate (50.0 mg, 0.13 mmol) in methanol (2.0 ml), and the mixture was reacted at room temperature for 3 hours. After the reaction was completed, the mixture was concentrated to obtain 43.0 mg of white solid 7-((3-chloro-5-fluorobenzyl)oxy)-1,2,3,4-tetrahydroisoquinoline hydrochloride, which was used directly in the next step. LC-MS: RT = 1.72 min, [M+H] + =292.13.

[0554] Step E: Synthesis of (S)-tert-butyl 2-((7-((3-chloro-5-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-2-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate

[0555]

[0556] At room temperature, (S)-tert-butyl 2-(chloromethyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (43.0 mg, 0.13 mmol) and cesium carbonate (84.5 mg, 0.26 mmol) were added to N,N-dimethylformamide (2.0 ml) containing 7-((3-chloro-5-fluorobenzyl)oxy)-1,2,3,4-tetrahydroisoquinoline (43.0 mg, 0.13 mmol) and reacted at 50 degrees Celsius for 2 hours. After the reaction was completed, water was added to quench, and ethyl acetate (20 ml × 3 times) was used for extraction. The organic phases were combined, washed with saturated brine (20 ml × 2 times), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (eluent: ethyl acetate / n-hexane = 2 / 1). 70.0 mg of yellow oily (S)-tert-butyl 2-((7-((3-chloro-5-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-2-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate was obtained (yield: 91.0%). LC-MS: RT = 2.02 min, [M+H] + =592.31.

[0557] Step F: Synthesis of (S)-2-((7-((3-chloro-5-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-2-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0558]

[0559] At room temperature, (S)-tert-butyl 2-((7-((3-chloro-5-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-2-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (70.0 mg, 0.12 mmol) was added to dichloromethane (1.0 ml), and trifluoroacetic acid (0.5 ml) was added dropwise. The mixture was reacted at room temperature for 2 hours. After the reaction was completed, the organic solvent was removed by concentration, and the resulting residue was purified by silica gel column chromatography (eluent: methanol / dichloromethane = 1 / 20). 30.0 mg of white solid (S)-2-((7-((3-chloro-5-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-2-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid was obtained (yield: 46.6%). LC-MS: RT=1.81 min, [M+H] + =536.26. 1 H NMR (500MHz, DMSO) δ12.76 (s, 1H), 8.26 (s, 1H), 7.81 (dd, J = 8.4, 1.3Hz, 1H), 7.67(d,J=8.4Hz,1H),7.36(dt,J=8.8,2.2Hz,1H),7.32(s,1H),7.23(dd,J=9.4,0.9Hz,1H),7.03(d,J= 8.3Hz,1H),6.79(d,J=7.1Hz,1H),6.71(d,J=0.6Hz,1H),5.05(s,2H),5.05–4.98(m,1H),4.78(dd,J=15 .3,7.3Hz,1H),4.64(dd,J=15.2,2.7Hz,1H),4.52–4.38(m,1H),4.31(dt,J=9.0,5.9Hz,1H),4.21–4.08 (m,1H),4.06–3.89(m,1H),3.80–3.49(m,2H),2.87–2.68(m,3H),2.67–2.54(m,1H),2.43–2.26(m,1H), 1.23(s,1H).

[0560] Embodiment 22

[0561] Synthesis of (S)-1-((oxetan-2-yl)methyl)-2-((7-((4-(trifluoromethyl)benzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0562]

[0563] The specific synthetic route is as follows:

[0564] Step A: Synthesis of tert-butyl 7-((4-(trifluoromethyl)benzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate

[0565]

[0566] Potassium carbonate (166 mg, 1.20 mmol) and 4-trifluoromethylbenzyl bromide (144 mg, 0.602 mmol) were added to a solution of 7-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxylic acid tert-butyl ester (100 mg, 0.402 mmol) in N,N-dimethylformamide (2.0 ml) at room temperature, and the mixture was reacted at room temperature for 1 hour. After the reaction was completed, saturated ammonium chloride solution was added to quench the mixture, and the mixture was extracted with ethyl acetate (30 ml × 3 times). The organic phases were combined, washed with saturated brine (30 ml × 2 times), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (eluent: n-hexane / ethyl acetate = 90 / 10). 101 mg of colorless oily tert-butyl 7-((4-(trifluoromethyl)benzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate was obtained (yield: 61.7%). LC-MS: RT = 2.33 min, [MH] - =406.36.

[0567] Step B: Synthesis of 7-((4-(trifluoromethyl)benzyl)oxy)-1,2,3,4-tetrahydroisoquinoline

[0568]

[0569] At room temperature, a solution of hydrogen chloride in 1,4-dioxane (1.0 ml, 4.0 mol / L) was added to a methanol solution (2.0 ml) containing tert-butyl 7-((4-(trifluoromethyl)benzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate (101 mg, 0.248 mmol) and reacted at room temperature for 0.5 hours. After the reaction was completed, the solvent was directly evaporated under reduced pressure to obtain a white solid 7-((4-(trifluoromethyl)benzyl)oxy)-1,2,3,4-tetrahydroisoquinoline hydrochloride, which was directly used in the next step. LC-MS: RT = 1.73 min, [M+H] + =308.20.

[0570] Step C: Synthesis of (S)-tert-butyl 1-((oxetan-2-yl)methyl)-2-((7-((4-(trifluoromethyl)benzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate

[0571]

[0572] At room temperature, 7-((4-(trifluoromethyl)benzyl)oxy)-1,2,3,4-tetrahydroisoquinoline obtained in the previous step was dissolved in N,N-dimethylformamide (2.0 ml), and N,N-diisopropylethylamine (64 mg, 0.50 mmol), cesium carbonate (161 mg, 0.50 mmol) and (S)-2-(chloromethyl)-1-((oxetane-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid tert-butyl ester (84 mg, 0.248 mmol) were added, and the temperature was raised to 50 degrees Celsius for 2 hours. After the reaction was completed, the reaction was quenched with saturated ammonium chloride solution, extracted with ethyl acetate (30 ml × 3 times), the organic phases were combined, washed with saturated brine (30 ml × 2 times), dried over anhydrous sodium sulfate, and concentrated. The residue was used directly in the next step. LC-MS: RT = 2.02 min, [M+H] + =608.30.

[0573] Step D: Synthesis of (S)-1-((oxetan-2-yl)methyl)-2-((7-((4-(trifluoromethyl)benzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0574]

[0575] To a dichloromethane solution (2.0 ml) containing the crude product (S)-tert-butyl 1-((oxetan-2-yl)methyl)-2-((7-((4-(trifluoromethyl)benzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate was added trifluoroacetic acid (1.0 ml) at room temperature, and the mixture was reacted at room temperature for 2 hours. After the reaction was completed, the solvent was removed by concentration, and the residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 96 / 4). 116 mg of white solid (S)-1-((oxetan-2-yl)methyl)-2-((7-((4-(trifluoromethyl)benzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid was obtained (total yield of three steps: 84.7%). LC-MS: RT = 1.82 min, [M+H] + = 552.27. 1H NMR (500MHz, DMSO) δ8.35 (s, 1H), 7.89 (dd, J=8.5, 1.3Hz, 1H), 7.80–7.72 (m, 3H), 7.63 (d, J=8.0Hz,2H),7.15(d,J=8.5Hz,1H),6.95–6.90(m,1H),6.86(s,1H),5.19(s,2H),5.03(ddd,J=14.5,7.3, 2.8Hz,1H),4.80(dd,J=15.5,7.1Hz,1H),4.71–4.59(m,2H),4.49–4.41(m,1H),4.34–4.21(m,2H),3.68– 3.50(m,4H),2.99(s,2H),2.74–2.61(m,1H),2.38–2.27(m,1H).

[0576] Embodiment 23

[0577] Synthesis of (S)-2-((7-((4-chloro-2-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0578]

[0579] The specific synthetic route is as follows:

[0580] Step A: Synthesis of tert-butyl 7-(4-chloro-2-fluorobenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate

[0581]

[0582] At room temperature, 1-(bromomethyl)-4-chloro-2-fluorobenzene (130.0 mg, 0.60 mmol), tert-butyl 7-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxylate (100.0 mg, 0.40 mmol) and potassium carbonate (100.0 mg, 0.80 mmol) were added to N,N-dimethylformamide (4.0 ml) and reacted at room temperature for 4.0 hours under nitrogen protection. After the reaction was completed, water was added to quench the reaction and ethyl acetate (50 ml × 3 times) was used for extraction. The organic phases were combined, washed with saturated brine (30 ml × 3 times), dried over anhydrous sodium sulfate, and finally purified by silica gel column chromatography (eluent: dichloromethane / methanol = 30 / 1) to obtain 106.0 mg of pale yellow solid tert-butyl 7-(4-chloro-2-fluorobenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate (yield: 67.9%). LC-MS: RT=2.29min,[M+H] + =392.17.

[0583] Step B: Synthesis of 7-(4-chloro-2-fluorobenzyl)oxy)-1,2,3,4-tetrahydroisoquinoline

[0584]

[0585] At room temperature, tert-butyl 7-(4-chloro-2-fluorobenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate (106.0 mg, 0.25 mmol) was added to a dioxane hydrochloric acid solution (1.00 mmol / ml, 5 ml) and reacted at room temperature for 1 hour under nitrogen protection. After the reaction was completed, the mixture was concentrated under reduced pressure. 80.0 mg of white solid 7-(4-chloro-2-fluorobenzyl)oxy)-1,2,3,4-tetrahydroisoquinoline (yield: 98.7%) was obtained and used directly in the next step. LC-MS: RT = 1.68 min, [M+H] + =292.16.

[0586] Step C: Synthesis of (S)-1-((oxetan-2-yl)methyl)-2-(((7-(4-chloro-2-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid tert-butyl ester

[0587]

[0588] At room temperature, 7-(4-chloro-2-fluorobenzyl)oxy)-1,2,3,4-tetrahydroisoquinoline (80.0 mg, 0.25 mmol), (S)-2-(chloromethyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid tert-butyl ester (79.8 mg, 0.27 mmol) and potassium carbonate (138.0 mg, 1.0 mmol) were added to N,N-dimethylformamide (3.0 ml), and N,N-diisopropylethylamine (0.50 ml) was added. Under nitrogen protection, the mixture was reacted at 50 degrees Celsius for 4.0 hours. After the reaction was completed, water was added to quench the mixture, and the mixture was extracted with ethyl acetate (50 ml × 3 times). The organic phases were combined, washed with saturated brine (30 ml × 3 times), dried over anhydrous sodium sulfate, and finally purified by silica gel column chromatography (eluent: dichloromethane / methanol = 20 / 1) to obtain 180.0 mg of white solid (S)-1-((oxetane-2-yl)methyl)-2-(((7-(4-chloro-2-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid tert-butyl ester (yield: 73.1%). LC-MS: RT = 2.07 min, [M+H] + =592.30.

[0589] Step D: Synthesis of (S)-1-((oxetan-2-yl)methyl)-2-(((7-(4-chloro-2-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0590]

[0591] To a solution of (S)-tert-butyl 1-((oxetan-2-yl)methyl)-2-(((7-(4-chloro-2-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (180.0 mg, 0.30 mmol) in dichloromethane (6.0 ml) was added trifluoroacetic acid (1.2 ml) at room temperature, and the mixture was reacted at room temperature for 3.0 hours. After the reaction was completed, water was added to quench, and the pH was adjusted to 6 with sodium bicarbonate aqueous solution (0.5 mol / L), extracted with dichloromethane (30 ml × 3 times), the organic phases were combined, washed with ammonium chloride aqueous solution (30 ml × 2 times), dried over anhydrous sodium sulfate, and finally purified by silica gel column chromatography (eluent: dichloromethane / methanol = 10 / 1) to obtain 6.0 mg of white solid (S)-1-((oxetane-2-yl)methyl)-2-(((7-(4-chloro-2-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (yield: 4.5%). LC-MS: RT = 1.81 min, [M+H] + =536.34. 1H NMR (500MHz, DMSO) δ8.25 (s, 1H), 7.82 (dd, J = 8.4, 1.6Hz, 1H), 7.66 (d, J=8.4Hz,1H),7.55(t,J=8.1Hz,1H),7.48(dd,J=10.0,2.1Hz,1H),7.32(dd,J=8.1,1.7Hz,1H),7.03(d, J=8.4Hz,1H),6.79(dd,J=8.3,2.8Hz,1H),6.74(d,J=2.6Hz,1H),5.05(s,2H),4.80(dd,J=15.3,7.2Hz ,1H),4.70–4.62(m,1H),4.46(dd,J=14.3,7.1Hz,1H),4.35(dt,J=9.0,6.0Hz,1H),4.10(d,J=13.6Hz, 1H),4.04(q,J=7.1Hz,1H),3.96(d,J=13.4Hz,1H),3.61(t,J=6.6Hz,1H),2.77(dd,J=16.3,7.2Hz,3H), 2.63(dd,J=15.3,4.2Hz,1H),2.43–2.34(m,1H),2.08(s,2H).

[0592] Embodiment 24

[0593] Synthesis of (S)-2-((7-((2-fluoro-6-(trifluoromethyl)benzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0594]

[0595] The specific synthetic route is as follows:

[0596] Step A: Synthesis of tert-butyl 7-((2-fluoro-6-(trifluoromethyl)benzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate

[0597]

[0598] To a solution of tert-butyl 7-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxylate (85.9 mg, 0.345 mmol) in N,N-dimethylformamide (5.0 ml) was added 2-(bromomethyl)-1-fluoro-3-(trifluoromethyl)benzene (80.1 mg, 0.313 mmol) and potassium carbonate (85.1 mg, 0.616 mmol) at room temperature, and the mixture was reacted at room temperature for 2 hours. After the reaction was completed, water was added to quench, extracted with ethyl acetate (30 ml x 2 times), washed with saturated brine (30 ml), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (eluent: ethyl acetate / n-hexane = 1 / 3. 84 mg of pale yellow solid 7-((2-fluoro-6-(trifluoromethyl)benzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylic acid tert-butyl ester was obtained (yield: 63.1%). LC-MS: RT = 2.18 min, [M+H] + =426.17.

[0599] Step B: Synthesis of 7-((2-fluoro-6-(trifluoromethyl)benzyl)oxy)-1,2,3,4-tetrahydroisoquinoline

[0600]

[0601] Dissolve tert-butyl 7-((2-fluoro-6-(trifluoromethyl)benzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate (84.0 mg, 0.197 mmol) in 5 ml of methanol, add 2 ml of 4 molar hydrochloric acid dioxane solution, and react at room temperature for 30 minutes. After the reaction is completed, concentrate to obtain 70 mg of 7-((2-fluoro-6-(trifluoromethyl)benzyl)oxy)-1,2,3,4-tetrahydroisoquinoline (yield: 98.5%). LC-MS: RT = 1.97 min, [M+H] + =326.27.

[0602] Step C: Synthesis of (S)-tert-butyl 2-((7-((2-fluoro-6-(trifluoromethyl)benzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate

[0603]

[0604] To a solution of 7-((2-fluoro-6-(trifluoromethyl)benzyl)oxy)-1,2,3,4-tetrahydroisoquinoline (70.0 mg, 0.192 mmol) in N,N-dimethylformamide (5.0 ml) was added (S)-tert-butyl 2-(chloromethyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (59.4 mg, 0.192 mmol) and potassium carbonate (53.1 mg, 0.384 mmol) at room temperature and reacted at 50°C for 3 hours. After the reaction was completed, water was added to quench, extracted with ethyl acetate (30 ml × 2 times), washed with saturated brine (30 ml), dried over anhydrous sodium sulfate, concentrated, and the resulting residue was purified by silica gel column chromatography (eluent: ethyl acetate / n-hexane = 5 / 1. 110 mg of light yellow solid (S)-2-((7-((2-fluoro-6-(trifluoromethyl)benzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetane-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid tert-butyl ester was obtained (yield: 91.6%). LC-MS: RT = 1.96 min, [M+H] + =626.27.

[0605] Step D: Synthesis of (S)-2-((7-((2-fluoro-6-(trifluoromethyl)benzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0606]

[0607] (S)-tert-butyl 2-((7-((2-fluoro-6-(trifluoromethyl)benzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (110 mg, 0.176 mmol) was dissolved in 4 ml of anhydrous dichloromethane, 2 ml of trifluoroacetic acid was added, and the mixture was reacted at room temperature for 40 minutes. After the reaction was completed, the reaction solution was poured into 20 ml of sodium bicarbonate solution, extracted with dichloromethane (30 ml × 2 times), the organic phases were combined, washed with saturated brine (20 ml × 2 times), dried over anhydrous sodium sulfate, and concentrated. The resulting residue was purified by silica gel column chromatography (eluent: methanol / dichloromethane = 10 / 1) to give 61 mg of a white solid (S)-2-((7-((2-fluoro-6-(trifluoromethyl)benzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetane-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (yield: 61%). 1H NMR (400MHz, DMSO) δ12.93(s,1H),8.36(d,J=0.5Hz,1H),7.89(dd,J=8.5,1.4Hz,1H),7.78(d,J= 8.5Hz,1H),7.75–7.63(m,3H),7.18(d,J=8.4Hz,1H),6.97–6.88(m,2H),5.10(s,2H),5.06-5.00(m,1H) ,4.81(dd,J=15.5,7.0Hz,2H),4.67(dd,J=15.5,2.5Hz,1H),4.48–4.40(m,2H),4.32–4.27(m,1H),3.08– 3.01(m,2H),2.83–2.54(m,2H),2.38–2.26(m,2H),1.47–1.08(m,2H). LC-MS:RT=1.80min,[M+H] + = 570.21.

[0608] Embodiment 25

[0609] Synthesis of (S)-2-((7-((5-fluoro-2-methylbenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-2-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0610]

[0611] The specific synthetic route is as follows:

[0612] Step A: Synthesis of tert-butyl 7-((5-fluoro-2-methylbenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate

[0613]

[0614] At room temperature, tert-butyl 7-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxylate (79.8 mg, 0.32 mmol) and potassium carbonate (89.0 mg, 0.64 mmol) were added to N,N-dimethylformamide (1.0 ml) containing 2-(bromomethyl)-4-fluoro-1-toluene (65.2 mg, 0.32 mmol) and reacted at room temperature for 2 hours. After the reaction was completed, water was added to quench the reaction, and ethyl acetate (20 ml × 3 times) was used for extraction. The organic phases were combined, washed with saturated brine (20 ml × 2 times), dried over anhydrous sodium sulfate, and concentrated. The resulting residue was purified by silica gel column chromatography (eluent: ethyl acetate / n-hexane = 1 / 5). 50.0 mg of yellow oily tert-butyl 7-((5-fluoro-2-methylbenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate was obtained (yield: 42.1%). LC-MS: RT = 2.33 min, [M + H] + =372.15.

[0615] Step B: Synthesis of 7-((5-fluoro-2-methylbenzyl)oxy)-1,2,3,4-tetrahydroisoquinoline

[0616]

[0617] At room temperature, a solution of hydrochloric acid in dioxane (1.0 ml, 4 mol / L) was added to tert-butyl 7-((5-fluoro-2-methylbenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate (50.0 mg, 0.13 mmol) in methanol (2.0 ml), and the mixture was reacted at room temperature for 3 hours. After the reaction was completed, the mixture was concentrated to obtain 39.9 mg of white solid 7-((5-fluoro-2-methylbenzyl)oxy)-1,2,3,4-tetrahydroisoquinoline, which was used directly in the next step. LC-MS: RT = 1.71 min, [M+H] + =272.23.

[0618] Step C: Synthesis of (S)-tert-butyl 2-((7-((5-fluoro-2-methylbenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-2-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate

[0619]

[0620] At room temperature, (S)-tert-butyl 2-(chloromethyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (44.0 mg, 0.13 mmol) and cesium carbonate (84.5 mg, 0.26 mmol) were added to N,N-dimethylformamide (2.0 ml) containing 7-((5-fluoro-2-methylbenzyl)oxy)-1,2,3,4-tetrahydroisoquinoline (39.9 mg, 0.13 mmol) and reacted at 50 degrees Celsius for 2 hours. After the reaction was completed, water was added to quench, and ethyl acetate (20 ml × 3 times) was used for extraction. The organic phases were combined, washed with saturated brine (20 ml × 2 times), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (eluent: ethyl acetate / n-hexane = 2 / 1). 65.0 mg of yellow oily (S)-tert-butyl 2-((7-((5-fluoro-2-methylbenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-2-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate were obtained (yield: 87.3%). LC-MS: RT = 1.98 min, [M+H] + =572.34.

[0621] Step D: Synthesis of (S)-2-((7-((5-fluoro-2-methylbenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-2-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0622]

[0623] At room temperature, (S)-tert-butyl 2-((7-((5-fluoro-2-methylbenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-2-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (65.0 mg, 0.11 mmol) was added to dichloromethane (1.0 ml), and trifluoroacetic acid (0.5 ml) was added dropwise. The mixture was reacted at room temperature for 2 hours. After the reaction was completed, the organic solvent was removed by concentration, and the resulting residue was purified by silica gel column chromatography (eluent: methanol / dichloromethane = 1 / 20). 34.0 mg of (S)-2-((7-((5-fluoro-2-methylbenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-2-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid was obtained as a white solid (yield: 59.8%). LC-MS: RT = 1.79 min, [M+H] + =516.26. 1H NMR (500MHz, DMSO) δ12.82 (s, 1H), 8.35 (s, 1H), 7.89 (dd, J = 8.5, 1.3Hz, 1H),7.77(d,J=8.5Hz,1H),7.29–7.11(m,3H),7.04(td,J=8.6,2.9Hz,1H),6.96(t,J=8.8Hz,1H),6.89(s ,1H),5.03(s,2H),5.00(dd,J=7.1,2.4Hz,1H),4.81(d,J=7.2Hz,1H),4.78(d,J=7.0Hz,1H),4.66(dd,J= 15.4,2.5Hz,2H),4.50–4.40(m,3H),4.35–4.23(m,1H),3.15–2.93(m,3H),2.73–2.58(m,1H),2.38–2.26(m, 1H),2.25(s,3H),1.22(s,1H).

[0624] Embodiment 26

[0625] Synthesis of (S)-1-((oxetan-2-yl)methyl)-2-((7-((3-chloro-2-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0626]

[0627] The specific synthetic route is as follows:

[0628] Step A: Synthesis of tert-butyl 7-((3-chloro-2-fluorobenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate

[0629]

[0630] At room temperature, potassium carbonate (90 mg, 0.64 mmol) and 3-chloro-2-fluorobenzyl bromide (86 mg, 0.39 mmol) were added to a solution of 7-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxylic acid tert-butyl ester (80 mg, 0.32 mmol) in N,N-dimethylformamide (2.0 ml), and the temperature was raised to 60 degrees Celsius for 1 hour. After the reaction was completed, saturated ammonium chloride solution was added to quench, and ethyl acetate (30 ml × 3 times) was used for extraction. The organic phases were combined, washed with saturated brine (30 ml × 2 times), dried over anhydrous sodium sulfate, and concentrated. The obtained residue was purified by silica gel column chromatography (eluent: n-hexane / ethyl acetate = 90 / 10). 60 mg of colorless oily 7-((3-chloro-2-fluorobenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylic acid tert-butyl ester was obtained (yield: 47.8%). LC-MS: RT = 2.34 min, [M-Boc + H] + =292.14.

[0631] Step B: Synthesis of 7-((3-chloro-2-fluorobenzyl)oxy)-1,2,3,4-tetrahydroisoquinoline

[0632]

[0633] At room temperature, a solution of hydrogen chloride in 1,4-dioxane (0.5 ml, 4.0 mol / L) was added to a methanol solution (1.0 ml) containing tert-butyl 7-((3-chloro-2-fluorobenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate (60 mg, 0.153 mmol) and reacted at room temperature for 1.5 hours. After the reaction was completed, the product was concentrated to obtain a white solid 7-((3-chloro-2-fluorobenzyl)oxy)-1,2,3,4-tetrahydroisoquinoline, which was directly used in the next step. LC-MS: RT = 1.72 min, [M+H] + =292.16.

[0634] Step C: Synthesis of (S)-1-((oxetan-2-yl)methyl)-2-((7-((3-chloro-2-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid tert-butyl ester

[0635]

[0636] At room temperature, 7-((3-chloro-2-fluorobenzyl)oxy)-1,2,3,4-tetrahydroisoquinoline obtained in the previous step was dissolved in N,N-dimethylformamide (2.0 ml), and N,N-diisopropylethylamine (57 mg, 0.44 mmol), cesium carbonate (143 mg, 0.44 mmol) and (S)-2-(chloromethyl)-1-((oxetane-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid tert-butyl ester (74 mg, 0.22 mmol) were added, and the temperature was raised to 50 degrees Celsius for 2 hours. After the reaction was completed, saturated ammonium chloride solution was added to quench, and ethyl acetate (30 ml × 3 times) was used for extraction. The organic phases were combined, washed with saturated brine (30 ml × 2 times), dried over anhydrous sodium sulfate, and concentrated. The residue was used directly in the next reaction. LC-MS: RT = 2.00 min, [M+H] + =592.30.

[0637] Step D: Synthesis of (S)-1-((oxetan-2-yl)methyl)-2-((7-((3-chloro-2-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0638]

[0639] To a dichloromethane solution (2.0 ml) containing the crude product (S)-tert-butyl 1-((oxetan-2-yl)methyl)-2-((7-((3-chloro-2-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate was added trifluoroacetic acid (1.0 ml) at room temperature, and the reaction was carried out at room temperature for 2 hours. After the reaction was completed, the solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 96 / 4). 81 mg of white solid (S)-1-((oxetan-2-yl)methyl)-2-((7-((3-chloro-2-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid was obtained (total yield of three steps: 47.3%). LC-MS: RT = 1.81 min, [M+H] + =536.23. 1H NMR (400MHz, DMSO) δ8.37(s,1H),7.90(dd,J=8.5,1.4Hz,1H),7.79(d,J=8.5Hz,1H),7.63–7.55 (m,1H),7.54–7.46(m,1H),7.26(t,J=7.9Hz,1H),7.17(d,J=8.5Hz,1H),6.99–6.93(m,1H),6.91(s,1H), 5.15(s,2H),5.07–4.98(m,1H),4.81(dd,J=15.5,7.0Hz,3H),4.72–4.63(m,1H),4.51–4.35(m,3H),4.35– 4.25(m,1H),3.72–3.61(m,2H),3.08–2.97(m,2H),2.74–2.62(m,1H),2.38–2.26(m,1H).

[0640] Embodiment 27

[0641] Synthesis of (S)-2-((7-((4-cyanobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0642]

[0643] The specific synthetic route is as follows:

[0644] Step A: Synthesis of tert-butyl 7-((4-cyanobenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate

[0645]

[0646] At room temperature, 4-cyanobenzyl bromide (235.3 mg, 1.2 mmol) and tert-butyl 7-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxylate (150.0 mg, 0.6 mmol) were dissolved in N,N-dimethylformamide (3 ml), and anhydrous potassium carbonate (250.0 mg, 1.8 mmol) was added. The mixture was reacted overnight at room temperature. After the reaction was complete, the mixture was diluted with ethyl acetate (100 ml), washed with water (30 ml × 2 times) and saturated brine (30 ml × 1 time), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 4 / 1) to obtain 225.0 mg of tert-butyl 7-((4-cyanobenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate (yield 89.9%). LC-MS: RT = 2.87 min, [M- t Bu] +=309.19.

[0647] Step B: Synthesis of 4-(((1,2,3,4-tetrahydroisoquinolin-7-yl)oxy)methyl)benzonitrile

[0648]

[0649] At room temperature, tert-butyl 7-((4-cyanobenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate (225.0 mg, 0.6 mmol) was dissolved in dichloromethane (4 ml), trifluoroacetic acid (1 ml) was added, and the mixture was reacted at room temperature for 1 hour. After the reaction was complete, the mixture was concentrated under reduced pressure to obtain 306.2 mg of light yellow oily 4-(((1,2,3,4-tetrahydroisoquinolin-7-yl)oxy)methyl)benzonitrile, which was directly used in the next step without further purification. LC-MS: RT = 1.43 min, [M+H] + =265.12.

[0650] Step C: Synthesis of (S)-tert-butyl 2-((7-((4-cyanobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate

[0651]

[0652] At room temperature, 4-(((1,2,3,4-tetrahydroisoquinolin-7-yl)oxy)methyl)benzonitrile (81.5 mg, 0.3 mmol) and (S)-tert-butyl 2-(chloromethyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (114.5 mg, 0.3 mmol) were dissolved in N,N-dimethylformamide (3 ml), and anhydrous potassium carbonate (115.3 mg, 829.5 μmol) was added. The mixture was reacted overnight at room temperature. After the reaction was complete, the mixture was diluted with ethyl acetate (100 ml), washed with water (30 ml × 2 times) and saturated brine (30 ml × 1 time), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1 to dichloromethane / methanol = 15 / 1) to obtain 164.0 mg of light yellow oily (S)-tert-butyl 2-((7-((4-cyanobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (yield 95.0%). LC-MS: RT = 2.87 min, [M+H] + =565.20.

[0653] Step D: Synthesis of (S)-2-((7-((4-cyanobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0654]

[0655] At room temperature, (S)-tert-butyl 2-((7-((4-cyanobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (105.3 mg, 186.4 μmol) was dissolved in dichloromethane (3 mL), and trifluoroacetic acid (1 mL) was added. The mixture was reacted at room temperature for 3 hours. After the reaction was completed, water (5 mL) was added to quench the mixture. The pH was adjusted to about 8 with saturated sodium bicarbonate aqueous solution, and the mixture was extracted with dichloromethane / methanol = 10 / 1 (30 mL × 3 times). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated. The obtained residue was purified by reverse phase HPLC (mobile phase: (0.1% aqueous ammonia / water) / acetonitrile = 95 / 5 to 55 / 45) and lyophilized to give 41.7 mg of white solid (S)-2-((7-((4-cyanobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (yield: 44.1%). LC-MS: RT = 1.63 min, [M+H] + =509.14. 1 H NMR (400MHz, CD 3 OD)δ8.31(s,1H), 7.97(d,J=8.4Hz,1H),7.69(s,3H),7.59(s,2H),7.02(d,J=8.3Hz,1H),6.79(s,1H),6.64(s,1H),5.19(s, 1H),5.10(s,2H),4.72(s,1H),4.58(d,J=8.5Hz,2H),4.41(s,2H),4.17(d,J=13.9H z, 1H), 4.06 (d, J = 13.8Hz, 1H), 3.65 (s, 2H), 2.84 (s, 3H), 2.69 (s, 1H), 2.46 (s, 1H).

[0656] Embodiment 28

[0657] Synthesis of (S)-2-((7-((4-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0658]

[0659] The specific synthetic route is as follows:

[0660] Step A: Synthesis of tert-butyl 7-((4-fluorobenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate

[0661]

[0662] At room temperature, 4-fluorobenzyl bromide (226.0 mg, 1.2 mmol) and tert-butyl 7-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxylate (150.3 mg, 0.6 mmol) were dissolved in N,N-dimethylformamide (3 ml), and anhydrous potassium carbonate (250.8 mg, 1.8 mmol) was added. The mixture was reacted overnight at room temperature. After the reaction was complete, it was diluted with ethyl acetate (100 ml), washed with water (30 ml × 2 times) and saturated brine (30 ml × 1 time), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 4 / 1) to obtain 200.0 mg of tert-butyl 7-((4-fluorobenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate (yield 93.0%). LC-MS: RT = 3.43 min, [M- t Bu] + =302.56.

[0663] Step B: Synthesis of 7-((4-fluorobenzyl)oxy)-1,2,3,4-tetrahydroisoquinoline

[0664]

[0665] At room temperature, tert-butyl 7-((4-fluorobenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate (254.2 mg, 0.7 mmol) was dissolved in dichloromethane (4 ml), trifluoroacetic acid (1 ml) was added, and the mixture was reacted at room temperature for 1 hour. After the reaction was complete, the mixture was concentrated under reduced pressure to obtain 323.0 mg of light yellow oily 7-((4-fluorobenzyl)oxy)-1,2,3,4-tetrahydroisoquinoline, which was directly used in the next step without further purification. L-MS: RT=1.72min, [M+H] + =258.20.

[0666] Step C: Synthesis of (S)-tert-butyl 2-((7-((4-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate

[0667]

[0668] At room temperature, 7-((4-fluorobenzyl)oxy)-1,2,3,4-tetrahydroisoquinoline (91.5 mg, 0.3 mmol) and (S)-tert-butyl 2-(chloromethyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (131.4 mg, 0.4 mmol) were dissolved in N,N-dimethylformamide (3 ml), and anhydrous potassium carbonate (146.2 mg, 1.0 mmol) was added. The mixture was reacted overnight at room temperature. After the reaction was complete, the mixture was diluted with ethyl acetate (100 ml), washed with water (30 ml × 2 times) and saturated brine (30 ml × 1 time), dried over anhydrous sodium sulfate, and concentrated. The obtained residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1 to dichloromethane / methanol = 15 / 1) to obtain 168.2 mg of light yellow oily (S)-tert-butyl 2-((7-((4-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (yield 85.1%). LC-MS: RT = 3.23 min, [M+H] + =558.20.

[0669] Step D: Synthesis of (S)-2-((7-((4-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0670]

[0671] At room temperature, (S)-tert-butyl 2-((7-((4-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (100.3 mg, 177.0 μmol) was dissolved in dichloromethane (3 ml), trifluoroacetic acid (1 ml) was added, and the reaction was carried out at room temperature for 3 hours. After the reaction was completed, water (5 ml) was added to quench the reaction, and the pH was adjusted to 8 with saturated sodium bicarbonate aqueous solution. The reaction was extracted with dichloromethane / methanol = 10 / 1 (30 ml × 3 times), and the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated. The obtained residue was purified by reverse phase HPLC (mobile phase: (0.1% aqueous ammonia / water) / acetonitrile = 95 / 5 to 55 / 45) and lyophilized to give 41.5 mg of white solid (S)-2-((7-((4-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (yield: 41.2%). LC-MS: RT = 1.82 min, [M+H] + =502.14. 1 H NMR (400MHz, CD 3 OD)δ8.31(s,1H),7.97(d,J=8.5Hz,1H),7.68(d,J=8.4Hz,1H),7.40(s,2H),7.16–6.94(m,3H),6.77(d,J=8.0Hz,1H),6.63(s,1H), 5.19(s,1H),4.97(s,2H),4.70(d,J=15.4Hz,1H),4.57(s,1H),4.41(s,1H),4.18(d,J=14.0Hz,1H),4.06 (d,J=13.9Hz,1H),3.66(s,2H),2.84(s,3H),2.69(s,1H),2.45(s,1H).

[0672] Embodiment 29

[0673] Synthesis of (S)-2-((7-((4-chlorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0674]

[0675] The specific synthetic route is as follows:

[0676] Step A: Synthesis of tert-butyl 7-((4-chlorobenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate

[0677]

[0678] At room temperature, 4-chlorobenzyl bromide (246.0 mg, 1.2 mmol) and tert-butyl 7-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxylate (150.0 mg, 0.6 mmol) were dissolved in N,N-dimethylformamide (3 ml), and anhydrous potassium carbonate (250.5 mg, 1.8 mmol) was added. The mixture was reacted overnight at room temperature. After the reaction was complete, it was diluted with ethyl acetate (100 ml), washed with water (30 ml × 2 times) and saturated brine (30 ml × 1 time), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 4 / 1) to obtain 200.0 mg of tert-butyl 7-((4-chlorobenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate (yield 93.0%). LC-MS: RT = 5.00 min, [M- t Bu] + =302.06.

[0679] Step B: Synthesis of 7-((4-chlorobenzyl)oxy)-1,2,3,4-tetrahydroisoquinoline

[0680]

[0681] At room temperature, tert-butyl 7-((4-chlorobenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate (200.0 mg, 0.5 mmol) was dissolved in dichloromethane (4 ml), trifluoroacetic acid (1 ml) was added, and the mixture was reacted at room temperature for 1 hour. After the reaction was complete, the mixture was concentrated under reduced pressure to obtain 254.0 mg of light yellow oily 7-((4-chlorobenzyl)oxy)-1,2,3,4-tetrahydroisoquinoline, which was directly used in the next step without further purification. LC-MS: RT=1.78min, [M+H] + =274.10.

[0682] Step C: Synthesis of (S)-tert-butyl 2-((7-((4-chlorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate

[0683]

[0684] At room temperature, 7-((4-chlorobenzyl)oxy)-1,2,3,4-tetrahydroisoquinoline (73.5 mg, 0.3 mmol) and (S)-tert-butyl 2-(chloromethyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (98.4 mg, 0.3 mmol) were dissolved in N,N-dimethylformamide (3 ml), and anhydrous potassium carbonate (121.2 mg, 0.9 mmol) was added. The mixture was reacted overnight at room temperature. After the reaction was complete, the mixture was diluted with ethyl acetate (100 ml), washed with water (30 ml × 2 times) and saturated brine (30 ml × 1 time), dried over anhydrous sodium sulfate, and concentrated. The obtained residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1 to dichloromethane / methanol = 15 / 1) to obtain 145.2 mg of light yellow oily (S)-tert-butyl 2-((7-((4-chlorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (yield 95.1%). LC-MS: RT = 3.63 min, [M+H] + =574.20.

[0685] Step D: Synthesis of (S)-2-((7-((4-chlorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0686]

[0687] At room temperature, (S)-tert-butyl 2-((7-((4-chlorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (145.2 mg, 252.0 μmol) was dissolved in dichloromethane (2 ml), and trifluoroacetic acid (1 ml) was added. The mixture was reacted at room temperature for 3 hours. After the reaction was completed, water (5 ml) was added to quench the reaction. The pH was adjusted to 8 with saturated sodium bicarbonate aqueous solution, and the mixture was extracted with dichloromethane / methanol = 10 / 1 (30 ml × 3 times). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated. The obtained residue was purified by reverse phase HPLC (mobile phase: (0.1% aqueous ammonia / water) / acetonitrile = 95 / 5 to 55 / 45) and lyophilized to give 90.5 mg of white solid (S)-2-((7-((4-chlorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (yield: 69.2%). LC-MS: RT = 2.13 min, [M+H] +=518.13. 1 H NMR (400MHz, CD 3 OD)δ8.31(s,1H),7.96(s,1H), 7.68(d,J=8.4Hz,1H),7.35(d,J=11.4Hz,4H),7.01(d,J=8.5Hz,1H),6.77(s,1H),6.63(s,1H),5.20(s, 1H),4.98(s,2H),4.70(d,J=15.2Hz,1H),4.57(s,1H),4.41(s,1H),4.17(d,J=13.8 Hz, 1H), 4.05 (d, J = 13.5Hz, 1H), 3.65 (s, 2H), 2.83 (s, 4H), 2.69 (s, 1H), 2.46 (s, 1H).

[0688] Embodiment 30

[0689] Synthesis of (S)-2-((7-((2-cyanobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0690]

[0691] The specific synthetic route is as follows:

[0692] Step A: Synthesis of tert-butyl 7-(2-cyanobenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate

[0693]

[0694] At room temperature, 2-(bromomethyl)benzonitrile (130.0 mg, 0.64 mmol), tert-butyl 7-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxylate (80.0 mg, 0.32 mmol) and potassium carbonate (138.0 mg, 1.00 mmol) were added to N,N-dimethylformamide (4.0 ml) and reacted at room temperature for 4.0 hours under nitrogen protection. After the reaction was completed, water was added to quench, and ethyl acetate (50 ml × 3 times) was used for extraction. The organic phases were combined, washed with saturated brine (30 ml × 3 times), dried over anhydrous sodium sulfate, concentrated, and finally purified by silica gel column chromatography (eluent: dichloromethane / methanol = 30 / 1) to obtain 120.0 mg of pale yellow solid tert-butyl 7-(2-cyanobenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate (yield: 62.5%). LC-MS: RT = 2.18 min, [M + Na] + =387.23.

[0695] Step B: Synthesis of 7-(2-cyanobenzyl)oxy)-1,2,3,4-tetrahydroisoquinoline

[0696]

[0697] At room temperature, tert-butyl 7-(2-cyanobenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate (120.0 mg, 0.30 mmol) was added to a dioxane hydrochloric acid solution (1.00 mmol / ml, 5 ml), and reacted at room temperature for 1 hour under nitrogen protection. After the reaction was completed, the mixture was concentrated under reduced pressure. 89.0 mg of white solid 7-(2-cyanobenzyl)oxy)-1,2,3,4-tetrahydroisoquinoline (yield: 90.2%) was obtained and used directly in the next step.

[0698] Step C: Synthesis of (S)-tert-butyl 1-((oxetan-2-yl)methyl)-2-(((7-(2-cyanobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate

[0699]

[0700] At room temperature, 7-(2-cyanobenzyl)oxy)-1,2,3,4-tetrahydroisoquinoline (80.0 mg, 0.27 mmol), (S)-tert-butyl 2-(chloromethyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (79.8 mg, 0.27 mmol) and potassium carbonate (138.0 mg, 1.0 mmol) were added to N,N-dimethylformamide (3.0 ml), and N,N-diisopropylethylamine (0.50 ml) was added, and the reaction was carried out at 50 °C under nitrogen protection for 4.0 hours. After the reaction was completed, water was added to quench the reaction, and the mixture was extracted with ethyl acetate (50 ml × 3 times). The organic phases were combined, washed with saturated brine (30 ml × 3 times), dried over anhydrous sodium sulfate, concentrated, and purified by silica gel column chromatography (eluent: dichloromethane / methanol = 20 / 1) to obtain 180.0 mg of white solid (S)-1-((oxetane-2-yl)methyl)-2-(((7-(2-cyanobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid tert-butyl ester (yield: 73.1%). LC-MS: RT = 1.89 min, [M+H] + =565.37.

[0701] Step D: Synthesis of (S)-1-((oxetan-2-yl)methyl)-2-(((7-(2-cyanobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0702]

[0703] Trifluoroacetic acid (1.2 ml) was added to a solution of (S)-tert-butyl 1-((oxetan-2-yl)methyl)-2-(((7-(2-cyanobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (180.0 mg, 0.30 mmol) in dichloromethane (6.0 ml) at room temperature, and the mixture was reacted at room temperature for 3.0 hours. After the reaction was completed, water was added to quench, and the pH was adjusted to 6 with sodium bicarbonate aqueous solution (0.5 mol / L), extracted with dichloromethane (30 ml × 3 times), the organic phases were combined, washed with ammonium chloride aqueous solution (30 ml × 2 times), dried over anhydrous sodium sulfate, concentrated, and purified by silica gel column chromatography (eluent: dichloromethane / methanol = 10 / 1) to obtain 45.0 mg of white solid (S)-1-((oxetane-2-yl)methyl)-2-(((7-(2-cyanobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (yield: 29.6%). LC-MS: RT = 1.70 min, [M+H] + =508.28. 1 H NMR (400MHz, DMSO) δ8.26 (s, 1H), 7.89 (d, J = 7.7Hz, 1H), 7.82 (dd, J = 8.4, 1.4 Hz,1H),7.78–7.64(m,3H),7.59–7.53(m,1H),7.05(d,J=8.4Hz,1H),6.82(dd,J=8.3,2.7Hz,1H),6.77(d, J=2.4Hz,1H),5.17(s,2H),5.05(d,J=4.9Hz,1H),4.81(dd,J=15.2,7.0Hz,1H),4.66(d,J=12.8Hz, 1H),4.45(dd,J=14.5,7.3Hz,1H),4.34(dt,J=11.7,5.8Hz,1H),4.11(d,J=13.6Hz,1H),3.96(d,J=13.6 Hz,1H),3.63(q,J=15.6Hz,2H),2.82–2.72(m,4H),2.61(d,J=6.1Hz,1H),2.37(t,J=13.7Hz,1H).

[0704] Embodiment 31

[0705] Synthesis of (S)-1-((oxetane-2-yl)methyl)-2-(((7-((1-(2,2,2-trifluoroethyl)-1H-indazol-6-yl)methoxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0706]

[0707] The specific synthetic route is as follows:

[0708] Step A: Synthesis of methyl 1-(2,2,2-trifluoroethyl)-1H-indazole-6-carboxylate

[0709]

[0710] At room temperature, 1,1,1-trifluoro-2-iodoethane (1.49 g, 7.15 mmol) and potassium carbonate (1.97 g, 14.3 mmol) were added to N,N-dimethylformamide (10 ml) containing 1H-indazole-6-carboxylic acid methyl ester (1.26 g, 7.15 mmol), and the temperature was raised to 80 degrees Celsius for 1 hour. After the reaction was completed, water was added to quench, ethyl acetate (30 ml × 2 times) was extracted, saturated brine (30 ml) was washed, dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (eluent: ethyl acetate / n-hexane = 1 / 2) to obtain 220 mg of white solid 1-(2,2,2-trifluoroethyl)-1H-indazole-6-carboxylic acid methyl ester (yield: 12.1%). LC-MS: RT = 1.91 min, [M+H] + =259.17.

[0711] Step B: Synthesis of 1-(2,2,2-trifluoroethyl)-1H-indazol-6-yl)methanol

[0712]

[0713] 1-(2,2,2-trifluoroethyl)-1H-indazole-6-carboxylic acid methyl ester (220 mg, 0.849 mmol) was dissolved in 5 ml of anhydrous tetrahydrofuran, and lithium aluminum hydride (39.5 mg, 1.04 mmol) was added at -10 degrees Celsius to react for 30 minutes. After the reaction was completed, water was added to quench, and ethyl acetate (30 ml × 2 times) was extracted. The organic phases were combined, washed with saturated brine (20 ml × 2 times), dried over anhydrous sodium sulfate, and concentrated. The resulting residue was purified by silica gel column chromatography (eluent: ethyl acetate / n-hexane = 1 / 1) to obtain 152 mg of white solid 1-(2,2,2-trifluoroethyl)-1H-indazole-6-yl)methanol (yield: 77.5%). LC-MS: RT = 1.86 min, [M+H] + =231.17.

[0714] Step C: Synthesis of 1-(2,2,2-trifluoroethyl)-1H-indazol-6-yl)bromomethyl

[0715]

[0716] 1-(2,2,2-trifluoroethyl)-1H-indazol-6-yl)methanol (152 mg, 0.661 mmol) was dissolved in 5 ml of anhydrous tetrahydrofuran, phosphorus tribromide (125.8 mg, 0.46 mmol) was added at -10 degrees Celsius, and the reaction was carried out at room temperature for 30 minutes. After the reaction was completed, water was added to quench the reaction, and ethyl acetate (30 ml × 2 times) was used for extraction. The organic phases were combined, washed with saturated brine (20 ml × 2 times), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (eluent: ethyl acetate / n-hexane = 1 / 2) to obtain 65 mg of light yellow solid 1-(2,2,2-trifluoroethyl)-1H-indazol-6-yl)bromomethyl (yield: 33.5%). LC-MS: RT = 1.96 min, [M+H] + =292.98.

[0717] Step D: Synthesis of tert-butyl 7-((1-(2,2,2-trifluoroethyl)-1H-indazol-6-yl)methoxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate

[0718]

[0719] To tert-butyl 7-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxylate (82.9 mg, 0.333 mmol) in N,N-dimethylformamide (5.0 ml) at room temperature were added 1-(2,2,2-trifluoroethyl)-1H-indazol-6-yl)bromomethyl (65.0 mg, 0.222 mmol) and potassium carbonate (61.2 mg, 0.444 mmol), and the mixture was reacted at room temperature for 2 hours. After the reaction was completed, water was added to quench, extracted with ethyl acetate (30 ml x 2 times), washed with saturated brine (30 ml), dried over anhydrous sodium sulfate, concentrated, and the resulting residue was purified by silica gel column chromatography (eluent: ethyl acetate / n-hexane = 1 / 3. 92 mg of pale yellow solid 7-((2-fluoro-6-(trifluoromethyl)benzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylic acid tert-butyl ester was obtained (yield: 89.7%). LC-MS: RT = 2.12 min, [M+H] + =462.19.

[0720] Step E: Synthesis of 7-((1-(2,2,2-trifluoroethyl)-1H-indazol-6-yl)methoxy)-1,2,3,4-tetrahydroisoquinoline

[0721]

[0722] Dissolve tert-butyl 7-((2-fluoro-6-(trifluoromethyl)benzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate (92.0 mg, 0.199 mmol) in 5 ml of methanol, add 2 ml of 4 molar hydrochloric acid dioxane solution, and react at room temperature for 30 minutes. After the reaction is completed, concentrate to obtain 77 mg of 7-((1-(2,2,2-trifluoroethyl)-1H-indazol-6-yl)methoxy)-1,2,3,4-tetrahydroisoquinoline (yield: 97.4%). LC-MS: RT = 1.96 min, [M+H] + =362.27.

[0723] Step F: Synthesis of (S)-tert-butyl 1-((oxetan-2-yl)methyl)-2-((7-((1-(2,2,2-trifluoroethyl)-1H-indazol-6-yl)methoxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate

[0724]

[0725] To a solution of 7-((1-(2,2,2-trifluoroethyl)-1H-indazol-6-yl)methoxy)-1,2,3,4-tetrahydroisoquinoline (77.0 mg, 0.194 mmol) in N,N-dimethylformamide (5.0 ml) at room temperature were added (S)-tert-butyl 2-(chloromethyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (61.4 mg, 0.194 mmol) and potassium carbonate (53.1 mg, 0.384 mmol), and the mixture was heated to 50°C for 3 hours. After the reaction was completed, water was added to quench, extracted with ethyl acetate (30 ml × 2 times), washed with saturated brine (30 ml), dried over anhydrous sodium sulfate, concentrated, and the residue was purified by silica gel column chromatography (eluent: ethyl acetate / n-hexane = 5 / 1. 102 mg of light yellow solid (S)-1-((oxetane-2-yl)methyl)-2-((7-((1-(2,2,2-trifluoroethyl)-1H-indazol-6-yl)methoxy)-3,4-dihydroisoquinolin)-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid tert-butyl ester was obtained (yield: 79.6%). LC-MS: RT = 1.92 min, [M+H] + =662.29.

[0726] Step G: Synthesis of (S)-1-((oxetan-2-yl)methyl)-2-((7-((1-(2,2,2-trifluoroethyl)-1H-indazol-6-yl)methoxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0727]

[0728] (S)-tert-butyl 1-((oxetan-2-yl)methyl)-2-((7-((1-(2,2,2-trifluoroethyl)-1H-indazol-6-yl)methoxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (102 mg, 0.154 mmol) was dissolved in 4 ml of anhydrous dichloromethane, 2 ml of trifluoroacetic acid was added, and the mixture was reacted at room temperature for 40 minutes. After the reaction was completed, the reaction solution was poured into 20 ml of sodium bicarbonate solution and extracted with dichloromethane (30 ml × 2 times). The organic phases were combined, washed with saturated brine (20 ml × 2 times), dried over anhydrous sodium sulfate, and concentrated. The resulting residue was purified by silica gel column chromatography (eluent: methanol / dichloromethane = 10 / 1) to give 35 mg of white solid (S)-1-((oxetane-2-yl)methyl)-2-((7-((1-(2,2,2-trifluoroethyl)-1H-indazol-6-yl)methoxy)-3,4-dihydroisoquinolin)-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (yield: 61%). 1 H NMR (400MHz, DMSO) δ12.92(s,1H),8.35(s,1H),8.20(s,1H),7.92–7.85(m, 2H),7.78(t,J=9.2Hz,2H),7.25(dd,J=8.2,0.7Hz,1H),7.15(d,J=8.4Hz,1H),6.97(dd,J=8.7,2.1Hz, 1H),6.90(s,1H),5.45–5.39(m,2H),5.20(s,2H),5.05–4.96(m,1H),4.79(dd,J=15.7,6.9Hz,2H),4.65(dd ,J=15.4,2.4Hz,1H),4.48–4.38(m,2H),4.31–4.24(m,1H),3.06–2.95(m,2H),2.80–2.54(m,2H),2.40–2.17 (m,2H),1.28–1.13(m,2H). LC-MS:RT=1.77min,[M+H] + =606.32.

[0729] Embodiment 32

[0730] Synthesis of (S)-2-((7-((2-chlorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0731]

[0732] The specific synthetic route is as follows:

[0733] Step A: Synthesis of tert-butyl 7-((2-chlorobenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate

[0734]

[0735] At room temperature, 2-chlorobenzyl bromide (82 mg, 0.40 mmol), tert-butyl 7-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxylate (100.0 mg, 0.40 mmol) and potassium carbonate (110 mg, 0.80 mmol) were added to N,N-dimethylformamide (5.0 ml), and N,N-diisopropylethylamine (0.50 ml) was added. The mixture was reacted at room temperature for 4 hours under nitrogen protection. After the reaction was completed, water was added to quench the mixture, and the mixture was extracted with ethyl acetate (30 ml × 3 times). The organic phases were combined, washed with saturated brine (30 ml × 3 times), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (eluent: n-hexane: ethyl acetate = 10:1) to obtain 72 mg of tert-butyl 7-((2-chlorobenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate as a white solid (yield: 66%). LC-MS: RT = 2.32 min, [M-100] + =274.16.

[0736] Step B: Synthesis of 7-((2-chlorobenzyl)oxy)-1,2,3,4-tetrahydroisoquinoline

[0737]

[0738] At room temperature, tert-butyl 7-((2-chlorobenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate (72 mg, 0.19 mmol) was added to a dioxane hydrochloric acid solution (1.00 mmol / ml, 2.5 ml) and reacted at room temperature for 1 hour under nitrogen protection. After the reaction was completed, the crude product 7-((2-chlorobenzyl)oxy)-1,2,3,4-tetrahydroisoquinoline was concentrated to obtain 70 mg of a light yellow solid, which was directly used in the next step. LC-MS: RT = 1.66 min, [M+H] + =274.17.

[0739] Step C: Synthesis of (S)-tert-butyl 2-((7-((2-chlorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate

[0740]

[0741] At room temperature, 7-((2-chlorobenzyl)oxy)-1,2,3,4-tetrahydroisoquinoline (70 mg, 0.26 mmol), (S)-tert-butyl 2-(chloromethyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (75 mg, 0.26 mmol) and potassium carbonate (69 mg, 0.50 mmol) were added to N,N-dimethylformamide (3.0 ml), and N,N-diisopropylethylamine (0.50 ml) was added, and the reaction was carried out at room temperature under nitrogen protection. After the reaction was completed, water was added to quench, and ethyl acetate (20 ml × 2 times) was used for extraction. The organic phases were combined, washed with saturated brine (30 ml × 3 times), dried over anhydrous sodium sulfate, and concentrated. The resultant was purified by silica gel column chromatography (eluent: n-hexane: ethyl acetate = 1:1) to obtain 60 mg of white solid (S)-2-((7-((2-chlorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-(oxetane-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid tert-butyl ester (yield: 41%). LC-MS: RT = 1.98 min, [M+H] + =574.28.

[0742] Step D: Synthesis of (S)-2-((7-((2-chlorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0743]

[0744] At room temperature, (S)-tert-butyl 2-((7-((2-chlorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (60 mg, 0.11 mmol) was dissolved in dichloromethane (5 mL), and trifluoroacetic acid (1 mL) was added to react for 1 hour. After the reaction was completed, the reaction was concentrated and the crude product was purified by HPLC to give 40 mg of white solid (S)-2-((7-((2-chlorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (yield: 74%). LC-MS: RT = 1.79 min, [M+H] + =518.23. 1 H NMR (500 MHz, DMSO-d 6 )δ8.10(s,1H),7.78(dd,J=8.4,1.2Hz,1H), 7.58–7.47(m,3H),7.41–7.30(m,2H),7.02(d,J=8.4Hz,1H),6.82-6.68(m,2H),5.15–4.96(m,3H),4.73 (dd,J=15.3,7.0Hz,1H),4.59(dd,J=15.2,2.9Hz,1H),4.44(dd,J=13.7,7.6Hz,1H),4.33(dt,J=8.9,5. 9Hz,1H),4.05(d,J=13.4Hz,1H),3.92(d,J=13.3Hz,1H),3.59(t,J=9.5Hz,3H),2.74(s,3H),2.64–2.56 (m,1H),2.41–2.32(m,1H).

[0745] Embodiment 33

[0746] Synthesis of (S)-7-fluoro-2-((4-(6-((1-(2-methoxyethyl)-1H-indazol-6-yl)methoxy)pyridin-2-yl)piperidin-1-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0747]

[0748] The specific synthetic route is as follows:

[0749] Step A: Synthesis of methyl (S)-2-fluoro-4-nitro-3-(((oxetane-2-yl)methyl)amino)benzoate

[0750]

[0751] Methyl 2,3-difluoro-4-nitrobenzoate (700 mg, 3.22 mmol) was dissolved in tetrahydrofuran (20.0 ml), triethylamine (623 mg, 4.83 mmol) and (S)-oxetane-2-ylmethylamine (308 mg, 3.54 mmol) were added, and the temperature was lowered to zero degrees Celsius for 2 hours. After the reaction, 40 ml of water was added for dilution, and ethyl acetate (20 ml × 3 times) was used for extraction. The organic phases were combined, washed with saturated brine (10 ml × 3 times), dried over anhydrous sodium sulfate, concentrated, and purified by silica gel column chromatography (eluent: n-hexane: ethyl acetate = 5:1) to obtain 530 mg of colorless oily (S)-methyl 2-fluoro-4-nitro-3-(((oxetane-2-yl)methyl)amino)benzoate (yield: 59.0%).

[0752] Step B: Synthesis of methyl (S)-4-amino-2-fluoro-3-(((oxetane-2-yl)methyl)amino)benzoate

[0753]

[0754] At room temperature, (S)-2-fluoro-4-nitro-3-(((oxetane-2-yl)methyl)amino)benzoic acid methyl ester (530.0 mg, 1.9 mmol) was dissolved in methanol (10 ml), saturated ammonium chloride solution (1 ml) and reduced iron powder (1.1 g, 19 mmol) were added, and the mixture was reacted at room temperature for 2 hours. After the reaction was completed, the mixture was filtered, the filtrate was concentrated under reduced pressure, and purified by silica gel column chromatography (eluent: n-hexane: ethyl acetate = 1:1) to obtain 450 mg of white solid methyl (S)-4-amino-2-fluoro-3-(((oxetane-2-yl)methyl)amino)benzoic acid methyl ester (yield: 77.3%). LC-MS: RT = 1.72 min, [M+H] + =255.18.

[0755] Step C: Synthesis of (S)-methyl 2-(chloromethyl)-7-fluoro-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate

[0756]

[0757] At room temperature, methyl (S)-4-amino-2-fluoro-3-(((oxetane-2-yl(methyl)amino)benzoate (350 mg, 1.47 mmol) was dissolved in tetrahydrofuran (4.0 ml) solution, 2-chloro-1,1,1-trimethoxyethane (382 mg, 2.94 mmol) was added, and the temperature was raised to 80 degrees Celsius for 2 hours. After the reaction was completed, it was diluted with water, extracted with ethyl acetate (30 ml × 3 times), and the organic phases were combined, washed with saturated brine (20 ml × 3 times), dried over anhydrous sodium sulfate, and concentrated to obtain 230 mg of light yellow solid (S)-2-(chloromethyl)-7-fluoro-1-((oxetane-2-yl(methyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (yield: 50.1%). LC-MS: RT = 1.85 min, [M+H] + =313.15.

[0758] Step D: Synthesis of (methyl (S)-7-fluoro-2-((4-(6-((1-(2-methoxyethyl)-1H-indazol-6-yl)methoxy)pyridin-2-yl)piperidin-1-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester

[0759]

[0760] At room temperature, (S)-methyl 2-(chloromethyl)-7-fluoro-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (100 mg, 0.32 mmol) and potassium carbonate (88 mg, 0.64 mmol) were dissolved in N,N-dimethylformamide (7.0 ml). 1-(2-methoxyethyl)-6-(((6-(piperidin-4-yl)pyridin-2-yl)oxy)methyl)-1H-indazole (116 mg, 0.32 mmol) was added and the mixture was reacted at 50 °C for 3 h under nitrogen protection. After the reaction was completed, the mixture was diluted with water and extracted with ethyl acetate (20 ml × 3 times). The organic phases were combined, washed with saturated brine (10 ml × 3 times), dried over anhydrous sodium sulfate, concentrated, and finally purified by silica gel column chromatography (eluent: n-hexane: ethyl acetate = 0:1) to obtain 90 mg of a light yellow solid (methyl (S)-7-fluoro-2-((4-(6-((1-(2-methoxyethyl)-1H-indazol-6-yl)methoxy)pyridin-2-yl)piperidin-1-yl)methyl)-1-((oxetane-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (yield: 43.7%). LC-MS: RT = 1.77 min, [M+H] + =643.30.

[0761] Step D: Synthesis of (methyl(S)-7-fluoro-2-((4-(6-((1-(2-methoxyethyl)-1H-indazol-6-yl)methoxy)pyridin-2-yl)piperidin-1-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0762]

[0763] At room temperature, (methyl (S)-7-fluoro-2-((4-(6-((1-(2-methoxyethyl)-1H-indazol-6-yl)methoxy)pyridin-2-yl)piperidin-1-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (90 mg, 0.14 mmol) was dissolved in a solution of tetrahydrofuran (2.0 ml), water (1 ml) and methanol (1 ml), and lithium hydroxide monohydrate (17 mg, 0.42 mmol) was added and reacted at room temperature for 1 hour. After the reaction was completed, 15% citric acid was added to adjust the pH to 6, and ethyl acetate (10 ml × 3 times) was used for extraction. The organic phases were combined and saturated brine (10 ml × 3 times) was added. The mixture was washed, dried over anhydrous sodium sulfate, concentrated, and the crude product was purified by preparative high performance liquid chromatography to obtain 14 mg of (S)-7-fluoro-2-((4-(6-((1-(2-methoxyethyl)-1H-indazol-6-yl)methoxy)pyridin-2-yl)piperidin-1-yl)methyl)-1-((oxetane-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (yield: 24.7%). LC-MS: RT = 1.66 min, [M+H] + =629.20. 1H NMR (400MHz, DMSO) δ8.01 (s, 1H), 7.77 (dd, J = 8.3, 1.3Hz, 1H), 7.41 (d, J = 8.5Hz, 1H), 7.21 (dt, J = 16.0, 7.5Hz, 3H), 7.10 (d, J = 7.3Hz, 1H),6.99(d,J=8.4Hz,1H),6.75(dd,J=8.4,2.6Hz,1H),6.69(d,J=2.6Hz,1H),5.10–4.99(m,1H),4.97 (s,2H),4.69(dd,J=15.2,6.9Hz,1H),4.56(dd,J=15.2,3.3Hz,1H),4.44(dd,J=13.6,7.7Hz,1H),4.33(dt, J=9.0,5.9Hz,1H),4.03(d,J=13.3Hz,1H),3.90(d,J=13.3Hz,1H),3.65–3.52(m,2H),2.73(s,4H), 2.67–2.55(m,2H),2.38(dt,J=11.1,7.2Hz,1H),2.29(s,3H).

[0764] Embodiment 34

[0765] Synthesis of (S)-2-((7-((4-chloro-2-fluorobenzyl)amino)-3,4-dihydroisoquinolin-2(1H)-2-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0766]

[0767] The specific synthetic route is as follows:

[0768] Step A: Synthesis of tert-butyl 7-((4-chloro-2-fluorobenzyl)amino)-3,4-dihydroisoquinoline-2(1H)-carboxylate

[0769]

[0770] At room temperature, tert-butyl 7-amino-3,4-dihydroisoquinoline-2(1H)-carboxylate (100.0 mg, 0.40 mmol) and potassium carbonate (110.4 mg, 0.80 mmol) were added to N,N-dimethylformamide (2.0 ml) containing 1-(bromomethyl)-4-chloro-2-fluoro-1-toluene (90.0 mg, 0.40 mmol) and reacted at room temperature for 2 hours. After the reaction was completed, water was added to quench the reaction, and ethyl acetate (20 ml × 3 times) was used for extraction. The organic phases were combined, washed with saturated brine (20 ml × 2 times), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (eluent: ethyl acetate / n-hexane = 1 / 5). The obtained yellow oily substance was tert-butyl 7-((4-chloro-2-fluorobenzyl)amino)-3,4-dihydroisoquinoline-2(1H)-carboxylate (yield: 63.8%) (100.0 mg). LC-MS: RT = 2.27 min, [M+H] + =391.24.

[0771] Step B: Synthesis of 7-((4-chloro-2-fluorobenzyl)amino)-1,2,3,4-tetrahydroisoquinoline

[0772]

[0773] At room temperature, a solution of hydrochloric acid in dioxane (1.0 ml, 4 mol / L) was added to tert-butyl 7-((4-chloro-2-fluorobenzyl)amino)-3,4-dihydroisoquinoline-2(1H)-carboxylate (100.0 mg, 0.26 mmol) in methanol (2.0 ml), and the mixture was reacted at room temperature for 3 hours. After the reaction, the reaction solution was directly dried to obtain 85.1 mg of white solid 7-((4-chloro-2-fluorobenzyl)amino)-1,2,3,4-tetrahydroisoquinoline, which was directly used in the next step. LC-MS: RT = 1.70 min, [M+H] + =291.18.

[0774] Step C: Synthesis of (S)-tert-butyl 2-((7-((4-chloro-2-fluorobenzyl)amino)-3,4-dihydroisoquinolin-2(1H)-2-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate

[0775]

[0776] At room temperature, (S)-tert-butyl 2-(chloromethyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (85.7 mg, 0.26 mmol) and cesium carbonate (169.0 mg, 0.52 mmol) were added to N,N-dimethylformamide (2.0 ml) containing 7-((4-chloro-2-fluorobenzyl)amino)-1,2,3,4-tetrahydroisoquinoline (85.1 mg, 0.26 mmol) and the mixture was heated to 50 degrees Celsius for 2 hours. After the reaction was completed, water was added to quench the mixture, and the mixture was extracted with ethyl acetate (20 ml × 3 times). The organic phases were combined, washed with saturated brine (20 ml × 2 times), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (eluent: ethyl acetate / n-hexane = 2 / 1). 80.0 mg of yellow oily (S)-tert-butyl 2-((7-((4-chloro-2-fluorobenzyl)amino)-3,4-dihydroisoquinolin-2(1H)-2-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate was obtained (yield: 52.0%). LC-MS: RT = 1.93 min, [M+H] + =591.34.

[0777] Step D: Synthesis of (S)-2-((7-((4-chloro-2-fluorobenzyl)amino)-3,4-dihydroisoquinolin-2(1H)-2-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0778]

[0779] At room temperature, (S)-tert-butyl 2-((4-chloro-2-fluorobenzyl)amino)-3,4-dihydroisoquinolin-2(1H)-2-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (80.0 mg, 0.14 mmol) was added to dichloromethane (1.0 ml), and trifluoroacetic acid (0.5 ml) was added dropwise. The mixture was reacted at room temperature for 2 hours. After the reaction was completed, the organic solvent was removed by concentration, and the obtained residue was purified by silica gel column chromatography (eluent: methanol / dichloromethane = 1 / 20). 29.0 mg of white solid (S)-2-((7-((4-chloro-2-fluorobenzyl)amino))-3,4-dihydroisoquinolin-2(1H)-2-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid was obtained (yield: 38.8%). LC-MS: RT = 1.76 min, [M+H] + =533.29. 1H NMR (400MHz, DMSO) δ12.95 (s, 1H), 8.35 (s, 1H), 7.89 (d, J = 8.5Hz, 1H), 7.77(d,J=8.5Hz,1H),7.39(dd,J=10.0,2.0Hz,1H),7.34(t,J=8.2Hz,1H),7.23(dd,J=8.3,1.9Hz,1H), 6.93(d,J=8.3Hz,1H),6.54(d,J=9.5Hz,1H),6.31(s,1H),5.06–4.95(m,1H),4.94–4.69(m,3H),4.68– 4.57(m,1H),4.54–4.33(m,3H),4.32–4.18(m,3H),3.05–2.81(m,3H),2.74–2.58(m,1H),2.39–2.20(m,1H), 1.24(dd,J=11.1,5.0Hz,1H).

[0780] Embodiment 35

[0781] Synthesis of (S)-1-((oxetane-2-yl)methyl)-2-(((7-(2-(trifluoromethoxy)benzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0782]

[0783] The specific synthetic route is as follows:

[0784] Step A: Synthesis of tert-butyl 7-(2-(trifluoromethoxy)benzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate

[0785]

[0786] At room temperature, 1-(bromomethyl)-2-(trifluoromethoxy)benzene (200.0 mg, 0.80 mmol), tert-butyl 7-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxylate (100.0 mg, 0.40 mmol) and potassium carbonate (138.0 mg, 1.00 mmol) were added to N,N-dimethylformamide (4.0 ml) and reacted at room temperature for 4.0 hours under nitrogen protection. After the reaction was completed, water was added to quench, and ethyl acetate (50 ml × 3 times) was used for extraction. The organic phases were combined, washed with saturated brine (30 ml × 3 times), dried over anhydrous sodium sulfate, concentrated, and finally purified by silica gel column chromatography (eluent: dichloromethane / methanol = 30 / 1) to obtain 100.0 mg of light yellow solid 7-(2-(trifluoromethoxy)benzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylic acid tert-butyl ester (yield: 62.5%). LC-MS: RT = 2.34 min, [M+H-100] + =324.21.

[0787] Step B: Synthesis of 7-(2-(trifluoromethoxy)benzyl)oxy)-1,2,3,4-tetrahydroisoquinoline

[0788]

[0789] At room temperature, tert-butyl 7-(2-(trifluoromethoxy)benzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate (100.0 mg, 0.25 mmol) was added to a dioxane hydrochloric acid solution (1.00 mmol / ml, 5 ml) and reacted for 1 hour under nitrogen protection. After the reaction was completed, the mixture was concentrated. 80.0 mg of white solid 7-(2-(trifluoromethoxy)benzyl)oxy)-1,2,3,4-tetrahydroisoquinoline (yield: 90.2%) was obtained and used directly in the next step. LC-MS: RT = 1.72 min, [M+H] + =324.18.

[0790] Step C: Synthesis of (S)-1-((oxetan-2-yl)methyl)-2-(((7-(2-(trifluoromethoxy)benzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester

[0791]

[0792] 7-(2-(trifluoromethoxy)benzyl)oxy)-1,2,3,4-tetrahydroisoquinoline (80.0 mg, 0.27 mmol), (S)-methyl 2-(chloromethyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (79.8 mg, 0.27 mmol) and potassium carbonate (138.0 mg, 1.0 mmol) were added to N,N-dimethylformamide (3.0 ml) at room temperature, and N,N-diisopropylethylamine (0.50 ml) was added. Under nitrogen protection, the temperature was raised to 50 °C and the reaction was carried out for 4.0 hours. After the reaction was completed, water was added to quench, and ethyl acetate (50 ml × 3 times) was used for extraction. The organic phases were combined, washed with saturated brine (30 ml × 3 times), dried over anhydrous sodium sulfate, concentrated, and purified by silica gel column chromatography (eluent: dichloromethane / methanol = 20 / 1) to obtain 95.0 mg of yellow solid (S)-1-((oxetane-2-yl)methyl)-2-(((7-(2-(trifluoromethoxy)benzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (yield: 60.5%). LC-MS: RT = 1.95 min, [M+H] + =582.28.

[0793] Step D: Synthesis of (S)-1-((oxetan-2-yl)methyl)-2-(((7-(2-(trifluoromethoxy)benzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0794]

[0795] To a solution of (S)-1-((oxetan-2-yl)methyl)-2-(((7-(2-(trifluoromethoxy)benzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (90.0 mg, 0.15 mmol) in tetrahydrofuran (6.0 ml) and methanol (2.0 ml) was added a solution of lithium hydroxide (42 mg, 1.00 mmol) in water (2.0 ml) at room temperature, and the mixture was reacted at room temperature for 3.0 hours. After the reaction was completed, water was added to quench, and the pH was adjusted to 6 with aqueous ammonium chloride solution (0.5 mol / L), extracted with dichloromethane (30 ml × 3 times), and the organic phases were combined, washed with aqueous ammonium chloride solution (30 ml × 2 times), dried over anhydrous sodium sulfate, concentrated, and purified by silica gel column chromatography (eluent: dichloromethane / methanol = 10 / 1) to obtain 26.0 mg of white solid (S)-1-((oxetane-2-yl)methyl)-2-(((7-(2-(trifluoromethoxy)benzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (yield: 29.5%). LC-MS: RT = 1.82 min, [M+H] + =568.28. 1 H NMR (500MHz, DMSO) δ8.25(d,J=1.1Hz,1H),7.81(dd,J=8.4,1.6Hz,1H),7.66(d,J=8.5Hz,1H),7.51(t,J =7.9Hz,1H),7.44(d,J=7.9Hz,1H),7.39(s,1H),7.30(d,J=9.1Hz,1H),7.02(d,J=8.4Hz,1H),6.79(dd, J=8.4,2.7Hz,1H),6.71(d,J=2.6Hz,1H),5.09(s,2H),5.04(ddd,J=14.4,7.2,2.6Hz,1H),4.79(dd,J=1 5.3,7.3Hz,1H),4.65(dd,J=15.2,2.9Hz,1H),4.44(dd,J=14.3,7.2Hz,1H),4.33(dt,J=9.0,5.8Hz,1H), 4.09(d,J=13.5Hz,1H),3.95(d,J=13.5Hz,1H),3.60(d,J=7.0Hz,2H),2.77(dd,J=16.0,8.0Hz,4H), 2.66–2.55(m,1H),2.37(dt,J=16.0,7.0Hz,1H).

[0796] Embodiment 36

[0797] Synthesis of (S)-1-((oxetane-2-yl)methyl)-2-((7-(pyridin-2-ylmethoxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0798]

[0799] The specific synthetic route is as follows:

[0800] Step A: Synthesis of tert-butyl 7-(pyridin-2-ylmethoxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate

[0801]

[0802] At room temperature, 2-(bromomethyl)pyridine (68.4 mg, 0.40 mmol), tert-butyl 7-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxylate (100.0 mg, 0.40 mmol) and cesium carbonate (260.9 mg, 0.80 mmol) were added to N,N-dimethylformamide (4.0 ml), and N,N-diisopropylethylamine (0.50 ml) was added. Under nitrogen protection, the temperature was raised to 50 degrees Celsius and the reaction was carried out for 4.0 hours. After the reaction was completed, water was added to quench, and ethyl acetate (50 ml × 3 times) was used for extraction. The organic phases were combined, washed with saturated brine (30 ml × 3 times), dried over anhydrous sodium sulfate, concentrated, and purified by silica gel column chromatography (eluent: dichloromethane / methanol = 30 / 1) to obtain 102.0 mg of light yellow solid 7-(pyridin-2-ylmethoxy)-3,4-dihydroisoquinoline-2(1H)-carboxylic acid tert-butyl ester (yield: 73.5%). LC-MS: RT = 2.05 min, [M+H] + =341.25.

[0803] Step B: Synthesis of 7-(pyridin-2-ylmethoxy)-1,2,3,4-tetrahydroisoquinoline

[0804]

[0805] At room temperature, tert-butyl 7-(pyridin-2-ylmethoxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate (102.0 mg, 0.30 mmol) was added to a dioxane hydrochloric acid solution (1.00 mmol / ml, 5 ml) and reacted at room temperature for 1 hour under nitrogen protection. After the reaction was completed, the mixture was concentrated under reduced pressure. 65.0 mg of light yellow solid 7-(pyridin-2-ylmethoxy)-1,2,3,4-tetrahydroisoquinoline (yield: 90.2%) was obtained and used directly in the next step. LC-MS: RT = 1.08 min, [M+H] + =241.21.

[0806] Step C: Synthesis of (S)-1-((oxetan-2-yl)methyl)-2-((7-(pyridin-2-ylmethoxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester

[0807]

[0808] 7-(Pyridin-2-ylmethoxy)-1,2,3,4-tetrahydroisoquinoline (65.0 mg, 0.27 mmol), (S)-methyl 2-(chloromethyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (79.8 mg, 0.27 mmol) and cesium carbonate (176.0 mg, 0.54 mmol) were added to N,N-dimethylformamide (3.0 ml) at room temperature, and N,N-diisopropylethylamine (0.50 ml) was added. Under nitrogen protection, the temperature was raised to 50 °C and the reaction was carried out for 4.0 hours. After the reaction was completed, water was added to quench the reaction, and the mixture was extracted with ethyl acetate (50 ml × 3 times). The organic phases were combined, washed with saturated brine (30 ml × 3 times), dried over anhydrous sodium sulfate, concentrated, and purified by silica gel column chromatography (eluent: dichloromethane / methanol = 20 / 1) to obtain 98.2 mg of white solid (S)-1-((oxetane-2-yl)methyl)-2-((7-(pyridin-2-ylmethoxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (yield: 73.1%). LC-MS: RT = 1.73 min, [M+H] + =499.33.

[0809] Step D: Synthesis of (S)-1-((oxetan-2-yl)methyl)-2-(((7-(pyridin-2-ylmethoxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0810]

[0811] At room temperature, lithium hydroxide (32.0 mg, 0.8 mmol) aqueous solution (3.0 ml) and methanol (3.0 ml) were added dropwise to tetrahydrofuran (12.0 ml) containing (S)-1-((oxetane-2-yl)methyl)-2-(((7-(pyridin-2-ylmethoxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (98.2 mg, 0.20 mmol) and the reaction was carried out at room temperature for 3.0 hours. After the reaction was completed, water was added to quench the reaction, and the pH was adjusted to 6 with aqueous ammonium chloride solution (0.5 mol / L), extracted with dichloromethane (30 ml×3 times), and the organic phases were combined and the aqueous ammonium chloride solution (30 ml×2 times) was added. The mixture was washed, dried over anhydrous sodium sulfate, concentrated, and purified by silica gel column chromatography (eluent: dichloromethane / methanol = 10 / 1) to give 90.0 mg of a pale yellow solid (S)-1-((oxetan-2-yl)methyl)-2-(((7-(pyridin-2-ylmethoxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (yield: 90.1%). LC-MS: RT = 1.59 min, [M+H] + =485.42. 1 H NMR (500MHz, DMSO) δ8.56 (ddd,J=4.8,1.7,0.9Hz,1H),8.27(d,J=1.0Hz,1H),7.85–7.79(m,2H),7.68(d,J=8.9Hz,1H),7.47(d,J =7.8Hz,1H),7.33(ddd,J=7.5,4.8,1.1Hz,1H),7.03(d,J=8.5Hz,1H),6.80(dd,J=8.4,2.7Hz,1H),6.73 (d,J=2.7Hz,1H),5.11(s,2H),5.07–5.01(m,1H),4.81(dd,J=15.3,7.3Hz,1H),4.66(dd,J=15.3,2.8Hz, 1H),4.49–4.42(m,1H),4.39–4.32(m,1H),4.10(d,J=13.5Hz,1H),3.96(d,J=13.5Hz,1H),3.67–3.55(m, 2H),2.81–2.72(m,4H),2.66–2.58(m,1H),2.4–2.34(m,1H).

[0812] Embodiment 37

[0813] Synthesis of (S)-2-((2-((4-fluoro-2-(trifluoromethyl)benzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0814]

[0815] The specific synthetic route is as follows:

[0816] Step A: Synthesis of tert-butyl 7-((4-fluoro-2-(trifluoromethyl)benzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate

[0817]

[0818] At room temperature, 4-fluoro-2-(trifluoromethyl)benzyl bromide (124 mg, 0.48 mmol), tert-butyl 7-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxylate (100.0 mg, 0.40 mmol) and cesium carbonate (260 mg, 0.80 mmol) were added to N,N-dimethylformamide (5.0 ml), and N,N-diisopropylethylamine (0.50 ml) was added. The reaction was carried out at room temperature for 4 hours under nitrogen protection. After the reaction was completed, water was added to quench, and ethyl acetate (30 ml × 3 times) was used for extraction. The organic phases were combined, washed with saturated brine (30 ml × 3 times), dried over anhydrous sodium sulfate, concentrated, and purified by silica gel column chromatography (eluent: n-hexane: ethyl acetate = 10:1) to obtain 76 mg of white solid 7-((4-fluoro-2-(trifluoromethyl)benzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylic acid tert-butyl ester (yield: 49%). LC-MS: RT = 2.30 min, [M-100] + =326.19.

[0819] Step B: Synthesis of 7-((4-fluoro-2-(trifluoromethyl)benzyl)oxy)-1,2,3,4-tetrahydroisoquinoline

[0820]

[0821] At room temperature, tert-butyl 7-((4-fluoro-2-(trifluoromethyl)benzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate (76 mg, 0.18 mmol) was added to a dioxane hydrochloric acid solution (1.00 mmol / ml, 5 ml) and reacted at room temperature for 1 hour under nitrogen protection. After the reaction was completed, the crude product 65 mg of pale yellow solid 7-((4-fluoro-2-(trifluoromethyl)benzyl)oxy)-1,2,3,4-tetrahydroisoquinoline was directly used in the next step. LC-MS: RT = 1.70 min, [M+H] +=326.20.

[0822] Step C: Synthesis of (S)-tert-butyl 2-((2-((4-fluoro-2-(trifluoromethyl)benzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate

[0823]

[0824] 7-((4-fluoro-2-(trifluoromethyl)benzyl)oxy)-1,2,3,4-tetrahydroisoquinoline (65 mg, 0.20 mmol), (S)-tert-butyl 2-(chloromethyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (67 mg, 0.20 mmol) and cesium carbonate (130 mg, 0.40 mmol) were added to N,N-dimethylformamide (3.0 ml) at room temperature, and N,N-diisopropylethylamine (0.50 ml) was added, and the reaction was carried out at room temperature under nitrogen protection. After the reaction was completed, water was added to quench the reaction, and the mixture was extracted with ethyl acetate (20 ml × 2 times). The organic phases were combined, washed with saturated brine (30 ml × 3 times), dried over anhydrous sodium sulfate, concentrated, and purified by silica gel column chromatography (eluent: n-hexane: ethyl acetate = 1:1) to obtain 90 mg of white solid (S)-2-((2-((4-fluoro-2-(trifluoromethyl)benzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetane-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid butyl ester (yield: 72%). LC-MS: RT = 2.04 min, [M+H] + =626.34.

[0825] Step D: (S)-2-((2-((4-fluoro-2-(trifluoromethyl)benzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0826]

[0827] At room temperature, (S)-butyl 2-((2-((4-fluoro-2-(trifluoromethyl)benzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (90 mg, 0.14 mmol) was dissolved in dichloromethane (5 mL), and trifluoroacetic acid (1 mL) was added to react for 1 hour. After the reaction was completed, the reaction was concentrated and the crude product was purified by HPLC to give 59 mg of white solid (S)-2-((2-((4-fluoro-2-(trifluoromethyl)benzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (yield: 74%). LC-MS: RT = 1.82 min, [M + H] + =570.28. 1 H NMR (500 MHz, DMSO-d 6 )δ8.35(s,1H),7.92– 7.86(m,1H),7.79(dd,J=13.0,7.1Hz,2H),7.69(dd,J=9.2,2.6Hz,1H),7.59(td,J=8.4,2.6Hz,1H),7.16 (d,J=8.4Hz,1H),6.94–6.85(m,2H),5.14(s,2H),5.02(d,J=6.9Hz,1H),4.85–4.62(m,4H),4.55–4.19(m, 5H), 3.01 (s, 3H), 2.66 (dd, J = 16.5, 9.1Hz, 1H), 2.38–2.27 (m, 1H).

[0828] Embodiment 38

[0829] Synthesis of (S)-1-((oxetane-2-yl)methyl)-2-((7-(pyridin-4-ylmethoxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0830]

[0831] The specific synthetic route is as follows:

[0832] Step A: Synthesis of tert-butyl 7-(pyridin-4-ylmethoxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate

[0833]

[0834] Potassium carbonate (133 mg, 0.96 mmol) and 4-(bromomethyl)pyridine (106 mg, 0.42 mmol) were added to a solution of 7-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxylic acid tert-butyl ester (80 mg, 0.32 mmol) in N,N-dimethylformamide (2.0 ml) at room temperature, and the mixture was reacted for 4 hours at room temperature. After the reaction was completed, saturated ammonium chloride solution was added to quench the mixture, and the mixture was extracted with ethyl acetate (30 ml × 3 times). The organic phases were combined, washed with saturated brine (30 ml × 2 times), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (eluent: n-hexane / ethyl acetate = 1 / 1). 20 mg of colorless oily tert-butyl 7-(pyridin-4-ylmethoxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate was obtained (yield: 18.3%). LC-MS: RT = 1.84 min, [M + H] + =341.25.

[0835] Step B: Synthesis of 7-(pyridin-4-ylmethoxy)-1,2,3,4-tetrahydroisoquinoline

[0836]

[0837] At room temperature, a solution of hydrogen chloride in 1,4-dioxane (0.2 ml, 4.0 mol / L) was added to a methanol solution (0.5 ml) containing tert-butyl 7-(pyridin-4-ylmethoxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate (20 mg, 0.0588 mmol) and reacted at room temperature for 1 hour. After the reaction was completed, the mixture was concentrated to obtain a white solid 7-(pyridin-4-ylmethoxy)-1,2,3,4-tetrahydroisoquinoline, which was directly used in the next reaction. LC-MS: RT = 0.28 min, [M+H] + =241.20.

[0838] Step C: Synthesis of (S)-1-(oxetane-2-ylmethyl)-2-((7-(pyridin-4-ylmethoxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid tert-butyl ester

[0839]

[0840] At room temperature, 7-(pyridin-4-ylmethoxy)-1,2,3,4-tetrahydroisoquinoline obtained in the previous step was dissolved in N,N-dimethylformamide (2.0 ml), and N,N-diisopropylethylamine (57 mg, 0.44 mmol), cesium carbonate (143 mg, 0.44 mmol) and (S)-2-(chloromethyl)-1-((oxetane-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid tert-butyl ester (20 mg, 0.059 mmol) were added, and heated to 50 degrees Celsius for 2 hours. After the reaction was completed, saturated ammonium chloride solution was added to quench, and ethyl acetate (30 ml × 3 times) was used for extraction. The organic phases were combined, washed with saturated brine (30 ml × 2 times), dried over anhydrous sodium sulfate, and concentrated. The residue was used directly in the next step. LC-MS: RT = 1.72 min, [M+H] + =541.37.

[0841] Step D: Synthesis of (S)-1-((oxetan-2-yl)methyl)-2-((7-(pyridin-4-ylmethoxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0842]

[0843] Trifluoroacetic acid (1.0 ml) was added to a dichloromethane solution (2.0 ml) containing the crude product (S)-1-((oxetan-2-yl(methyl)-2-((7-(pyridin-4-ylmethoxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid tert-butyl ester at room temperature. The reaction was allowed to proceed for 2 hours at room temperature. After the reaction was completed, the product was concentrated and the residue was purified by preparative HPLC to give 3.0 mg of a white solid (S)-1-((oxetan-2-yl)methyl)-2-((7-(pyridin-4-ylmethoxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (total yield for three steps: 10.5%). LC-MS: RT = 1.52 min, [M+H] + =485.30.

[0844] Embodiment 39

[0845] Synthesis of (S)-2-((7-(Benzyloxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0846]

[0847] The specific synthetic route is as follows:

[0848] Step A: Synthesis of tert-butyl 7-(benzyloxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate

[0849]

[0850] At room temperature, benzyl bromide (226.0 mg, 1.2 mmol) and tert-butyl 7-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxylate (150.9 mg, 0.6 mmol) were dissolved in N,N-dimethylformamide (3 ml), anhydrous potassium carbonate (250.6 mg, 1.8 mmol) was added, and the mixture was reacted overnight at room temperature. After the reaction was complete, the mixture was diluted with ethyl acetate (100 ml), washed with water (30 ml × 2 times) and saturated brine (30 ml × 1 time), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 4 / 1) to obtain 100.1 mg of tert-butyl 7-(benzyloxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate (yield 46.5%). LC-MS: RT = 3.50 min, [M- t Bu] + =284.11.

[0851] Step B: Synthesis of 7-(Benzyloxy)-1,2,3,4-tetrahydroisoquinoline

[0852]

[0853] At room temperature, tert-butyl 7-(benzyloxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate (120.0 mg, 0.3 mmol) was dissolved in dichloromethane (4 ml) solution, trifluoroacetic acid (1 ml) was added, and the reaction was carried out at room temperature for 1 hour. After the reaction was complete, the mixture was concentrated under reduced pressure to obtain 160.0 mg of light yellow oily 7-(benzyloxy)-1,2,3,4-tetrahydroisoquinoline, which was directly used in the next step without further purification. LC-MS: RT = 1.52 min, [M+H] + =240.32.

[0854] Step C: Synthesis of (S)-tert-butyl 2-((7-(benzyloxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate

[0855]

[0856] At room temperature, 7-(benzyloxy)-1,2,3,4-tetrahydroisoquinoline (60.5 mg, 0.2 mmol) and (S)-2-(chloromethyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid tert-butyl ester (65.7 mg, 0.2 mmol) were dissolved in N,N-dimethylformamide (3 ml), anhydrous potassium carbonate (71.2 mg, 0.5 mmol) was added, and the mixture was reacted overnight at room temperature. After the reaction was complete, the mixture was diluted with ethyl acetate (100 ml), washed with water (30 ml × 2 times) and saturated brine (30 ml × 1 time), dried over anhydrous sodium sulfate, and concentrated. The obtained residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1 to dichloromethane / methanol = 15 / 1) to obtain 101.9 mg of light yellow oily (S)-tert-butyl 2-((7-(benzyloxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (yield 75.2%). LC-MS: RT = 3.15 min, [M+H] + =540.22.

[0857] Step D: Synthesis of (S)-2-((7-(benzyloxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0858]

[0859] At room temperature, (S)-2-((7-(benzyloxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetane-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid tert-butyl ester (100.3 mg, 185.5 μmol) was dissolved in dichloromethane (3 ml), trifluoroacetic acid (1 ml) was added, and the reaction was carried out at room temperature for 3 hours. After the reaction was completed, water (5 ml) was added to quench the reaction, and the pH was adjusted to 8 with saturated sodium bicarbonate aqueous solution, and extracted with dichloromethane / methanol = 10 / 1 (30 ml × 3 times), and the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated. The obtained residue was purified by reverse phase HPLC (mobile phase: (0.1% aqueous ammonia / water) / acetonitrile = 95 / 5 to 55 / 45) and lyophilized to give 31.5 mg of white solid (S)-2-((7-(benzyloxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (yield: 35.1%). LC-MS: RT = 2.11 min, [M+H] + =484.16. 1H NMR (400MHz, CD 3 OD)δ8.36(d,J=1.5Hz,1H),8.02(dd,J=8.5,1.5Hz,1H),7.73(d,J=8.5Hz,1H),7.43(d,J=7.1Hz,2H),7.37(t,J=7.4Hz,2H),7.31(t,J=7.1 Hz,1H),7.05(d,J=8.4Hz,1H),6.82(dd,J=8.4,2.6Hz,1H),6.68(d,J=2.6Hz,1H),5.24(qd,J=7.1,2.5 Hz,1H),4.89(d,J=7.2Hz,1H),4.74(dd,J=15.3,2.7Hz,1H),4.62(td,J=8.0,5.9Hz,1H),4.46(dt,J= 9.2,5.9Hz,1H),4.23(d,J=13.8Hz,1H),4.11(d,J=13.8Hz,1H),3.77–3.66(m,2H),2.89 (t,J=4.2Hz,4H), 2.73(dtd,J=11.4,8.2,6.1Hz,1H), 2.50(ddt,J=11.4,9.1,7.1Hz,1H).

[0860] Embodiment 40

[0861] Synthesis of (S)-2-((7-((3-methoxybenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetane-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0862]

[0863] The specific synthetic route is as follows:

[0864] Step A: Synthesis of tert-butyl 7-((3-methoxybenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate

[0865]

[0866] At room temperature, tert-butyl 7-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxylate (80 mg, 0.321 mmol) and potassium carbonate (88.6 mg, 0.642 mmol) were added to N,N-dimethylformamide (2.0 ml) containing 1-(bromomethyl)-3-methoxybenzene (96.8 mg, 0.482 mmol) and the temperature was raised to 50 degrees Celsius for 3 hours to complete the reaction. Water (20 ml) was added to quench the mixture, and the mixture was extracted with ethyl acetate (10 ml × 3 times), washed with saturated brine (20 ml × 3 times), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (eluent: ethyl acetate / n-hexane = 1 / 5). 72 mg of tert-butyl 7-((3-methoxybenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate was obtained as a yellow oil (yield: 61.1%). LC-MS: RT = 2.25 min, [M + H] + =370.19.

[0867] Step B: Synthesis of 7-((3-methoxybenzyl)oxy)-1,2,3,4-tetrahydroisoquinoline

[0868]

[0869] At room temperature, a solution of hydrochloric acid in 1,4-dioxane (3 ml, 4 mol / L) was added to a solution of tert-butyl 7-((3-methoxybenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate (72 mg, 0.195 mmol) in methanol (3 ml), and the mixture was reacted at room temperature for 3 hours. After the reaction was completed, the mixture was concentrated to obtain 73 mg of a white solid 7-((3-methoxybenzyl)oxy)-1,2,3,4-tetrahydroisoquinoline, which was directly used in the next step.

[0870] Step C: Synthesis of (S)-tert-butyl 2-((7-((3-methoxybenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate

[0871]

[0872] To a solution of 7-((3-methoxybenzyl)oxy)-1,2,3,4-tetrahydroisoquinoline (73 mg, 0.195 mmol) in N,N-dimethylformamide (2.0 ml) at 25°C were added N,N-diisopropylethylamine (0.2 ml), potassium carbonate (54 mg, 0.39 mmol) and (S)-tert-butyl 2-(chloromethyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (66 mg, 0.195 mmol). The mixture was heated to 50°C for 3 hours under nitrogen protection. After the reaction was completed, water was added to quench the reaction, and the product was extracted with ethyl acetate (20 ml × 2 times), washed with saturated brine (20 ml × 3), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (eluent: ethyl acetate / n-hexane = 4 / 1. 80 mg of yellow solid (S)-2-((7-((3-methoxybenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetane-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid tert-butyl ester was obtained (yield: 72.1%). LC-MS: RT = 1.94 min, [M+H] + =570.38.

[0873] Step D: Synthesis of (S)-2-((7-((3-methoxybenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0874]

[0875] To a solution of (S)-tert-butyl 2-((7-((3-methoxybenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (80 mg, 0.14 mmol) in dichloromethane (2 mL) was added trifluoroacetic acid (1 mL) dropwise at 25°C for 1 hour. After the reaction was completed, water was added to quench, extracted with ethyl acetate (20 ml × 2 times), washed with saturated brine (20 ml × 2), dried over anhydrous sodium sulfate, concentrated, and the resulting residue was purified by silica gel column chromatography (eluent: methanol / dichloromethane = 1 / 12. 31 mg of white solid (S)-2-((7-((3-methoxybenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetane-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid was obtained (yield: 43.2%). LC-MS: RT = 1.75 min, [M+H] + =514.30. NMR data: 1H NMR (400 MHz, DMSO-d 6 )δ8.24(d,J=1.0Hz,1H),7.80(dd,J=8.4,1.5Hz,1H),7.65(d,J=8.5Hz,1H), 7.26(t,J=8.1Hz,1H),6.99(d,J=8.5Hz,1H),6.95(d,J=7.2Hz,2H),6.85(dd,J=8.2,1.6Hz,1H),6.76 (dd,J=8.4,2.6Hz,1H),6.68(d,J=2.5Hz,1H),5.06–5.00(m,1H),4.98(s,2H),4.78(dd,J=15.2,7.3Hz, 1H), 4.64 (dd, J=15.3, 2.7Hz, 1H), 4.43 (dd, J=13.6, 7.7Hz, 1H), 4.32 (dt, J=9.0, 5.9Hz, 1H), 4.08 (d, J= 13.5Hz,1H),3.93(d,J=13.5Hz,1H),3.72(d,J=6.1Hz,3H),3.58(q,J=15.4Hz,2H ),2.75(dd,J=17.0,7.8Hz,4H),2.65–2.55(m,1H),2.35(dt,J=11.0,7.0Hz,1H).

[0876] Embodiment 41

[0877] Synthesis of (S)-2-((7-((3-cyanobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0878]

[0879] The specific synthetic route is as follows:

[0880] Step A: Synthesis of 3-(bromomethyl)benzonitrile

[0881]

[0882] At room temperature, 3-(Hydroxymethyl)benzonitrile (500 mg, 3.76 mmol), triphenylphosphine (1.97 g, 7.52 mmol), carbon tetrabromide (1.86 g, 5.64 mmol) were dissolved in dichloromethane (10 ml) and reacted at room temperature for 1 hour. After the reaction was completed, the mixture was concentrated and the crude product was purified by column chromatography (eluent: ethyl acetate / n-hexane = 1 / 10) to obtain 550 mg of white solid 3-(bromomethyl)benzonitrile (yield: 75%). LC-MS: RT = 2.17 min, [M+H]+ = 196.03

[0883] Step B: Synthesis of tert-butyl 7-((3-cyanobenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate

[0884]

[0885] At room temperature, 3-(bromomethyl)benzonitrile (130 mg, 0.6 mmol), tert-butyl 7-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxylate (100 mg, 0.4 mmol), potassium carbonate (165 mg, 1.2 mmol) were dissolved in N,N-dimethylformamide (5 ml) and reacted at room temperature for 5 hours. After the reaction was completed, saturated sodium chloride was added to quench, and ethyl acetate was extracted (10 ml × 2 times). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated. The crude product was purified by silica gel column chromatography (eluent: ethyl acetate / n-hexane = 1 / 3) to obtain 60 mg of white solid tert-butyl 7-((3-cyanobenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate (yield: 27%). LC-MS: RT = 1.87 min, [M+H] + =365.27.

[0886] Step C: Synthesis of 3-(((1,2,3,4-tetrahydroisoquinolin-7-yl)oxy)methyl)benzonitrile

[0887]

[0888] At room temperature, white solid tert-butyl 7-((3-cyanobenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate (60 mg, 0.16 mmol) was dissolved in dioxane (2 ml), and hydrogen chloride dioxane solution (2 ml) was added under ice-water bath, and stirred at room temperature for 0.5 hours. After the reaction was completed, the mixture was concentrated to obtain crude 3-(((1,2,3,4-tetrahydroisoquinolin-7-yl)oxy)methyl)benzonitrile. LC-MS: RT = 1.67 min, [M+H] + =265.25.

[0889] Step D: Synthesis of (S)-tert-butyl 2-((7-(3-cyanobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate

[0890]

[0891] 3-(((1,2,3,4-tetrahydroisoquinolin-7-yl)oxy)methyl)benzonitrile (0.16 mmol) was dissolved in N,N-dimethylformamide (2 ml) at room temperature, and (S)-methyl 2-(chloromethyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (67 mg, 0.23 mmol) and cesium carbonate (186 mg, 0.57 mmol) were added and reacted at room temperature for 5 hours. After the reaction was completed, saturated sodium chloride was added to quench, and the mixture was extracted with ethyl acetate (10 ml x 2 times). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated. The crude product was purified by silica gel column chromatography (eluent: ethyl acetate / n-hexane = 1 / 1) to obtain 100 mg of colorless oily liquid (S)-2-((7-(3-cyanobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetane-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid tert-butyl ester (yield: 42%). LC-MS: RT = 1.89 min, [M+H] + =565.35.

[0892] Step E: Synthesis of (S)-2-((7-(3-cyanobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0893]

[0894] At room temperature, (S)-2-((7-(3-cyanobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid tert-butyl ester (100 mg, 0.06 mmol) was dissolved in dichloromethane (5 ml), trifluoroacetic acid (1 ml) was added, and the reaction was continued for 1 hour. After the reaction was completed, the reaction mixture was concentrated, and the crude product was purified by HPLC to obtain 4.5 mg of white solid (S)-2-((7-(3-cyanobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (yield: 6%). LC-MS: RT = 1.65 min, [M+H] +=509.35.

[0895] Embodiment 42

[0896] Synthesis of (S)-2-((7-((4-bromobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0897]

[0898] The specific synthetic route is as follows:

[0899] Step A: Synthesis of tert-butyl 7-((4-bromobenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate

[0900]

[0901] At 25°C, tert-butyl 7-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxylate (80 mg, 0.321 mmol) and potassium carbonate (88.6 mg, 0.642 mmol) were added to N,N-dimethylformamide (2.0 ml) containing 1-(bromomethyl)-4-bromobenzene (120.5 mg, 0.482 mmol) and the temperature was raised to 50°C for 3 hours. After the reaction was completed, water (20 ml) was added to quench the reaction, and the mixture was extracted with ethyl acetate (10 ml × 3 times), washed with saturated brine (20 ml × 3 times), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: ethyl acetate / n-hexane = 1 / 5). 75 mg of yellow oily tert-butyl 7-((4-bromobenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate was obtained (yield: 55.9%). LC-MS: RT = 2.22 min, [M+H] + =418.09.

[0902] Step B: Synthesis of 7-((4-bromobenzyl)oxy)-1,2,3,4-tetrahydroisoquinoline

[0903]

[0904] At 25 degrees Celsius, a solution of hydrochloric acid in 1,4-dioxane (3 ml, 4 mol / L) was added to tert-butyl 7-((4-bromobenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate (75 mg, 0.179 mmol) in methanol (3 ml) and reacted for 3 hours. After the reaction was completed, 78 mg of white solid 7-((4-bromobenzyl)oxy)-1,2,3,4-tetrahydroisoquinoline was obtained by concentration and used directly in the next step.

[0905] Step C: Synthesis of (S)-tert-butyl 2-((7-((4-bromobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate

[0906]

[0907] To a solution of 7-((4-bromobenzyl)oxy)-1,2,3,4-tetrahydroisoquinoline (78 mg, 0.179 mmol) in N,N-dimethylformamide (2.0 ml) at 25°C were added N,N-diisopropylethylamine (0.2 ml) and potassium carbonate (49 mg, 0.358 mmol), and finally (S)-tert-butyl 2-(chloromethyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (60 mg, 0.179 mmol). The mixture was heated to 50°C for 3 hours under nitrogen protection. After the reaction was completed, water was added to quench, extracted with ethyl acetate (20 ml × 2 times), washed with saturated brine (20 ml × 3), dried over anhydrous sodium sulfate, concentrated, and the resulting residue was purified by silica gel column chromatography (eluent: ethyl acetate / n-hexane = 4 / 1. 71 mg of yellow solid (S)-2-((7-((4-bromobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetane-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid tert-butyl ester was obtained (yield: 64.3%). LC-MS: RT = 2.02 min, [M+H] + =618.27.

[0908] Step D: Synthesis of (S)-2-((7-((4-bromobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0909]

[0910] To a solution of (S)-tert-butyl 2-((7-((4-bromobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (71 mg, 0.115 mmol) in dichloromethane (2 mL) was added trifluoroacetic acid (1 mL) dropwise at 25°C and reacted for 1 hour. After the reaction was completed, water was added to quench, extracted with ethyl acetate (20 ml × 2 times), washed with saturated brine (20 ml × 2), dried over anhydrous sodium sulfate, concentrated, and the resulting residue was purified by silica gel column chromatography (eluent: methanol / dichloromethane = 1 / 10. 33 mg of white solid (S)-2-((7-((4-bromobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetane-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid was obtained (yield: 51.1%). LC-MS: RT = 1.81 min, [M+H] + =562.20. NMR data: 1 H NMR (400 MHz, DMSO-d 6 )δ8.35(s,1H),7.89(dd,J=8.5,1.4Hz,1H),7.77(d,J=8.5Hz,1H),7.58– 7.53(m,2H),7.36(t,J=7.6Hz,2H),7.13(t,J=7.3Hz,1H),6.91(d,J=8.4Hz,1H),6.84(s,1H),5.08–4.97 (m,3H),4.79(dd,J=15.6,7.1Hz,2H),4.65(dd,J=15.5,2.5Hz,1H),4.43(dd,J=13.6,7.8Hz,2H),4.28( dt,J=9.0,6.0Hz,1H),4.01(q,J=7.1Hz,1H),3.00(s,2H),2.66(ddd,J=18.3,13.2,7.4Hz,1H),2.30(dq, J=11.5,7.1Hz,1H),1.97(s,1H).

[0911] Embodiment 43

[0912] Synthesis of (S)-2-((7-((2-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0913]

[0914] The specific synthetic route is as follows:

[0915] Step A: Synthesis of tert-butyl 7-((2-chlorobenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate

[0916]

[0917] At room temperature, 2-chlorobenzyl bromide (150 mg, 0.80 mmol), tert-butyl 7-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxylate (100.0 mg, 0.40 mmol) and cesium carbonate (260 mg, 0.80 mmol) were added to N,N-dimethylformamide (5.0 ml), and N,N-diisopropylethylamine (0.50 ml) was added. The mixture was reacted at room temperature under nitrogen protection. After the reaction was completed, water was added to quench the mixture, and the mixture was extracted with ethyl acetate (30 ml × 3 times). The organic phases were combined, washed with saturated brine (30 ml × 3 times), dried over anhydrous sodium sulfate, concentrated, and purified by silica gel column chromatography (eluent: n-hexane: ethyl acetate = 10:1) to obtain 90 mg of tert-butyl 7-((2-fluorobenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate as a white solid (yield: 87%). LC-MS: RT = 2.23 min, [M-100] + =258.18.

[0918] Step B: Synthesis of 7-((2-fluorobenzyl)oxy)-1,2,3,4-tetrahydroisoquinoline

[0919]

[0920] At room temperature, tert-butyl 7-((2-fluorobenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate (70 mg, 0.20 mmol) was added to a solution of dioxane in hydrochloric acid (1.00 mmol / ml, 2.5 ml) and reacted at room temperature for 1 hour under nitrogen protection. After the reaction was completed, the crude product 60 mg of pale yellow solid 7-((2-fluorobenzyl)oxy)-1,2,3,4-tetrahydroisoquinoline was concentrated and used directly in the next step. LC-MS: RT = 1.65 min, [M+H] + =258.19.

[0921] Step C: Synthesis of (S)-tert-butyl 2-((7-((2-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate

[0922]

[0923] 7-((2-Fluorobenzyl)oxy)-1,2,3,4-tetrahydroisoquinoline (60 mg, 0.23 mmol), (S)-tert-butyl 2-(chloromethyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (79 mg, 0.23 mmol) and cesium carbonate (152 mg, 0.47 mmol) were added to N,N-dimethylformamide (5.0 ml) at room temperature, and N,N-diisopropylethylamine (0.50 ml) and N 2 Under protection, react at room temperature. After the reaction is completed, water is added to quench, and ethyl acetate (20 ml × 2 times) is used for extraction. The organic phases are combined, washed with saturated brine (30 ml × 3 times), dried over anhydrous sodium sulfate, concentrated, and purified by silica gel column chromatography (eluent: n-hexane: ethyl acetate = 1:1) to obtain 70 mg of white solid (S)-2-((7-((2-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetane-2-yl(methyl)-1H-benzo[d]imidazole-6-carboxylic acid tert-butyl ester (yield: 54%). LC-MS: RT = 1.98 min, [M+H] + =558.32.

[0924] Step D: Synthesis of (S)-2-((7-((2-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0925]

[0926] At room temperature, (S)-tert-butyl 2-((7-((2-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (70 mg, 0.13 mmol) was dissolved in dichloromethane (5 mL), trifluoroacetic acid (1 mL) was added, and the reaction was allowed to proceed for 1 hour. After the reaction was completed, the reaction mixture was concentrated and the crude product was purified by HPLC to give 50 mg of white solid (S)-2-((7-((2-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (yield: 77%). LC-MS: RT = 1.75 min, [M+H] + =502.29. 1 H NMR (500 MHz, DMSO-d 6)δ8.19(s,1H),7.79(dd,J=8.4,1.5Hz,1H), 7.60(d,J=8.4Hz,1H),7.50(td,J=7.6,1.6Hz,1H),7.41–7.35(m,1H),7.25–7.17(m,2H),7.01(d,J=8.4 Hz,1H),6.77(dd,J=8.4,2.6Hz,1H),6.72(d,J=2.5Hz,1H),5.07–5.00(m,3H),4.76(dd,J=15.2,7.2Hz, 1H), 4.62 (dd, J=15.2, 2.8Hz, 1H), 4.43 (dd, J=13.6, 7.7Hz, 1H), 4.32 (dt, J=9.0, 5.9Hz, 1H), 4.07 (d, J= 13.5Hz, 1H), 3.93 (d, J = 13.5Hz, 1H), 3.59 (t, J = 11.1Hz, 2H), 2.75 (dd, J = 14.4, 7.0Hz, 4H), 2.61 (ddd, J = 8.6, 8.1, 5.6Hz, 1H), 2.39–2.31 (m, 1H).

[0927] Embodiment 44

[0928] Synthesis of 1-(((S)-oxetane-2-yl)methyl)-2-((7-(1-phenylethoxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0929]

[0930] The specific synthetic route is as follows:

[0931] Step A: Synthesis of tert-butyl 7-(1-phenylethoxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate

[0932]

[0933] At room temperature, (1-bromoethyl)benzene (147.2 mg, 0.80 mmol), tert-butyl 7-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxylate (100.0 mg, 0.40 mmol) and cesium carbonate (260.9 mg, 0.80 mmol) were added to N,N-dimethylformamide (4.0 ml), and N,N-diisopropylethylamine (0.50 ml) was added. Under nitrogen protection, the temperature was raised to 50 degrees Celsius and the reaction was carried out for 4.0 hours. After the reaction was completed, water was added to quench, and ethyl acetate (50 ml × 3 times) was used for extraction. The organic phases were combined, washed with saturated brine (30 ml × 3 times), dried over anhydrous sodium sulfate, concentrated, and purified by silica gel column chromatography (eluent: dichloromethane / methanol = 10 / 1) to obtain 88.3 mg of light yellow solid 7-(1-phenylethoxy)-3,4-dihydroisoquinoline-2(1H)-carboxylic acid tert-butyl ester (yield: 62.4%). LC-MS: RT = 2.12 min, [M+H] + =354.33.

[0934] Step B: Synthesis of 7-(1-phenylethoxy)-1,2,3,4-tetrahydroisoquinoline

[0935]

[0936] At room temperature, tert-butyl 7-(1-phenylethoxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate (88.3 mg, 0.25 mmol) was added to a solution of dioxane in hydrochloric acid (1.00 mmol / ml, 5 ml) and reacted at room temperature for 1 hour under nitrogen protection. After the reaction was completed, the mixture was concentrated. 55.4 mg of light yellow solid 7-(1-phenylethoxy)-1,2,3,4-tetrahydroisoquinoline (yield: 87.3%) was obtained and used directly in the next step. LC-MS: RT = 1.68 min, [M+H] + =254.23.

[0937] Step C: Synthesis of 1-(((S)-oxetan-2-yl)methyl)-2-((7-(1-phenylethoxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester

[0938]

[0939] 7-(1-phenylethoxy)-1,2,3,4-tetrahydroisoquinoline (55.4 mg, 0.22 mmol), (S)-methyl 2-(chloromethyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (65.3 mg, 0.22 mmol) and cesium carbonate (143.4 mg, 0.44 mmol) were added to N,N-dimethylformamide (3.0 ml) at room temperature, and N,N-diisopropylethylamine (0.50 ml) was added. Under nitrogen protection, the temperature was raised to 50 °C and the reaction was carried out for 4.0 hours. After the reaction was completed, water was added to quench, and ethyl acetate (50 ml × 3 times) was used for extraction. The organic phases were combined, washed with saturated brine (30 ml × 3 times), dried over anhydrous sodium sulfate, concentrated, and purified by silica gel column chromatography (eluent: dichloromethane / methanol = 20 / 1) to obtain 67.4 mg of white solid 1-(((S)-oxetane-2-yl)methyl)-2-((7-(1-phenylethoxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (yield: 60.1%). LC-MS: RT = 1.85 min, [M+H] + =512.36.

[0940] Step D: Synthesis of 1-(((S)-oxetan-2-yl)methyl)-2-((7-(1-phenylethoxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0941]

[0942] To a solution of 1-(((S)-oxetan-2-yl)methyl)-2-((7-(1-phenylethoxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (67.4 mg, 0.13 mmol) in tetrahydrofuran (3.0 ml) was added dropwise an aqueous solution (1.0 ml) of lithium hydroxide (21.8 mg, 0.52 mmol) at room temperature, and methanol (1.0 ml) was added, and the mixture was reacted at room temperature for 3.0 hours. After the reaction was completed, water was added to quench, and the pH was adjusted to 6 with aqueous ammonium chloride solution (0.5 mol / L), extracted with dichloromethane (30 ml × 3 times), and the organic phases were combined, washed with aqueous ammonium chloride solution (30 ml × 2 times), dried over anhydrous sodium sulfate, concentrated, and purified by silica gel column chromatography (eluent: dichloromethane / methanol = 10 / 1) to obtain 51.0 mg of light yellow solid 1-(((S)-oxetane-2-yl)methyl)-2-((7-(1-phenylethoxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (yield: 78.0%). LC-MS: RT = 1.77 min, [M+H] + = 498.32.

[0943] Embodiment 45

[0944] Synthesis of (S)-1-((oxetane-2-yl)methyl)-2-((7-phenethyl-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0945]

[0946] The specific synthetic route is as follows:

[0947] Step A: Synthesis of 7-phenylvinyl-1,2,3,4-tetrahydroisoquinoline

[0948]

[0949] At room temperature, styrene boronic acid (168 mg, 1.13 mmol), 7-bromo-1,2,3,4-tetrahydroisoquinoline (200 mg, 0.94 mol), palladium catalyst (70 mg) and potassium phosphate (299 mg, 1.41 mmol) were dissolved in a mixed solvent (12 ml, dioxane / water = 10 / 2), and the temperature was raised to 80 degrees Celsius for reflux reaction. After the reaction was completed, the mixture was filtered, washed with dichloromethane, and the filtrate was concentrated. The crude product was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 5 / 1) to obtain 210 mg of yellow solid 7-phenylvinyl-1,2,3,4-tetrahydroisoquinoline (yield: 95%). LC-MS: RT = 1.70 min.

[0950] Step B: Synthesis of 7-phenylethyl-1,2,3,4-tetrahydroisoquinoline

[0951]

[0952] At room temperature, 7-phenylethyl-1,2,3,4-tetrahydroisoquinoline (210 mg, 0.89 mmol) was dissolved in methanol (15 ml), palladium carbon (100 mg) was added, hydrogen was replaced, and the reaction was carried out at room temperature for 2 hours. After the reaction was completed, the methanol was filtered and washed, and the crude product 100 mg of light yellow solid 7-phenylethyl-1,2,3,4-tetrahydroisoquinoline (yield: 47%) was obtained and directly used in the next step. LC-MS: RT = 1.66 min, [M + H] + =238.23.

[0953] Step C: Synthesis of (S)-1-((oxetane-2-yl)methyl)-2-((7-phenethyl-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid tert-butyl ester

[0954]

[0955] 7-Phenethyl-1,2,3,4-tetrahydroisoquinoline (91 mg, 0.38 mmol), (S)-tert-butyl 2-(chloromethyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (129 mg, 0.38 mmol) and cesium carbonate (247 mg, 0.76 mmol) were added to N,N-dimethylformamide (3.0 ml) at room temperature, and N,N-diisopropylethylamine (0.50 ml) was added and reacted at room temperature. After the reaction was completed, water was added to quench the reaction, and the mixture was extracted with ethyl acetate (30 ml × 3 times). The organic phases were combined, washed with saturated brine (30 ml × 3 times), dried over anhydrous sodium sulfate, concentrated, and purified by silica gel column chromatography (eluent: dichloromethane: methanol = 10: 1) to obtain 50 mg of white solid (S)-1-((oxetane-2-yl)methyl)-2-((7-phenethyl-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid tert-butyl ester (yield: 25%). LC-MS: RT = 1.98 min, [M+H] + =538.37.

[0956] Step D: Synthesis of (S)-1-((oxetane-2-yl)methyl)-2-((7-phenethyl-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0957]

[0958] At room temperature, (S)-1-((oxetane-2-yl)methyl)-2-((7-phenethyl-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid tert-butyl ester (50 mg, 0.09 mmol) was dissolved in dichloromethane (5 ml), trifluoroacetic acid (1 ml) was added, and the reaction was continued for 1 hour. After the reaction was completed, the reaction mixture was concentrated and the crude product was purified by HPLC to obtain 32 mg of white solid (S)-1-((oxetane-2-yl)methyl)-2-((7-phenethyl-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (yield: 74%). LC-MS: RT = 1.79 min, [M+H] + =482.32. 1 H NMR (500 MHz, DMSO-d 6 )δ8.35(s,1H),7.89(dd,J=8.5,1.3Hz,1H),7.77(d,J=8.5Hz, 1H),7.28–7.10(m,7H),7.02(s,1H),5.02(d,J=6.8Hz,1H),4.73(ddd,J=17.9,15.5,4.9Hz,5H),4.51–4.17 (m,5H),3.03(s,2H),2.83(s,4H),2.66(dd,J=15.5,9.7Hz,1H),2.32(td,J=16.3,7.4Hz,1H).

[0959] Embodiment 46

[0960] Synthesis of (S)-2-((7-((5-fluoro-2-methoxybenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-2-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0961]

[0962] The specific synthetic route is as follows:

[0963] Step A: Synthesis of tert-butyl 7-((5-fluoro-2-methoxybenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate

[0964]

[0965] At room temperature, tert-butyl 7-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxylate (99.6 mg, 0.40 mmol) and potassium carbonate (110.4 mg, 0.80 mmol) were added to N,N-dimethylformamide (2.0 ml) containing 2-(bromomethyl)-4-fluoro-1-methoxybenzene (87.6 mg, 0.40 mmol) and the mixture was heated to 50 degrees Celsius for 2 hours. After the reaction was completed, water was added to quench the mixture, and the mixture was extracted with ethyl acetate (20 ml × 3 times). The organic phases were combined, washed with saturated brine (20 ml × 2 times), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (eluent: ethyl acetate / n-hexane = 1 / 4). 70.0 mg of yellow oily tert-butyl 7-((5-fluoro-2-methoxybenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate was obtained (yield: 45.1%). LC-MS: RT = 2.30 min, [M+H] + =388.11.

[0966] Step B: Synthesis of 7-((5-fluoro-2-methoxybenzyl)oxy)-1,2,3,4-tetrahydroisoquinoline

[0967]

[0968] At room temperature, a solution of hydrochloric acid in dioxane (1.0 ml, 4 mol / L) was added to tert-butyl 7-((5-fluoro-2-methoxybenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate (70.0 mg, 0.18 mmol) in methanol (2.0 ml), and the mixture was reacted at room temperature for 3 hours. After the reaction was completed, the mixture was concentrated to obtain 58.3 mg of white solid 7-((5-fluoro-2-methoxybenzyl)oxy)-1,2,3,4-tetrahydroisoquinoline, which was used directly in the next step. LC-MS: RT = 1.68 min, [M+H] + =288.23.

[0969] Step C: Synthesis of (S)-2-((7-((5-fluoro-2-methoxybenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-2-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester

[0970]

[0971] At room temperature, (S)-methyl 2-(chloromethyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (53.1 mg, 0.18 mmol) and cesium carbonate (117.0 mg, 0.36 mmol) were added to N,N-dimethylformamide (2.0 ml) containing 7-((5-fluoro-2-methoxybenzyl)oxy)-1,2,3,4-tetrahydroisoquinoline (58.3 mg, 0.18 mmol) and the mixture was heated to 50 degrees Celsius for 2 hours. After the reaction was completed, water was added to quench the mixture, and the mixture was extracted with ethyl acetate (20 ml × 3 times). The organic phases were combined, washed with saturated brine (20 ml × 2 times), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (eluent: ethyl acetate / n-hexane = 2 / 1). 70.0 mg of yellow oily (S)-methyl 2-((7-((5-fluoro-2-methoxybenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-2-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate was obtained (yield: 71.2%). LC-MS: RT = 1.84 min, [M+H] + =546.32.

[0972] Step D: Synthesis of (S)-2-((7-((5-fluoro-2-methoxybenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-2-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0973]

[0974] At room temperature, (S)-2-((7-((5-fluoro-2-methoxybenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-2-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid tert-butyl ester (70.0 mg, 0.13 mmol) was added to a mixed solution of tetrahydrofuran (3.0 ml), methanol (1.0 ml) and water (1.0 ml), and lithium hydroxide monohydrate (21.8 mg, 0.52 mmol) and reacted at room temperature for 2 hours. After the reaction was completed, saturated ammonium chloride was added to quench, and ethyl acetate (20 ml × 3 times) was used for extraction. The organic phases were combined, washed with saturated brine (20 ml × 2 times), dried over anhydrous sodium sulfate, and concentrated. The obtained residue was purified by silica gel column chromatography (eluent: methanol / dichloromethane = 1 / 20). 19.0 mg of white solid (S)-2-((7-((5-fluoro-2-methoxybenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-2-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid was obtained (yield: 27.5%). LC-MS: RT=1.79 min, [M+H] + =532.30.

[0975] Embodiment 47

[0976] Synthesis of (S)-2-((2-((4-chloro-2-fluorobenzyl))-5,8-pyridinyl[3,4-d]pyrimidin-7(6H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0977]

[0978] The specific synthetic route is as follows:

[0979] Step A: Synthesis of tert-butyl 2-chloro-5,8-dihydropyridinyl[3,4-d]pyrimidine-7(6H)-carboxylate

[0980]

[0981] At room temperature, 2,4-dichloro-5,8-dihydropyridinium[3,4-d]pyrimidine-7(6H)-carboxylic acid tert-butyl ester (200.0 mg, 657.2 μmol) was dissolved in ethanol (3 ml), zinc powder (341.9 mg, 5.2 mmol) and 25% ammonia water (114.9 mg, 3.3 mmol) were added, and the temperature was raised to 90 degrees Celsius for reflux reaction for 15 hours. After the reaction was complete, the mixture was filtered, the filtrate was concentrated, and the residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 4 / 1) to obtain 71.9 mg of light yellow solid 2-chloro-5,8-dihydropyridinium[3,4-d]pyrimidine-7(6H)-carboxylic acid tert-butyl ester (yield 40.6%). LC-MS: RT = 2.70 min, [M- t Bu] + =214.01.

[0982] Step B: Synthesis of tert-butyl 2-((4-chloro-2-fluorobenzyl)oxy)-5,8-dihydropyridinium[3,4-d]pyrimidine-7(6H)-carboxylate

[0983]

[0984] Tert-butyl 2-chloro-5,8-dihydropyridino[3,4-d]pyrimidine-7(6H)-carboxylate (71.9 mg, 266.3 μmol), 2-fluoro-4-chlorobenzyl alcohol (85.6 mg, 533.2 μmol), 2-dicyclohexylphospho-2,4,6-triisopropylbiphenyl (12.7 mg, 26.6 μmol) and cesium carbonate (260.2 mg, 0.8 mmol) were dissolved in dioxane (10 mL) at room temperature. The reaction mixture was replaced with nitrogen three times, and under the protection of nitrogen, trisdibenzylideneacetone dipalladium (24.4 mg, 26.6 μmol, nitrogen was replaced three times, and the temperature was raised to reflux for reaction overnight. After the reaction was complete, the mixture was filtered, and the filtrate was diluted with ethyl acetate (80 ml), washed with water (30 ml × 2 times) and saturated brine (30 ml × 1 time), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 4 / 1) to obtain 56.5 mg of light yellow oily tert-butyl 2-((4-chloro-2-fluorobenzyl)oxy)-5,8-dihydropyridinyl[3,4-d]pyrimidine-7(6H)-carboxylate (yield: 53.8%). LC-MS: RT = 2.92 min, [M+H] + =393.95. 1 H NMR (400 MHz, CDCl 3)δ8.28(s,1H),7.11(t,J=9.2Hz,2H), 6.98(s,1H),5.43(s,2H),4.55(s,2H),3.67(d,J=7.0Hz,2H),2.75(s,2H),1.49(d,J=2.3Hz,9H).

[0985] Step C: Synthesis of 2-((4-chloro-2-fluorobenzyl)oxy)-5,6,7,8-tetrahydropyridinyl[3,4-d]pyrimidine

[0986]

[0987] At room temperature, tert-butyl 2-((4-chloro-2-fluorobenzyl)oxy)-5,8-dihydropyridinium[3,4-d]pyrimidine-7(6H)-carboxylate (130.2 mg, 331.3 μmol) was dissolved in dichloromethane (4 ml) solution, trifluoroacetic acid (1 ml) was added, and the reaction was carried out at room temperature for 2 hours. After the reaction was complete, the mixture was concentrated to obtain 97.1 mg of light yellow oily 2-((4-chloro-2-fluorobenzyl)oxy)-5,6,7,8-tetrahydropyridinium[3,4-d]pyrimidine, which was directly used in the next step without further purification.

[0988] Step D: Synthesis of (S)-tert-butyl 2-((2-((4-chloro-2-fluorobenzyl))-5,8-pyridinyl[3,4-d]pyrimidin-7(6H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate

[0989]

[0990] At room temperature, 2-((4-chloro-2-fluorobenzyl)oxy)-5,6,7,8-tetrahydropyridinium[3,4-d]pyrimidine (97.1 mg, 331.3 μmol) and (S)-tert-butyl 2-(chloromethyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (102.3 mg, 347.9 μmol) were dissolved in N,N-dimethylformamide (3 ml), anhydrous potassium carbonate (138.1 mg, 993.9 μmol) was added, and the mixture was reacted overnight at room temperature. After the reaction was complete, the mixture was diluted with ethyl acetate (100 ml), washed with water (30 ml × 2 times) and saturated brine (30 ml × 1 time), dried over anhydrous sodium sulfate, and concentrated. The obtained residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1 to dichloromethane / methanol = 15 / 1) to obtain 119.2 mg of light yellow oily (S)-2-((2-((4-chloro-2-fluorobenzyl)oxy)-5,8-dihydropyridinyl[3,4-d]pyrimidin-7(6H)-yl)methyl)-1-((oxetane-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid tert-butyl ester (yield 60.7%). LC-MS: RT = 3.25 min, [M+H] + =594.17.

[0991] Step E: Synthesis of (S)-2-((2-((4-chloro-2-fluorobenzyl))-5,8-pyridinyl[3,4-d]pyrimidin-7(6H)-yl)methyl)-1-((oxetane-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0992]

[0993] At room temperature, (S)-tert-butyl 2-((2-((4-chloro-2-fluorobenzyl)oxy)-5,8-dihydropyridinium[3,4-d]pyrimidin-7(6H)-yl)methyl)-1-((oxetane-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (119.2 mg, 201.1 μmol) was dissolved in dichloromethane (3 ml) and trifluoroacetic acid (1 ml) was added. The mixture was reacted at room temperature for 3 hours. After the reaction was completed, water (5 ml) was added to quench the reaction. The pH was adjusted to 8 with saturated sodium bicarbonate aqueous solution, and the mixture was extracted with dichloromethane / methanol = 10 / 1 (30 ml × 3 times). The organic phases were combined, dried over anhydrous sodium sulfate, and concentrated. The obtained residue was purified by reverse phase HPLC (mobile phase: (0.1% ammonia water / water) / acetonitrile = 95 / 5 to 55 / 45) and lyophilized to obtain 25.7 mg of white solid (S)-2-((2-((4-chloro-2-fluorobenzyl)oxy)-5,8-dihydropyridinyl[3,4-d]pyrimidin-7(6H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (yield: 24.0%). LC-MS: RT = 1.47 min, [M+H] + =538.10. 1 H NMR (400MHz, CD 3 OD)δ8.37(d,J=9.9Hz,2H),8.02(dd,J=8.5,1.6Hz,1H),7.74(d,J=8.4Hz,1H),7.55(t,J=8.1Hz, 1H),7.23(td,J=9.1,7.9,2.1Hz,2H),5.44(s,2H),5.24(dd,J=7.5,2.6Hz,1H),4.90–4.84(m,1H),4.73(dd, J=15.4,2.7Hz,1H),4.67–4.61(m,1H),4.46(dd,J=9.0,6.0Hz,1H),4.26(d,J=13.9Hz,1H),4.17(d,J= 13.7Hz, 1H), 3.73 (d, J = 6.9Hz, 2H), 2.93 (t, J = 5.6Hz, 2H), 2.88 (d, J = 5.5Hz, 2H), 2.75 (ddd, J = 11.8, 8.7, 6.2Hz, 1H), 2.54–2.45 (m, 1H).

[0994] Embodiment 48

[0995] Synthesis of (S)-2-((7-((3-chloro-4-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[0996]

[0997] The specific synthetic route is as follows:

[0998] Step A: Synthesis of tert-butyl 7-((3-chloro-4-fluorobenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate

[0999]

[1000] At room temperature, 3-chloro-4-fluorobenzyl bromide (200.0 mg, 0.9 mmol) and tert-butyl 7-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxylate (110.9 mg, 0.4 mmol) were dissolved in N,N-dimethylformamide (3 ml), and anhydrous potassium carbonate (185.5 mg, 1.3 mmol) was added. The mixture was reacted overnight at room temperature. After the reaction was complete, the mixture was diluted with ethyl acetate (100 ml), washed with water (30 ml × 2 times) and saturated brine (30 ml × 1 time), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 4 / 1) to obtain 169.0 mg of tert-butyl 7-((3-chloro-4-fluorobenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate (yield 98.2%). LC-MS: RT = 4.20 min, [M- t Bu] + =335.93.

[1001] Step B: Synthesis of 7-((3-chloro-4-fluorobenzyl)oxy)-1,2,3,4-tetrahydroisoquinoline

[1002]

[1003] At room temperature, tert-butyl 7-((3-chloro-4-fluorobenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate (209.2 mg, 0.7 mmol) was dissolved in dichloromethane (4 ml), trifluoroacetic acid (1 ml) was added, and the mixture was reacted at room temperature for 1 hour. After the reaction was complete, the mixture was concentrated to obtain 230.1 mg of light yellow oily 7-((3-chloro-4-fluorobenzyl)oxy)-1,2,3,4-tetrahydroisoquinoline, which was directly used in the next step without further purification. LC-MS: RT = 1.52 min, [M+H] + =292.06.

[1004] Step C: Synthesis of (S)-tert-butyl 2-((7-((3-chloro-4-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate

[1005]

[1006] At room temperature, 7-((3-chloro-4-fluorobenzyl)oxy)-1,2,3,4-tetrahydroisoquinoline (80.5 mg, 0.3 mmol) and (S)-tert-butyl 2-(chloromethyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (93.4 mg, 0.3 mmol) were dissolved in N,N-dimethylformamide (3 ml), anhydrous potassium carbonate (115.2 mg, 0.8 mmol) was added, and the mixture was reacted overnight at room temperature. After the reaction was complete, the mixture was diluted with ethyl acetate (100 ml), washed with water (30 ml × 2 times) and saturated brine (30 ml × 1 time), dried over anhydrous sodium sulfate, and concentrated. The obtained residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1 to dichloromethane / methanol = 15 / 1) to obtain 140.2 mg of light yellow oily (S)-2-((7-((3-chloro-4-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid tert-butyl ester (yield 86.4%). LC-MS: RT = 3.59 min, [M+H] + =592.18.

[1007] Step D: Synthesis of (S)-2-((7-((3-chloro-4-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[1008]

[1009] At room temperature, (S)-tert-butyl 2-((7-((3-chloro-4-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (140.1 mg, 236.0 μmol) was dissolved in dichloromethane (2 ml), trifluoroacetic acid (1 ml) was added, and the reaction was carried out at room temperature for 3 hours. After the reaction was completed, water (5 ml) was added to quench the reaction, and the pH was adjusted to 8 with saturated sodium bicarbonate aqueous solution. The mixture was extracted with dichloromethane / methanol = 10 / 1 (30 ml × 3 times), and the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated. The obtained residue was purified by reverse phase HPLC (mobile phase: (0.1% aqueous ammonia / water) / acetonitrile = 95 / 5 to 55 / 45) and lyophilized to give 62.5 mg of white solid (S)-2-((7-((3-chloro-4-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (yield: 50.4%). LC-MS: RT = 2.18 min, [M+H] + =536.24. 1 H NMR (400MHz, CD 3 OD)δ8.34(d, J=1.4Hz,1H),8.02(dd,J=8.5,1.5Hz,1H),7.72(d,J=8.4Hz,1H),7.55(dd,J=7.0,2.1Hz,1H),7.39 (ddd,J=7.1,4.6,2.1Hz,1H),7.25(t,J=8.8Hz,1H),7.06(d,J=8.4Hz,1H),6.82(dd,J=8.4,2.6Hz,1H), 6.68(d,J=2.6Hz,1H),5.24(tt,J=7.3,3.6Hz,1H),5.02–4.99(m,2H),4.89(d,J=7.2Hz,1H),4.74(dd,J =15.4,2.7Hz,1H),4.62(td,J=8.0,6.0Hz,1H),4.46(dt,J=9.0,5.9Hz,1H),4.21(d,J=13.7Hz,1H),4.10 (d,J=13.7Hz,1H),3.77–3.62(m,2H),2.88(s,4H),2.74(ddd,J=11.8,8.5,6.3Hz,1H),2.56–2.43(m,1H).

[1010] Embodiment 49

[1011] Synthesis of (S)-2-((7-((3,4-dichlorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetane-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[1012]

[1013] The specific synthetic route is as follows:

[1014] Step A: Synthesis of tert-butyl 7-((3,4-dichlorobenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate

[1015]

[1016] At room temperature, 1,2-dichlorobenzyl bromide (212.0 mg, 0.9 mmol) and tert-butyl 7-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxylate (110.9 mg, 0.4 mmol) were dissolved in N,N-dimethylformamide (3 ml), and anhydrous potassium carbonate (185.0 mg, 1.3 mmol) was added. The mixture was reacted overnight at room temperature. After the reaction was complete, the mixture was diluted with ethyl acetate (100 ml), washed with water (30 ml × 2 times) and saturated brine (30 ml × 1 time), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 4 / 1) to obtain 170.0 mg of tert-butyl 7-((3,4-dichlorobenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate (yield 94.4%). LC-MS: RT = 5.00 min, [M- t Bu] + =349.03.

[1017] Step B: Synthesis of 7-((3,4-dichlorobenzyl)oxy)-1,2,3,4-tetrahydroisoquinoline

[1018]

[1019] At room temperature, tert-butyl 7-((3,4-dichlorobenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate (170.0 mg, 0.4 mmol) was dissolved in dichloromethane (4 ml), trifluoroacetic acid (1 ml) was added, and the mixture was reacted at room temperature for 1 hour. After the reaction was complete, the mixture was concentrated to obtain 225.0 mg of light yellow oily 7-((4-chloro-3-fluorobenzyl)oxy)-1,2,3,4-tetrahydroisoquinoline, which was directly used in the next step without further purification. LC-MS: RT = 2.13 min, [M+H] + =308.17.

[1020] Step C: Synthesis of (S)-tert-butyl 2-((7-((3,4-dichlorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate

[1021]

[1022] At room temperature, 7-((3,4-dichlorobenzyl)oxy)-1,2,3,4-tetrahydroisoquinoline (80.5 mg, 260.0 μmol) and (S)-tert-butyl 2-(chloromethyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (93.4 mg, 260.0 μmol) were dissolved in N,N-dimethylformamide (3 ml), and anhydrous potassium carbonate (108.2 mg, 0.8 mmol) was added. The mixture was reacted overnight at room temperature. After the reaction was complete, the mixture was diluted with ethyl acetate (100 ml), washed with water (30 ml × 2 times) and saturated brine (30 ml × 1 time), dried over anhydrous sodium sulfate, and concentrated. The obtained residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1 to dichloromethane / methanol = 15 / 1) to obtain 101.2 mg of light yellow oily (S)-tert-butyl 2-((7-((3,4-dichlorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (yield 63.9%). LC-MS: RT = 4.02 min, [M+H] + =608.31.

[1023] Step D: Synthesis of (S)-2-((7-((3,4-dichlorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[1024]

[1025] At room temperature, (S)-tert-butyl 2-((7-((3,4-dichlorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (101.2 mg, 166.8 μmol) was dissolved in dichloromethane (2 ml), trifluoroacetic acid (1 ml) was added, and the reaction was carried out at room temperature for 3 hours. After the reaction was completed, water (5 ml) was added to quench the reaction, and the pH was adjusted to about 8 with saturated sodium bicarbonate aqueous solution. The mixture was extracted with dichloromethane / methanol = 10 / 1 (30 ml × 3 times), and the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated. The obtained residue was purified by reverse phase HPLC (mobile phase: (0.1% aqueous ammonia / water) / acetonitrile = 95 / 5 to 55 / 45) and lyophilized to give 59.5 mg of white solid (S)-2-((7-((3,4-dichlorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (yield: 65.9%). LC-MS: RT = 2.48 min, [M+H] + =555.23. 1 H NMR (400MHz, CD 3 OD)δ8.36 (d,J=1.4Hz,1H),8.02(dd,J=8.5,1.6Hz,1H),7.73(d,J=8.5Hz,1H),7.61(d,J=2.0Hz,1H),7.53(d,J =8.3Hz,1H),7.37(dd,J=8.2,2.0Hz,1H),7.06(d,J=8.4Hz,1H),6.82(dd,J=8.4,2.6Hz,1H),6.68(d,J =2.6Hz,1H),5.27–5.17(m,1H),5.03(s,2H),4.89(d,J=7.3Hz,1H),4.74(dd,J=15.3,2.6Hz,1H),4.62 (td,J=8.0,6.0Hz,1H),4.46(dt,J=9.2,6.0Hz,1H),4.22(d,J=13.8Hz,1H),4.11(d,J=13.7Hz,1H), 3.78–3.66(m,2H),2.88(d,J=3.4Hz,4H),2.73(dt,J=14.5,7.1Hz,1H),2.56–2.42(m,1H).

[1026] Embodiment 50

[1027] Synthesis of (S)-2-((7-((4-chloro-3-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[1028]

[1029] The specific synthetic route is as follows:

[1030] Step A: Synthesis of tert-butyl 7-((4-chloro-3-fluorobenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate

[1031]

[1032] At room temperature, 4-chloro-3-fluorobenzyl bromide (200.0 mg, 0.9 mmol) and tert-butyl 7-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxylate (110.5 mg, 0.4 mmol) were dissolved in N,N-dimethylformamide (3 ml), and anhydrous potassium carbonate (185.0 mg, 1.3 mmol) was added. The mixture was reacted overnight at room temperature. After the reaction was complete, the mixture was diluted with ethyl acetate (100 ml), washed with water (30 ml × 2 times) and saturated brine (30 ml × 1 time), dried over anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 4 / 1) to obtain 169.0 mg of tert-butyl 7-((4-chloro-3-fluorobenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate (yield 98.2%). LC-MS: RT = 5.00 min, [M- t Bu] + =336.00.

[1033] Step B: Synthesis of 7-((4-chloro-3-fluorobenzyl)oxy)-1,2,3,4-tetrahydroisoquinoline

[1034]

[1035] At room temperature, tert-butyl 7-((4-chloro-3-fluorobenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate (169.0 mg, 0.4 mmol) was dissolved in dichloromethane (4 ml), trifluoroacetic acid (1 ml) was added, and the mixture was reacted at room temperature for 1 hour. After the reaction was complete, the mixture was concentrated to obtain 246.0 mg of light yellow oily 7-((4-chloro-3-fluorobenzyl)oxy)-1,2,3,4-tetrahydroisoquinoline, which was directly used in the next step without further purification. LC-MS: RT = 1.90 min, [M+H] + = 292.19.

[1036] Step C: Synthesis of (S)-tert-butyl 2-((7-((4-chloro-3-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate.

[1037]

[1038] At room temperature, 7-((4-chloro-3-fluorobenzyl)oxy)-1,2,3,4-tetrahydroisoquinoline (80.5 mg, 0.3 mmol) and (S)-tert-butyl 2-(chloromethyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (93.4 mg, 0.3 mmol) were dissolved in N,N-dimethylformamide (3 ml), anhydrous potassium carbonate (115.2 mg, 0.8 mmol) was added, and the mixture was stirred at room temperature overnight. After the reaction was complete, the mixture was diluted with ethyl acetate (100 ml), washed with water (30 ml × 2 times) and saturated brine (30 ml × 1 time), dried over anhydrous sodium sulfate, and concentrated. The obtained residue was purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 1 / 1 to dichloromethane / methanol = 15 / 1) to obtain 122.2 mg of light yellow oily (S)-2-((7-((4-chloro-3-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid tert-butyl ester (yield 75.3%). LC-MS: RT = 3.67 min, [M+H] + =592.18.

[1039] Step D: Synthesis of (S)-2-((7-((4-chloro-3-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[1040]

[1041] At room temperature, (S)-tert-butyl 2-((7-((4-chloro-3-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (101.2 mg, 170.8 μmol) was dissolved in dichloromethane (2 ml), trifluoroacetic acid (1 ml) was added, and the reaction was carried out at room temperature for 3 hours. After the reaction was completed, water (5 ml) was added to quench the reaction, and the pH was adjusted to 8 with saturated sodium bicarbonate aqueous solution. The mixture was extracted with dichloromethane / methanol = 10 / 1 (30 ml × 3 times), and the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated. The obtained residue was purified by reverse phase HPLC (mobile phase: (0.1% aqueous ammonia / water) / acetonitrile = 95 / 5 to 55 / 45) and lyophilized to give 50.5 mg of white solid (S)-2-((7-((4-chloro-3-fluorobenzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (yield: 55.1%). LC-MS: RT = 2.22 min, [M+H] + =536.17. 1 H NMR (400MHz, CD 3 OD)δ8.40(d, J=1.6Hz,1H),8.03(dd,J=8.5,1.6Hz,1H),7.77(d,J=8.4Hz,1H),7.56(t,J=7.9Hz,1H),7.42(dd,J= 10.2,1.9Hz,1H),7.32(dd,J=8.3,1.9Hz,1H),7.11(d,J=8.4Hz,1H),6.88(dd,J=8.4,2.7Hz,1H),6.75 (d,J=2.6Hz,1H),5.24(qd,J=7.4,2.5Hz,1H),5.10(s,2H),4.95(dd,J=15.3,7.3Hz,1H),4.77(dd,J= 15.3,2.6Hz,1H),4.62(dd,J=8.2,6.2Hz,1H),4.49(dt,J=9.1,5.9Hz,1H),4.25(d,J=13.7Hz,1H),4.11 (d,J=13.7Hz,1H),3.80–3.68(m,2H),2.91(d,J=2.5Hz,4H),2.77(dtd,J=11.4,8.1,6.1Hz,1H),2.68(p, J=1.9Hz, 1H), 2.53 (ddt, J=11.4, 9.1, 7.1Hz, 1H).

[1042] Embodiment 51

[1043] Synthesis of (S)-2-((7-((2,6-benzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[1044]

[1045] The specific synthetic route is as follows:

[1046] Step A: Synthesis of tert-butyl 7-((2,6-difluorobenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate

[1047]

[1048] At room temperature, tert-butyl 7-hydroxy-3,4-dihydroisoquinoline-2(1H)-carboxylate (80.0 mg, 0.32 mmol), 2-bromomethyl-1,3-difluorobenzene (69.8 mg, 0.34 mmol) and cesium carbonate (209.4 mg, 0.64 mmol) were added to 10 ml of dry DMF and heated to 50 degrees Celsius for 4 hours. After the reaction, the reaction solution was cooled to room temperature, poured into 40 ml of ice-water solution, stirred for 30 minutes, and then filtered and the filter cake was washed with water. After the filter cake was dried, 100 mg of white solid tert-butyl 7-((2,6-difluorobenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate was obtained (yield: 83.3%).

[1049] Step B: Synthesis of 7-((2,6-difluorobenzyl)oxy)-1,2,3,4-tetrahydroisoquinoline

[1050]

[1051] At room temperature, tert-butyl 7-((2,6-difluorobenzyl)oxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate (100 mg, 0.27 mmol) was dissolved in 10 ml of methanol solvent, and 10 ml of 4 M / L hydrochloric acid dioxane solution was added under ice bath, and the mixture was reacted at room temperature for 2 hours.

[1052] After the reaction was completed, the reaction solution was evaporated to dryness to obtain 108 mg of white solid 7-((2,6-difluorobenzyl)oxy)-1,2,3,4-tetrahydroisoquinoline (yield: 148.0%). LC-MS: RT = 1.61 min, [M+H] + =276.21.

[1053] Step C: Synthesis of (S)-tert-butyl 2-((7-((2,6-benzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate

[1054]

[1055] At room temperature, the intermediate 7-((2,6-difluorobenzyl)oxy)-1,2,3,4-tetrahydroisoquinoline (100 mg, 0.27 mmol) and (S)-tert-butyl 2-(chloromethyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (89 mg, 0.27 mmol), potassium carbonate (75 mg, 0.54 mmol) and potassium iodide (90 mg, 0.54 mmol) were added to 10 ml of DMF solution and heated to 50 °C for 10 hours. After the reaction, the reaction solution was poured into ice water to precipitate solids, which were filtered and washed with water to obtain 105 mg of a white product (S)-2-((7-((2,6-benzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetane-2-yl(methyl)-1H-benzo[d]imidazole-6-carboxylic acid tert-butyl ester (yield: 67.7%). LC-MS: RT = 1.98 min, [M+H] + =576.33.

[1056] Step D: Synthesis of (S)-2-((7-((2,6-benzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid

[1057]

[1058] At room temperature, the intermediate (S)-2-((7-((2,6-benzyl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-((oxetane-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid tert-butyl ester (100 mg, 0.17 mmol) was dissolved in 6 ml of dichloromethane, and 0.5 ml of trifluoroacetic acid was added dropwise under ice bath. The reaction was carried out at room temperature for 4 hours. After the reaction was completed, 20 ml o...

Claims

1. Compounds of formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein: A is selected from a benzene ring, a thiophene ring, a pyridine ring, a pyridazine ring, a quinoline ring, and an indazole ring; R 1 Selected from hydrogen, halogen, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Haloalkoxy, methylsulfonyl; m is 0, 1, 2 or 3; W is selected from -OCH2-, -CH2O-, -CH2CH2O-, -CH2CH2-, -NHCH2- or -CH2NH-; Said Selected from L is selected from -CH2; R 2 is hydrogen; R 3 is hydrogen; Where p is 0, 1 or 2; R 4 is oxetane-2-ylmethyl; Z 1 , Z 2 and Z 3 Each independently is -CR Z or N, each R Z is independently H.

2. The compound according to claim 1, or its stereoisomers, tautomers, or pharmaceutically acceptable salts, characterized in that: A is selected from a benzene ring, a thiophene ring, a pyridine ring, a pyridazine ring, a quinoline ring, and an indazole ring; R1 is selected from hydrogen, cyano, fluorine, chlorine, bromine, methyl, trifluoromethoxy, methoxy, trifluoromethyl, 2,2,2-trifluoroethyl, methanesulfonyl; W is -OCH2-, -CH2O-, -CH2CH2O-, -CH2CH2-, -NHCH2- or -CH2NH-; Selected from R 2 is hydrogen; R 3 is hydrogen; Where p is 0, 1 or 2; R 4 is oxetane-2-ylmethyl; L is selected from -CH2; Z 1 、Z 2 、Z 3 is CH or N.

3. The compound according to claim 1, or its stereoisomers, tautomers, or pharmaceutically acceptable salts, characterized in that: Selected from the following compounds:

4. The compound according to claim 1, or its stereoisomers, tautomers, or pharmaceutically acceptable salts, characterized in that: The pharmaceutically acceptable salt refers to a salt prepared from a compound and a pharmaceutically acceptable acid or base.

5. The compound according to any one of claims 1 to 4, or its stereoisomers, tautomers, or pharmaceutically acceptable salts, characterized in that: One or more hydrogen atoms in the compound are substituted with deuterium isotopes.

6. A pharmaceutical composition, characterized in that The invention comprises the compound according to any one of claims 1 to 5, or a stereoisomer, a tautomer, a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers.

7. Use of the compound according to any one of claims 1 to 5, or its stereoisomer, or its tautomer, or its pharmaceutically acceptable salt, in the preparation of a medicament for treating GLP-1 related diseases.

8. The use according to claim 7, characterized in that The GLP-1 related disease is selected from diabetes related diseases.